piracetam has been researched along with Seizures in 396 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 9.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 9.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "To evaluate the efficacy of Levetiracetam in the management of neonatal seizures." | 9.22 | Efficacy of Levetiracetam in neonatal seizures: a systematic review. ( Hussain, AM; Sharma, D; Sharma, SS, 2022) |
| "This was an open-label study (N01281 [NCT00419393]) assessing the long-term safety of extended-release levetiracetam (LEV XR) in patients with partial-onset seizures (POS); the study was a follow-up to a double-blind, randomized, historical controlled, multicenter, conversion to monotherapy study (N01280 [NCT00419094])." | 9.22 | Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study. ( Ceja, H; Chung, S; Gawłowicz, J; Lu, S; McShea, C; Schiemann, J, 2016) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in the management of seizures in neonates." | 9.22 | Efficacy and safety of levetiracetam in the management of seizures in neonates. ( Asadi, F; Moradian, M; Moradian, N; Sedighi, M; Vakiliamini, M, 2016) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 9.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| "To evaluate the efficacy of levetiracetam (LEV) and the usefulness of measurement of its blood levels during the follow-up of patients with focal seizures." | 9.20 | The efficacy of levetiracetam for focal seizures and its blood levels in children. ( Ishii, M; Iwasaki, T; Nonoda, Y; Toki, T, 2015) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 9.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "Following the first period of the multicenter, open-label, single-armed N01223 trial, the second period of the N01223 trial was conducted to evaluate long-term safety, along with the efficacy of adjunctive levetiracetam treatment (individualized dose range, 20-60 mg/kg/day or 1,000-3,000 mg/day) in Japanese pediatric patients with uncontrolled partial-onset seizures (POS)." | 9.20 | [Effects of Long-Term Treatment with Levetiracetam as an Adjunctive Therapy in Japanese Children with Uncontrolled Partial-Onset Seizures: A Multicenter, Open-Label Study]. ( Nakamura, H; Osawa, M; Suzuki, A; Yokoyama, T; Yoshida, K, 2015) |
| "Levetiracetam is effective in individuals with electrical status epilepticus during sleep with tolerable side effects." | 9.19 | Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. ( Cai, FC; Chen, X; Chen, XQ; Gao, L; Huang, SP; Pang, BD; Yang, ZX; Zhang, WN; Zhao, M; Zou, LP, 2014) |
| "A multicenter, open-label, single-armed study (N01223) was conducted to evaluate efficacy and safety of levetiracetam (LEV) as an add-on therapy in Japanese pediatric patients with uncontrolled partial-onset seizures (POS)." | 9.17 | [Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation]. ( Nakamura, H; Osawa, M; Suzuki, A; Yokoyama, T; Yoshida, K, 2013) |
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 9.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 9.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 9.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| "Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy." | 9.12 | [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers]. ( Auriel, E; Blatt, I; Chistik, V; Margolin, N; Neufeld, M, 2007) |
| "To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy." | 9.10 | Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. ( Ben-Menachem, E; Edrich, P; Sander, JW; Schmidt, B; Van Vleymen, B, 2003) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 9.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "To report the results of a combined case series analysis of subcutaneous levetiracetam (Keppra) for the management of seizures in palliative care patients." | 8.98 | Subcutaneous levetiracetam for the management of seizures at the end of life. ( Bradley, V; Bush, O; Curtin, J; Hedges, V; Naessens, K; Presswood, M; Sutherland, AE, 2018) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 8.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "Levetiracetam is a novel antiepileptic drug (AED) with proven efficacy against partial seizures, but there is limited information about its effectiveness against generalized seizures." | 8.82 | Levetiracetam: preliminary efficacy in generalized seizures. ( Hirsch, E; Kasteleijn-Nolst Trenité, DG, 2003) |
| "Levetiracetam, the S-enantiomer of alpha-ethyl-2-oxo-1-pyrollidine acetamide, is approved for use as adjunctive therapy in adult patients with partial onset seizures." | 8.80 | Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. ( Dooley, M; Plosker, GL, 2000) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 8.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| "We aimed to evaluate the blood concentration of levetiracetam (LEV), as a second-line drug, in patients with status epilepticus (SE) in an emergency clinical setting." | 8.02 | Blood concentration of levetiracetam after bolus administration in patients with status epilepticus. ( Hotta, M; Kaneko, J; Kondo, M; Kubota, M; Kuno, M; Nagano, M; Sugaya, K; Tagami, T; Takase, H; Unemoto, K, 2021) |
| "A retrospective chart review over a 7-year period was conducted at the American University of Beirut to identify neonates with electrographically proven seizures treated with levetiracetam." | 7.96 | High-Dose Levetiracetam for Neonatal Seizures: A Retrospective Review. ( Darwich, M; Hanneyan, S; Hnaini, M; Jaafar, F; Koleilat, N; Maalouf, FI; Mikati, IE; Nabout, R; Obeid, M; Rahal, S; Shbarou, RM, 2020) |
| "This study developed a population pharmacokinetic (PK) model of levetiracetam (LEV) for treating neonatal seizures (NS) and determined the influence of clinically relevant covariates to explain the interindividual variability and residual error." | 7.88 | Population pharmacokinetics of levetiracetam in neonates with seizures. ( Gómez-Ruiz, LM; Lima-Rogel, V; López-López, EJ; Medellín-Garibay, SE; Milán-Segovia, RC; Romano-Moreno, S; Romero-Méndez, C, 2018) |
| "This study was conducted to develop a population pharmacokinetic (PK) model of levetiracetam in Korean neonates with seizures." | 7.88 | Population pharmacokinetic model of levetiracetam in Korean neonates with seizures . ( Jung, YS; Lee, SM; Park, K; Park, MS, 2018) |
| "We enrolled patients with epilepsy who were treated with branded levetiracetam for at least 6 months of sustained use." | 7.88 | Brand name to generic substitution of levetiracetam in patients with epilepsy. ( Dae, SJ; Gha-Hyun, L, 2018) |
| "The aim of this study was to evaluate the risk factors, clinical implications, and prognosis of new-onset seizures that occurred after pediatric liver transplantation, and to assess the efficacy of levetiracetam treatment." | 7.85 | Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam. ( Arslan, M; Güngör, S; Kılıç, B; Selimoğlu, MA; Yılmaz, S, 2017) |
| "Levetiracetam is used in the treatment of some forms of epilepsy." | 7.85 | Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. ( Company-Albir, MJ; Marqués-Miñana, MR; Poveda, JL; Ruíz-Ramos, J; Solana Altabella, A; Vicent, C, 2017) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 7.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 7.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "CYT-evoked alterations in the protection provided by some antiepileptic drugs against seizures can be of serious concern for epileptic smokers, who might demonstrate therapeutic failure to lacosamide, levetiracetam, and pregabalin, resulting in possible breakthrough seizure attacks." | 7.85 | Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. ( Florek-Łuszczki, M; Kondrat-Wróbel, MW; Tutka, P; Zaluska, K; Żółkowska, D; Łuszczki, JJ, 2017) |
| "The objective of this study was to determine the efficacy and safety of levetiracetam in treatment of neonatal seizures due to hypoxic ischemic encephalopathy." | 7.85 | Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy. ( Schapiro, M; Thomas, C; Venkatesan, C; Young, S, 2017) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 7.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury." | 7.83 | Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis. ( Chung, MG; O'Brien, NF, 2016) |
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 7.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "This noninterventional, observational, postauthorization safety study (SP0942, NCT00771927) evaluated the incidence of predefined cardiovascular- (CV) and psychiatric-related treatment-emergent adverse events (TEAEs), in patients with epilepsy and uncontrolled partial-onset seizures, when initiating adjunctive therapy with lacosamide or another approved antiepileptic drug (AED) according to standard medical practice." | 7.83 | A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. ( Brunnert, M; De Backer, M; Doty, P; Eckhardt, K; Schulze-Bonhage, A; Steinhoff, BJ, 2016) |
| "In this propensity score-matched cohort analysis, levetiracetam prophylaxis was ineffective in preventing seizures as the rate of seizures was similar whether patients did or did not receive the drug." | 7.83 | Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis. ( Friese, R; Gruessner, A; Joseph, B; Khalil, M; Kulvatunyou, N; Latifi, R; O'Keeffe, T; Rhee, P; Wynne, J; Zangbar, B, 2016) |
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 7.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 7.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "Intravenous levetiracetam is an option for treatment of status epilepticus (SE) and acute repetitive seizures (ARS)." | 7.81 | Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A; Wiwattanadittakul, N, 2015) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 7.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "TO determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy." | 7.81 | [Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models]. ( Chen, T; Li, MQ; Liu, L; Zhang, WW, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 7.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "Levetiracetam (LEV), used for both partial and generalized seizures, is a frequently preferred antiepileptic because of its few side effects." | 7.80 | Hypokalemia and hypomagnesaemia related to levetiracetam use. ( Aksoy, D; Cevik, B; Kurt, S; Pekdas, E; Solmaz, V, 2014) |
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 7.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| "Levetiracetam is an antiepileptic medication that has been reported to be both well-tolerated and effective in treating generalized tonic-clonic, myoclonic, and partial-onset seizures." | 7.80 | Levetiracetam as a possible contributor to acute kidney injury. ( Hohler, AD; Montouris, GD; Spengler, DC, 2014) |
| "Levetiracetam has been proven to be effective in both partial and generalized seizures in children." | 7.80 | Efficacy and safety of IV levetiracetam in children with acute repetitive seizures. ( Ağın, H; Akarcan, SE; Celik, T; Güzel, O; İşgüder, R; Ünalp, A; Yılmaz, Ü, 2014) |
| "Levetiracetam (LEV) and tiagabine (TGB) are utilized for the treatment of seizures, including neonatal seizures." | 7.80 | Profile of anticonvulsant action of levetiracetam, tiagabine and phenobarbital against seizures evoked by DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) in neonatal rats. ( Beck, VC; Forcelli, PA; Gutherz, SB; Kulick, CV; Medvedeva, N; Soper, C, 2014) |
| " In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures." | 7.80 | Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. ( Albertini, G; De Sarro, G; Gallelli, L; Gratteri, S; Iemolo, F; Manes, MT; Mercuri, NB; Quirino, G; Sanzaro, E; Scaglione, F; Siniscalchi, A, 2014) |
| "To explore the effects of levetiracetam (LEV) on the changes of bone mineral density (BMD) and bone metabolism in the treatment of middle-aged and elderly patients with generalized tonic-clonic seizures." | 7.80 | [Clinical efficacy of levetiracetam on bone mineral density and bone metabolism in middle-aged and elderly patients with generalized tonic-clonic seizures]. ( Chen, X; Wang, H, 2014) |
| "Emotional apneas (EA) are non-epileptic paroxysmal events affecting 5% of healthy children." | 7.80 | [Pathophysiology, differential diagnosis and treatment of severe emotional apnea: based on report case]. ( Esquivel P, N; Hernández CH, M; López E, M, 2014) |
| "In this case series we report on eight neonates with refractory seizures who received intravenous levetiracetam when seizures did not respond to two or more conventional anticonvulsants." | 7.79 | Intravenous levetiracetam for treatment of neonatal seizures. ( Kohan, R; Nagarajan, L; Rakshasbhuvankar, A; Rao, S; Simmer, K, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| " The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20 min after onset of seizures elicited by soman." | 7.79 | Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats. ( Aas, P; Enger, S; Mariussen, E; Myhrer, T, 2013) |
| "Compare neurodevelopment after levetiracetam (LEV) and phenobarbital (PB) for neonatal seizures." | 7.79 | Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. ( Maitre, NL; Slaughter, JC; Smolinsky, C; Stark, AR, 2013) |
| "To report the effectiveness and safety of intravenous levetiracetam in the treatment of children with acute repeated seizures, and status epilepticus in a children's hospital." | 7.78 | Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. ( Appleton, R; Kneen, R; Kumar, R; McTague, A; Spinty, S, 2012) |
| "To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting." | 7.77 | Clinical experience with generic levetiracetam in people with epilepsy. ( Chaluvadi, S; Chiang, S; Friedman, DE; Goldsmith, CE; Tran, L, 2011) |
| "We report on 4 patients having an increased incidence of seizures when treatment was switched from brand name levetiracetam (Keppra) to generic levetiracetam formulations." | 7.77 | Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. ( Fitzgerald, CL; Jacobson, MP, 2011) |
| "The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures." | 7.77 | Pharmacokinetics of levetiracetam in neonates with seizures. ( Balmakund, T; Meinzen-Derr, J; Merhar, SL; Schibler, KR; Sherwin, CM; Shi, J; Vinks, AA, 2011) |
| "In this retrospective study of institutionalized patients with mental retardation, we present the efficacy and safety of sequential treatment with intrarectal diazepam (IRD) gel (Diastat) and intravenous levetiracetam (IVL) in comparison with either treatment alone for acute repetitive or prolonged seizures (ARPS)." | 7.76 | Sequential intrarectal diazepam and intravenous levetiracetam in treating acute repetitive and prolonged seizures. ( Milteer, WE; Modur, PN; Zhang, S, 2010) |
| "We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months." | 7.76 | Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrlíková, I, 2010) |
| "We review our experience with high-dose intravenous levetiracetam (IV-LEV) for acute seizure exacerbations in nine children with medically intractable epilepsy." | 7.76 | High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. ( Depositario-Cabacar, DT; Peters, JM; Pong, AW; Riviello, JJ; Rotenberg, A; Roth, J; Takeoka, M, 2010) |
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 7.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 7.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| "In this study, patients with glioma treated with levetiracetam and phenytoin had similar seizure control." | 7.76 | Seizures in patients with glioma treated with phenytoin and levetiracetam. ( Anderson, SK; Lachance, DH; Merrell, RT; Meyer, FB, 2010) |
| "Levetiracetam may be effective in children with acute seizures or status epilepticus." | 7.76 | Intravenous levetiracetam in the management of acute seizures in children. ( Huff, AD; Knupp, KG; Reiter, PD; Valuck, RJ, 2010) |
| "We describe two patients with epilepsy who presented with nonepileptic seizures (NES) when started on levetiracetam (LEV), which disappeared or significantly decreased when LEV was discontinued." | 7.76 | Nonepileptic seizures under levetiracetam therapy. ( Arzy, S; Genoud, D; Ghika, J; Groppa, S; Ignatenco, A; Kaplan, PW; Seeck, M, 2010) |
| "This case is the first report of a patient who had phenobarbital (PB) withdrawal seizures after having been seizure-free for 3 years following temporal lobe surgery." | 7.75 | Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. ( Bidlack, JM; Morris, HH, 2009) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 7.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "A 17-year-old girl who had started on levetiracetam because of new onset partial complex seizures developed acute renal failure and biopsy-confirmed interstitial nephritis 10 days after starting the drug." | 7.75 | Levetiracetam induced interstitial nephritis and renal failure. ( Hurwitz, KA; Ingulli, EG; Krous, HF, 2009) |
| " Levetiracetam (LEV) is a new antiepileptic agent with broad-spectrum effects on seizures and animal models of epilepsy." | 7.74 | Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. ( Aguiar, LM; Almeida, JP; Fonseca, FN; Fonteles, MM; Freitas, RM; Júnior, HV; Nascimento, VS; Oliveira, AA; Sousa, FC; Viana, GS, 2007) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 7.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| "Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy." | 7.74 | Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up. ( Myrianthopoulou, P; Papacostas, SS; Papathanasiou, ES; Stylianidou, G, 2007) |
| "Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study." | 7.74 | Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. ( Belcastro, V; Calabresi, P; Costa, C; Galletti, F; Parnetti, L; Pisani, F, 2007) |
| "Levetiracetam (LEV) is a new antiepileptic drug effective as adjunctive therapy for partial seizures." | 7.73 | Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement. ( Aguiar, LM; Fonteles, MM; Freitas, RM; Nascimento, VS; Nogueira, CR; Oliveira, AA; Sousa, FC; Viana, GS, 2005) |
| "Effects of NEF on fully amygdala-kindled seizures and development of amygdala-kindled seizures were investigated in rats and compared with those of levetiracetam (LEV), a pyrrolidone-type antiepileptic drug (AED)." | 7.73 | Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. ( Kasai, Y; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A; Yamauchi, T; Yamazaki, O, 2005) |
| " We report a case of a patient with refractory epilepsy with daily seizures who initially responded to levetiracetam daily therapy, but then returned to baseline seizure frequency." | 7.73 | Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. ( French, JA; Friedman, D, 2006) |
| "The protective and adverse effect potentials of levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide) in rodent models of seizures and epilepsy were compared with the profile of several currently prescribed and newly developed antiepileptic drugs." | 7.70 | Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. ( Gobert, J; Klitgaard, H; Matagne, A; Wülfert, E, 1998) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 6.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 6.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 6.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| "At present, neonatal seizures are usually treated with Phenobarbital (PB) despite the limited efficacy and the potential risk this treatment holds for the developing brain." | 6.75 | Levetiracetam in the treatment of neonatal seizures: a pilot study. ( Bast, T; Bussmann, C; Ebinger, F; Fürwentsches, A; Philippi, H; Pöschl, J; Ramantani, G; Rating, D; Schubert, S, 2010) |
| "Seizure activity following spontaneous intracerebral hemorrhage (sICH) can worsen patients' comorbidity." | 6.72 | Phenytoin prophylaxis and functional outcomes following spontaneous intracerebral hemorrhage: A systematic review and meta-analysis. ( Bzhilyanskaya, V; Fairchild, M; Lurie, T; Pourmand, A; Powell, E; Rashid, A; Rehan, MA; Tran, QK, 2021) |
| "Treatment with levetiracetam is efficacious, and levetiracetam-treated patients require significantly lower doses of immunosuppressant medications to achieve an equivalent antirejection effect." | 6.71 | Levetiracetam for seizures after liver transplantation. ( Bergethon, PR; Freeman, R; Glass, GA; Mithoefer, A; Stankiewicz, J, 2005) |
| "Levetiracetam (LEV) is a newer AED not approved for neonates." | 6.58 | A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures. ( Lancaster, S; Manganas, LN; McHugh, DC, 2018) |
| "Many cases were reported on neonatal seizures control in using LEV in certain clinical conditions." | 6.53 | The treatment of neonatal seizures: focus on Levetiracetam. ( Loiacono, G; Masci, M; Verrotti, A; Zaccara, G, 2016) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 6.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Characteristics of ideal seizure prophylaxis include lack of overlapping toxicity with the conditioning regimen, lack of interference with engraftment of donor cells, and minimal potential for pharmacokinetic drug interactions." | 6.44 | Optimal prevention of seizures induced by high-dose busulfan. ( Anderson, GD; Bubalo, JS; Eberly, AL; McCune, JS, 2008) |
| " In the second stage, the dose-response relationship in improving patients was determined by fitting the data to an E(max) model including a placebo effect." | 6.44 | Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. ( Snoeck, E; Stockis, A, 2007) |
| "Levetiracetam has specific characteristics that make it an optimal choice for many patient populations." | 6.42 | Role of levetiracetam in the treatment of epilepsy. ( Brodie, MJ; French, JA, 2003) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 5.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "In this study, we evaluated the dose-response efficacy of levetiracetam (12." | 5.46 | Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury. ( Cao, Y; Liao, Z; Lu, XM; Mountney, A; Shear, DA; Tortella, FC, 2017) |
| "We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis." | 5.46 | Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. ( Bongiovanni, LG; Casari, R; Faccini, M; Federico, A; Franchini, E; Lugoboni, F; Morbioli, L; Tamburin, S, 2017) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 5.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| "Antiseizure/anticonvulsant drugs and seizures in medial temporal lobe structures may cause gonadal dysfunction, including infertility, decreased libido, and potency." | 5.46 | Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats. ( Cincioğlu-Palabiyik, M; Ertoy-Baydar, D; Karahan, H; Kelicen-Uğur, P; Sara, Y; Üner, M, 2017) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 5.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 5.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 5.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 5.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 5.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "Levetiracetam (LEV) is a unique, effective, relatively safe antiepileptic drug that preferentially interacts with synaptic vesicle protein 2A (SV2A)." | 5.42 | Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats. ( Abdel-Wahab, BA; Habeeb, SM; Khateeb, MM; Shaikh, IA, 2015) |
| " The dosage of immunosuppressants did not change before and after levetiracetam treatment, and there were no changes in hematological and biochemical data before and after treatment." | 5.42 | Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation. ( Chen, CL; Chen, NC; Chuang, YC; Lin, CH; Lin, TK; Tsai, MH, 2015) |
| "Neonatal seizures are often refractory to treatment with initial antiseizure medications." | 5.40 | Levetiracetam-induced anaphylaxis in a neonate. ( Ariguloglu, EA; Koklu, E; Koklu, S, 2014) |
| "This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid after a craniotomy for supratentorial brain tumors." | 5.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 5.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "No more seizures occurred in patients receiving 1-3 g LEV preoperatively." | 5.37 | Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. ( Donat, M; Oberndorfer, S; Roessler, K; Zachenhofer, I, 2011) |
| " No severe adverse effects were observed." | 5.37 | Levetiracetam: safety and efficacy in neonatal seizures. ( Dinger, J; Ikonomidou, C; Ramantani, G; Rating, D; Walter, B, 2011) |
| "Levetiracetam was considered effective if administration was associated with a greater than 50% seizure reduction within 24 hours." | 5.37 | Levetiracetam for treatment of neonatal seizures. ( Abend, NS; Clancy, RR; Dlugos, DJ; Gutierrez-Colina, AM; Monk, HM, 2011) |
| " In Group B, LEV was given at 420 mg/ml for the first 2 weeks followed by doubling the dosage (840 mg/ml) in the following 2 weeks." | 5.37 | Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats. ( Arita, K; Hanaya, R; Kumafuji, K; Kurisu, K; Sasa, M; Serikawa, T; Sugata, S; Tokudome, M, 2011) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| " Maintenance dosing of Phenobarbital was initiated and no further seizures were noted." | 5.36 | Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. ( Brannon Morris, E; Ledet, DS; Rubnitz, JE; Wheless, JW, 2010) |
| "Levetiracetam therapy was effective in 58." | 5.36 | Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. ( Cai, F; Cao, J; Li, S; Xiao, N, 2010) |
| "The mean monthly seizure frequency for all types of seizures during the baseline period was 21." | 5.36 | Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. ( Balestri, M; Cilio, MR; Cusmai, R; D'Orsi, G; Fusco, L; Margiotta, ML; Nardello, R; Patanè, S; Russo, S; Specchio, LM; Specchio, N; Striano, P; Striano, S; Vigevano, F, 2010) |
| "Levetiracetam treatment for 25 days, initiated 24 hours after induction of kainate-induced SE, significantly decreased the mean duration of spontaneous EEG seizures 58 days later." | 5.36 | Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. ( Kato, N; Kudo, K; Maru, E; Shibasaki, T; Sugaya, Y, 2010) |
| "Patients ≥ 16 years with partial-onset seizures (had received levetiracetam oral solution for ≥ 28 days) completed a study questionnaire assessing overall acceptability of levetiracetam oral solution, specific organoleptic characteristics (taste, taste intensity, aftertaste), ease of use and convenience." | 5.36 | Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study. ( Matías-Guíu, J; Mauri, JA; Molins, A; Villar, E, 2010) |
| "Children with brain tumors and other cancers can suffer from seizures." | 5.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "Levetiracetam has been a commonly prescribed oral anticonvulsant for the use of adjunctive therapy for partial seizures in adults with favorable tolerability, and it has been recently approved for children older than age 4 years." | 5.34 | Levetiracetam for the treatment of neonatal seizures. ( Rotenberg, JS; Shoemaker, MT, 2007) |
| "Levetiracetam was generally well tolerated, and adverse events were relatively uncommon in patients who responded to treatment." | 5.33 | Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. ( Chuck, G; Collins, JJ; Franz, DN; Leonard, JM; Tudor, C, 2006) |
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 5.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 5.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "To evaluate the efficacy of Levetiracetam in the management of neonatal seizures." | 5.22 | Efficacy of Levetiracetam in neonatal seizures: a systematic review. ( Hussain, AM; Sharma, D; Sharma, SS, 2022) |
| "This was an open-label study (N01281 [NCT00419393]) assessing the long-term safety of extended-release levetiracetam (LEV XR) in patients with partial-onset seizures (POS); the study was a follow-up to a double-blind, randomized, historical controlled, multicenter, conversion to monotherapy study (N01280 [NCT00419094])." | 5.22 | Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study. ( Ceja, H; Chung, S; Gawłowicz, J; Lu, S; McShea, C; Schiemann, J, 2016) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in the management of seizures in neonates." | 5.22 | Efficacy and safety of levetiracetam in the management of seizures in neonates. ( Asadi, F; Moradian, M; Moradian, N; Sedighi, M; Vakiliamini, M, 2016) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 5.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| "To evaluate the efficacy of levetiracetam (LEV) and the usefulness of measurement of its blood levels during the follow-up of patients with focal seizures." | 5.20 | The efficacy of levetiracetam for focal seizures and its blood levels in children. ( Ishii, M; Iwasaki, T; Nonoda, Y; Toki, T, 2015) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 5.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "Following the first period of the multicenter, open-label, single-armed N01223 trial, the second period of the N01223 trial was conducted to evaluate long-term safety, along with the efficacy of adjunctive levetiracetam treatment (individualized dose range, 20-60 mg/kg/day or 1,000-3,000 mg/day) in Japanese pediatric patients with uncontrolled partial-onset seizures (POS)." | 5.20 | [Effects of Long-Term Treatment with Levetiracetam as an Adjunctive Therapy in Japanese Children with Uncontrolled Partial-Onset Seizures: A Multicenter, Open-Label Study]. ( Nakamura, H; Osawa, M; Suzuki, A; Yokoyama, T; Yoshida, K, 2015) |
| "Levetiracetam is effective in individuals with electrical status epilepticus during sleep with tolerable side effects." | 5.19 | Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. ( Cai, FC; Chen, X; Chen, XQ; Gao, L; Huang, SP; Pang, BD; Yang, ZX; Zhang, WN; Zhao, M; Zou, LP, 2014) |
| "A multicenter, open-label, single-armed study (N01223) was conducted to evaluate efficacy and safety of levetiracetam (LEV) as an add-on therapy in Japanese pediatric patients with uncontrolled partial-onset seizures (POS)." | 5.17 | [Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation]. ( Nakamura, H; Osawa, M; Suzuki, A; Yokoyama, T; Yoshida, K, 2013) |
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 5.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 5.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 5.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| " The safety of intravenous levetiracetam has been established in prospective studies of adult epilepsy and healthy participants." | 5.14 | Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. ( Clarke, D; Durmeier, M; Ellis, M; Hovinga, CA; McGregor, A; Perkins, F; Wheless, JW, 2009) |
| "In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage (NCT00618436) patients received IV load with either LEV or fosphenytoin followed by standard IV doses of LEV or PHT." | 5.14 | Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. ( Lindsell, CJ; Sangha, KS; Shutter, LA; Szaflarski, JP, 2010) |
| "We searched key databases using combinations of the following terms: "levetiracetam," "prophylaxis," "ICH," "intracerebral hemorrhage," "intraparenchymal hemorrhage." | 5.12 | A Systematic Review and Meta-Analysis of Antiepileptic Prophylaxis in Spontaneous Intracerebral Hemorrhage. ( Church, EW; Cockroft, KM; Gigliotti, MJ; Simon, SD; Wilkinson, DA, 2021) |
| "Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy." | 5.12 | [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers]. ( Auriel, E; Blatt, I; Chistik, V; Margolin, N; Neufeld, M, 2007) |
| "To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy." | 5.10 | Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. ( Ben-Menachem, E; Edrich, P; Sander, JW; Schmidt, B; Van Vleymen, B, 2003) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 5.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "To report the results of a combined case series analysis of subcutaneous levetiracetam (Keppra) for the management of seizures in palliative care patients." | 4.98 | Subcutaneous levetiracetam for the management of seizures at the end of life. ( Bradley, V; Bush, O; Curtin, J; Hedges, V; Naessens, K; Presswood, M; Sutherland, AE, 2018) |
| " On the basis of currently available Level III evidence, patients treated with either levetiracetam or phenytoin have similar incidences of early seizures after TBI." | 4.93 | Should Levetiracetam or Phenytoin Be Used for Posttraumatic Seizure Prophylaxis? A Systematic Review of the Literature and Meta-analysis. ( Barker, F; Evans, LT; Fierst, TM; Hoes, K; Hymel, C; Khan, NR; Klimo, P; Mayer, R; VanLandingham, MA, 2016) |
| "Clinically significant side effects of the new anticonvulsants, such as metabolic acidosis from topiramate, autoimmune reactions from lamotrigine, hyponatremia from oxcarbazepine, or psychosis from levitiracetam can cause serious morbidity and mortality if unrecognized." | 4.86 | Emergent complications of the newer anticonvulsants. ( Dang, CV; Nelson, L; Wade, JF; Wasserberger, J, 2010) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 4.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "Levetiracetam is a novel antiepileptic drug (AED) with proven efficacy against partial seizures, but there is limited information about its effectiveness against generalized seizures." | 4.82 | Levetiracetam: preliminary efficacy in generalized seizures. ( Hirsch, E; Kasteleijn-Nolst Trenité, DG, 2003) |
| " Levetiracetam is one of the new generation of AEDs licensed as an add-on therapy for the treatment of patients with partial-onset seizures." | 4.82 | Safety profile of levetiracetam. ( Arroyo, S; Crawford, P, 2003) |
| "Levetiracetam, the S-enantiomer of alpha-ethyl-2-oxo-1-pyrollidine acetamide, is approved for use as adjunctive therapy in adult patients with partial onset seizures." | 4.80 | Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. ( Dooley, M; Plosker, GL, 2000) |
| "In conclusion, the results of this study demonstrate no statistically significant difference in the cumulative incidence of early posttraumatic seizures within 7 days of TBI between three different levetiracetam dosing strategies." | 4.31 | Evaluation of Levetiracetam Dosing Strategies for Seizure Prophylaxis Following Traumatic Brain Injury. ( Kaleem, S; Komisarow, J; Kram, B; Lee, HJ; Ohman, K; Schultheis, J; Sigmon, J; Vatsaas, C; Yang, Z, 2023) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 4.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| "Subcutaneous levetiracetam was well tolerated and effective in controlling seizures in palliative care when oral administration or intravenous access was not an option." | 4.31 | Experience of Subcutaneous Levetiracetam in Palliative Care. ( Diaz-Forero, AF; Estrada, J; Gaviria-Carrillo, M; Mora-Muñoz, L; Rodríguez, JH; Torres-Ballesteros, V; Vargas-Osorio, J; Vélez Van Meerbeke, A, 2023) |
| "Patients may experience a reduced incidence of clinical and electroencephalographic seizures with levetiracetam dosing >1000-mg TDD." | 4.31 | Levetiracetam dosing for seizure prophylaxis in neurocritical care patients. ( Ansari, S; Davis, GE; Findlay, MC; Hawryluk, GWJ; Hedges, A; Menacho, ST; Wolfe, BM, 2023) |
| "Nonadherence to levetiracetam (LEV) use can result in subtherapeutic concentrations and increase the risk of the occurrence of seizures." | 4.12 | Effect of Nonadherence on Levetiracetam Pharmacokinetics and Remedial Dose Recommendations Using Monte Carlo Simulations. ( Methaneethorn, J, 2022) |
| "We aimed to evaluate the blood concentration of levetiracetam (LEV), as a second-line drug, in patients with status epilepticus (SE) in an emergency clinical setting." | 4.02 | Blood concentration of levetiracetam after bolus administration in patients with status epilepticus. ( Hotta, M; Kaneko, J; Kondo, M; Kubota, M; Kuno, M; Nagano, M; Sugaya, K; Tagami, T; Takase, H; Unemoto, K, 2021) |
| "A retrospective chart review over a 7-year period was conducted at the American University of Beirut to identify neonates with electrographically proven seizures treated with levetiracetam." | 3.96 | High-Dose Levetiracetam for Neonatal Seizures: A Retrospective Review. ( Darwich, M; Hanneyan, S; Hnaini, M; Jaafar, F; Koleilat, N; Maalouf, FI; Mikati, IE; Nabout, R; Obeid, M; Rahal, S; Shbarou, RM, 2020) |
| " Repeat video-EEG 2 months after initiation of levetiracetam treatment disclosed a >95% decrease in frequency of myoclonic seizures, and absence seizures were no longer evident." | 3.88 | Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs. ( Cortez, MA; Fischer, A; James, FMK; Kluger, G; Lohi, H; Neßler, JN; Tipold, A; Wielaender, F, 2018) |
| "This study developed a population pharmacokinetic (PK) model of levetiracetam (LEV) for treating neonatal seizures (NS) and determined the influence of clinically relevant covariates to explain the interindividual variability and residual error." | 3.88 | Population pharmacokinetics of levetiracetam in neonates with seizures. ( Gómez-Ruiz, LM; Lima-Rogel, V; López-López, EJ; Medellín-Garibay, SE; Milán-Segovia, RC; Romano-Moreno, S; Romero-Méndez, C, 2018) |
| "This study was conducted to develop a population pharmacokinetic (PK) model of levetiracetam in Korean neonates with seizures." | 3.88 | Population pharmacokinetic model of levetiracetam in Korean neonates with seizures . ( Jung, YS; Lee, SM; Park, K; Park, MS, 2018) |
| "We enrolled patients with epilepsy who were treated with branded levetiracetam for at least 6 months of sustained use." | 3.88 | Brand name to generic substitution of levetiracetam in patients with epilepsy. ( Dae, SJ; Gha-Hyun, L, 2018) |
| "The aim of this study was to evaluate the risk factors, clinical implications, and prognosis of new-onset seizures that occurred after pediatric liver transplantation, and to assess the efficacy of levetiracetam treatment." | 3.85 | Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam. ( Arslan, M; Güngör, S; Kılıç, B; Selimoğlu, MA; Yılmaz, S, 2017) |
| "Levetiracetam is used in the treatment of some forms of epilepsy." | 3.85 | Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. ( Company-Albir, MJ; Marqués-Miñana, MR; Poveda, JL; Ruíz-Ramos, J; Solana Altabella, A; Vicent, C, 2017) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 3.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 3.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "CYT-evoked alterations in the protection provided by some antiepileptic drugs against seizures can be of serious concern for epileptic smokers, who might demonstrate therapeutic failure to lacosamide, levetiracetam, and pregabalin, resulting in possible breakthrough seizure attacks." | 3.85 | Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. ( Florek-Łuszczki, M; Kondrat-Wróbel, MW; Tutka, P; Zaluska, K; Żółkowska, D; Łuszczki, JJ, 2017) |
| "Infants with seizures were overwhelmingly exposed to phenobarbital, despite a significant increase in levetiracetam exposure." | 3.85 | Changing antiepileptic drug use for seizures in US neonatal intensive care units from 2005 to 2014. ( Ahmad, KA; Ahmad, SF; Bennett, MM; Clark, RH; Desai, SJ; Ng, YT; Tolia, VN, 2017) |
| "The objective of this study was to determine the efficacy and safety of levetiracetam in treatment of neonatal seizures due to hypoxic ischemic encephalopathy." | 3.85 | Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy. ( Schapiro, M; Thomas, C; Venkatesan, C; Young, S, 2017) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 3.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "Levetiracetam is an antiepileptic drug used for the treatment of generalised or partial seizures, either alone or in a combination therapy." | 3.85 | Levetiracetam Induced Increase in Creatine Phosphokinase Levels. ( Ain, Q-; Khan, MA; Khan, SA; Memon, MH; Shahbaz, N; Younus, SM, 2017) |
| "The primary objective of this study was to determine the effectiveness of a lower dose of levetiracetam (500 mg every 12 hours) to prevent early seizures after traumatic brain injury (TBI)." | 3.83 | Low-dose levetiracetam for seizure prophylaxis after traumatic brain injury. ( Kurita, A; Patanwala, AE; Truong, E, 2016) |
| "To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury." | 3.83 | Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis. ( Chung, MG; O'Brien, NF, 2016) |
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 3.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "Levetiracetam, a second-generation antiepileptic drug, is frequently used for managing partial-onset seizures." | 3.83 | Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. ( Hashi, S; Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Tsuda, M; Yano, I; Yonezawa, A, 2016) |
| "This noninterventional, observational, postauthorization safety study (SP0942, NCT00771927) evaluated the incidence of predefined cardiovascular- (CV) and psychiatric-related treatment-emergent adverse events (TEAEs), in patients with epilepsy and uncontrolled partial-onset seizures, when initiating adjunctive therapy with lacosamide or another approved antiepileptic drug (AED) according to standard medical practice." | 3.83 | A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. ( Brunnert, M; De Backer, M; Doty, P; Eckhardt, K; Schulze-Bonhage, A; Steinhoff, BJ, 2016) |
| "In this propensity score-matched cohort analysis, levetiracetam prophylaxis was ineffective in preventing seizures as the rate of seizures was similar whether patients did or did not receive the drug." | 3.83 | Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis. ( Friese, R; Gruessner, A; Joseph, B; Khalil, M; Kulvatunyou, N; Latifi, R; O'Keeffe, T; Rhee, P; Wynne, J; Zangbar, B, 2016) |
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 3.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 3.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "Intravenous levetiracetam is an option for treatment of status epilepticus (SE) and acute repetitive seizures (ARS)." | 3.81 | Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A; Wiwattanadittakul, N, 2015) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 3.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "TO determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy." | 3.81 | [Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models]. ( Chen, T; Li, MQ; Liu, L; Zhang, WW, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 3.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "To assess interactions between retigabine and levetiracetam in suppressing maximal electroshock-induced tonic seizures in Albino Swiss mice, type II isobolographic analysis was used." | 3.81 | Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis. ( Czuczwar, SJ; Florek-Luszczki, M; Luszczki, JJ; Miziak, B; Zagaja, M, 2015) |
| " Diazepam produced a dose-dependent protection against 6-Hz seizures in control and pilocarpine mice, both at 2 weeks and 8 weeks after SE, but with a more pronounced increase in potency in post-SE animals at 2 weeks." | 3.81 | Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. ( Kaminski, RM; Leclercq, K, 2015) |
| " The treatment was given 1 and 5 min after exposure to a supralethal dose of nerve agents, and the results showed that the triple regimen successfully prevented or terminated seizures and preserved the lives of rats exposed to 5×LD50 of soman, sarin, cyclosarin, or VX, but solely 3×LD50 of tabun was managed by this regimen." | 3.81 | Supralethal poisoning by any of the classical nerve agents is effectively counteracted by procyclidine regimens in rats. ( Aas, P; Enger, S; Mariussen, E; Myhrer, T, 2015) |
| " However, EEG was abnormal and the boy was diagnosed as a case of Landau-Kleffner syndrome (LKS) and treated with sodium valproate, levetiracetam and steroids." | 3.81 | Landau-Kleffner syndrome: an uncommon dealt with case in Southeast Asia. ( Afsar, S; Dixit, NS; Motwani, N; Sharma, N, 2015) |
| "Levetiracetam is a reasonable alternative to (fos)phenytoin for prophylaxis of early posthemorrhagic seizures." | 3.80 | Levetiracetam versus (fos)phenytoin for seizure prophylaxis in pediatric patients with intracranial hemorrhage. ( Bansal, S; Blalock, D; Carpenter, JL; Dean, NP; Kebede, T, 2014) |
| "Levetiracetam generally appears to have a similar efficacy to phenytoin in preventing clinical and/or electrographic seizures following acute/subacute SDH diagnosis, though patients with midline shift >0 mm may have associated with a higher risk of electrographic seizures on levetiracetam compared with patients on phenytoin." | 3.80 | Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis. ( Chou, SH; Du, R; Lee, JW; Radic, JA, 2014) |
| " Oral treatment with levetiracetam resolved his seizures." | 3.80 | Generalised electrographic seizures presenting as perioral myoclonia. ( Dearborn, JL; Kaplan, PW, 2014) |
| "Levetiracetam is a frequently used drug in the therapy of partial onset, myoclonic and generalized tonic-clonic seizures." | 3.80 | A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. ( Bahte, SK; Hiss, M; Kielstein, JT; Lichtinghagen, R, 2014) |
| "Levetiracetam (LEV), used for both partial and generalized seizures, is a frequently preferred antiepileptic because of its few side effects." | 3.80 | Hypokalemia and hypomagnesaemia related to levetiracetam use. ( Aksoy, D; Cevik, B; Kurt, S; Pekdas, E; Solmaz, V, 2014) |
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 3.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| "Levetiracetam is an antiepileptic medication that has been reported to be both well-tolerated and effective in treating generalized tonic-clonic, myoclonic, and partial-onset seizures." | 3.80 | Levetiracetam as a possible contributor to acute kidney injury. ( Hohler, AD; Montouris, GD; Spengler, DC, 2014) |
| "To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epileptic seizures in pregnant women." | 3.80 | The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. ( Eadie, M; Graham, J; Lander, C; O'Brien, T; Vajda, FJ, 2014) |
| " Secondary end points were presence of early seizures (0 to 7 days post-TBI) or late seizures (8 days post-TBI to phone interview), use of anticonvulsant medication when interviewed, medication-related hospital complications, and a summary of phenytoin (PHT) and LEV dosing regimens." | 3.80 | Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury. ( Gabriel, WM; Rowe, AS, 2014) |
| "Levetiracetam has been proven to be effective in both partial and generalized seizures in children." | 3.80 | Efficacy and safety of IV levetiracetam in children with acute repetitive seizures. ( Ağın, H; Akarcan, SE; Celik, T; Güzel, O; İşgüder, R; Ünalp, A; Yılmaz, Ü, 2014) |
| "Levetiracetam (LEV) and tiagabine (TGB) are utilized for the treatment of seizures, including neonatal seizures." | 3.80 | Profile of anticonvulsant action of levetiracetam, tiagabine and phenobarbital against seizures evoked by DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) in neonatal rats. ( Beck, VC; Forcelli, PA; Gutherz, SB; Kulick, CV; Medvedeva, N; Soper, C, 2014) |
| " In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures." | 3.80 | Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. ( Albertini, G; De Sarro, G; Gallelli, L; Gratteri, S; Iemolo, F; Manes, MT; Mercuri, NB; Quirino, G; Sanzaro, E; Scaglione, F; Siniscalchi, A, 2014) |
| "To explore the effects of levetiracetam (LEV) on the changes of bone mineral density (BMD) and bone metabolism in the treatment of middle-aged and elderly patients with generalized tonic-clonic seizures." | 3.80 | [Clinical efficacy of levetiracetam on bone mineral density and bone metabolism in middle-aged and elderly patients with generalized tonic-clonic seizures]. ( Chen, X; Wang, H, 2014) |
| "Emotional apneas (EA) are non-epileptic paroxysmal events affecting 5% of healthy children." | 3.80 | [Pathophysiology, differential diagnosis and treatment of severe emotional apnea: based on report case]. ( Esquivel P, N; Hernández CH, M; López E, M, 2014) |
| "In this case series we report on eight neonates with refractory seizures who received intravenous levetiracetam when seizures did not respond to two or more conventional anticonvulsants." | 3.79 | Intravenous levetiracetam for treatment of neonatal seizures. ( Kohan, R; Nagarajan, L; Rakshasbhuvankar, A; Rao, S; Simmer, K, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Twelve patients received a levetiracetam load of 25 to 50 mg/kg for neonatal seizures." | 3.79 | Role of intravenous levetiracetam for acute seizure management in preterm neonates. ( Cipriani, C; Crisp, E; Khan, O; Kirmani, B; Wright, C, 2013) |
| " The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20 min after onset of seizures elicited by soman." | 3.79 | Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats. ( Aas, P; Enger, S; Mariussen, E; Myhrer, T, 2013) |
| "Compare neurodevelopment after levetiracetam (LEV) and phenobarbital (PB) for neonatal seizures." | 3.79 | Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. ( Maitre, NL; Slaughter, JC; Smolinsky, C; Stark, AR, 2013) |
| "Recent data indicate comparable efficacy and safety for levetiracetam (LEV) when compared with phenytoin (PHT) for prophylaxis of early seizures after traumatic brain injury." | 3.78 | A cost-minimization analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury. ( Barnett, CC; Beauchamp, K; Bensard, DD; Biffl, WL; Burlew, CC; Johnson, JL; Moore, EE; Pieracci, FM; Stoval, RT; Tebockhorst, S, 2012) |
| "Levetiracetam (LEV) is increasingly used in the treatment of neonatal seizures." | 3.78 | A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ( Capparelli, EV; Farrell, MJ; Haas, RH; Mower, A; Sharpe, CM; Soldin, SJ, 2012) |
| "To report the effectiveness and safety of intravenous levetiracetam in the treatment of children with acute repeated seizures, and status epilepticus in a children's hospital." | 3.78 | Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. ( Appleton, R; Kneen, R; Kumar, R; McTague, A; Spinty, S, 2012) |
| "Taking into account the various risk factors for seizures, the early reduction of concomitant AEDs was not associated with worse seizure rates during follow-up in real-life users of levetiracetam." | 3.78 | Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users. ( Droz-Perroteau, C; Dureau-Pournin, C; Fourrier-Réglat, A; Jové, J; Lassalle, R; Lavernhe, G; Marchal, C; Moore, N; Robinson, P; Vespignani, H, 2012) |
| "Despite similarities in hemorrhage type and severity at onset, patients receiving levetiracetam had better cognition at discharge and fewer seizures than patients receiving phenytoin." | 3.77 | Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage. ( Ehtisham, A; Heinrichs, RJ; Janzen, JM; Taylor, S, 2011) |
| "To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting." | 3.77 | Clinical experience with generic levetiracetam in people with epilepsy. ( Chaluvadi, S; Chiang, S; Friedman, DE; Goldsmith, CE; Tran, L, 2011) |
| "We report on 4 patients having an increased incidence of seizures when treatment was switched from brand name levetiracetam (Keppra) to generic levetiracetam formulations." | 3.77 | Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. ( Fitzgerald, CL; Jacobson, MP, 2011) |
| "Results from studies based on microinfusions into seizure controlling brain sites (area tempestas, medial septum, perirhinal cortex, posterior piriform cortex) have shown that procyclidine, muscimol, caramiphen, and NBQX, but not ketamine, exert anticonvulsant effects against soman-induced seizures." | 3.77 | Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats. ( Aas, P; Enger, S; Jonassen, M; Myhrer, T, 2011) |
| "The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures." | 3.77 | Pharmacokinetics of levetiracetam in neonates with seizures. ( Balmakund, T; Meinzen-Derr, J; Merhar, SL; Schibler, KR; Sherwin, CM; Shi, J; Vinks, AA, 2011) |
| " However, zonisamide- and carbamazepine-treated animals had IT values similar to those of controls, but only zonisamide significantly decreased absence seizure development." | 3.77 | Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. ( Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011) |
| "Levetiracetam (LEV) inhibits partial refractory epilepsy in human, and both convulsive and absence-like seizures in the spontaneously epileptic rat (SER)." | 3.77 | Modulation of abnormal synaptic transmission in hippocampal CA3 neurons of spontaneously epileptic rats (SERs) by levetiracetam. ( Arita, K; Hanaya, R; Kiura, Y; Kurisu, K; Sasa, M; Serikawa, T, 2011) |
| "In this retrospective study of institutionalized patients with mental retardation, we present the efficacy and safety of sequential treatment with intrarectal diazepam (IRD) gel (Diastat) and intravenous levetiracetam (IVL) in comparison with either treatment alone for acute repetitive or prolonged seizures (ARPS)." | 3.76 | Sequential intrarectal diazepam and intravenous levetiracetam in treating acute repetitive and prolonged seizures. ( Milteer, WE; Modur, PN; Zhang, S, 2010) |
| "We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months." | 3.76 | Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrlíková, I, 2010) |
| " Levetiracetam, 40 mg/kg, suppressed the development of kindling measured as severity of seizures and AD duration." | 3.76 | Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. ( Christensen, KV; Egebjerg, J; Kallunki, P; Leffers, H; Sánchez, C; Watson, WP, 2010) |
| "We review our experience with high-dose intravenous levetiracetam (IV-LEV) for acute seizure exacerbations in nine children with medically intractable epilepsy." | 3.76 | High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. ( Depositario-Cabacar, DT; Peters, JM; Pong, AW; Riviello, JJ; Rotenberg, A; Roth, J; Takeoka, M, 2010) |
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 3.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 3.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| "We present a patient with cryptogenic focal epilepsy and another with Dravet syndrome, who experienced seizure aggravation and negative myoclonus, associated with continuous spikes and waves during slow sleep, induced by levetiracetam." | 3.76 | Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies. ( Caraballo, RH; Cersósimo, R; De los Santos, C, 2010) |
| "In this study, patients with glioma treated with levetiracetam and phenytoin had similar seizure control." | 3.76 | Seizures in patients with glioma treated with phenytoin and levetiracetam. ( Anderson, SK; Lachance, DH; Merrell, RT; Meyer, FB, 2010) |
| "Levetiracetam may be effective in children with acute seizures or status epilepticus." | 3.76 | Intravenous levetiracetam in the management of acute seizures in children. ( Huff, AD; Knupp, KG; Reiter, PD; Valuck, RJ, 2010) |
| "We describe two patients with epilepsy who presented with nonepileptic seizures (NES) when started on levetiracetam (LEV), which disappeared or significantly decreased when LEV was discontinued." | 3.76 | Nonepileptic seizures under levetiracetam therapy. ( Arzy, S; Genoud, D; Ghika, J; Groppa, S; Ignatenco, A; Kaplan, PW; Seeck, M, 2010) |
| "This case is the first report of a patient who had phenobarbital (PB) withdrawal seizures after having been seizure-free for 3 years following temporal lobe surgery." | 3.75 | Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. ( Bidlack, JM; Morris, HH, 2009) |
| "To characterize the interactions between levetiracetam and the antiepileptic drugs gabapentin, tiagabine, and vigabatrin in suppressing pentylenetetrazole-induced clonic seizures in mice, type II isobolographic analysis was used." | 3.75 | Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. ( Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 3.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "A 17-year-old girl who had started on levetiracetam because of new onset partial complex seizures developed acute renal failure and biopsy-confirmed interstitial nephritis 10 days after starting the drug." | 3.75 | Levetiracetam induced interstitial nephritis and renal failure. ( Hurwitz, KA; Ingulli, EG; Krous, HF, 2009) |
| "This study was designed so as to characterize the interactions between levetiracetam (LEV) and the conventional antiepileptic drugs (AEDs) clonazepam (CZP), ethosuximide (ETS), phenobarbital (PB), and valproate (VPA) in suppressing pentylenetetrazole (PTZ)-induced clonic seizures in mice by use of type II isobolographic analysis." | 3.75 | Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. ( Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2009) |
| "To study the incidence and extent of the occasionally noted hypotension after intravenous (IV) infusions of fosphenytoin (FOS) and levetiracetam (LEV) in patients presenting with acute cerebral symptoms." | 3.75 | Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms. ( Farooq, MU; Kassab, MY; Lobeck, IN; Majid, A; Xie, Y, 2009) |
| "The purpose of the study was to assess changes in cognitive functions and quality of life in patients with epilepsy over one year of treatment with levetiracetam (LEV) as add-on therapy." | 3.74 | Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. ( Escartín, A; García, C; López-Góngora, M; Martínez-Domeño, A, 2008) |
| " Levetiracetam (LEV) is a new antiepileptic agent with broad-spectrum effects on seizures and animal models of epilepsy." | 3.74 | Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. ( Aguiar, LM; Almeida, JP; Fonseca, FN; Fonteles, MM; Freitas, RM; Júnior, HV; Nascimento, VS; Oliveira, AA; Sousa, FC; Viana, GS, 2007) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 3.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| "Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy." | 3.74 | Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up. ( Myrianthopoulou, P; Papacostas, SS; Papathanasiou, ES; Stylianidou, G, 2007) |
| "Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study." | 3.74 | Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. ( Belcastro, V; Calabresi, P; Costa, C; Galletti, F; Parnetti, L; Pisani, F, 2007) |
| "The effects of brivaracetam and levetiracetam on epileptiform activity and seizure expression were examined in rat hippocampal slices, corneally kindled mice, audiogenic seizure-susceptible mice, maximal electroshock and pentylenetetrazol seizures in mice, hippocampal-kindled rats, amygdala-kindled rats and genetic absence epilepsy rats." | 3.74 | Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. ( Kenda, B; Klitgaard, H; Margineanu, DG; Matagne, A; Michel, P, 2008) |
| "NEF inhibited electroshock-induced seizures at nontoxic doses, whereas it had no effect on seizures chemically induced by pentylenetetrazole, bicuculline, picrotoxin, strychnine, or N-methyl-D-aspartate." | 3.73 | Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats. ( Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A, 2005) |
| "Levetiracetam (LEV) is a new antiepileptic drug effective as adjunctive therapy for partial seizures." | 3.73 | Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement. ( Aguiar, LM; Fonteles, MM; Freitas, RM; Nascimento, VS; Nogueira, CR; Oliveira, AA; Sousa, FC; Viana, GS, 2005) |
| "The long-lasting antiseizure effects of levetiracetam (LEV) have been observed in the spontaneously epileptic rat (SER) that expresses both tonic and absence-like seizures." | 3.73 | Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). ( Ishihara, K; Ji-qun, C; Nagayama, T; Sasa, M; Serikawa, T; Yan, HD, 2005) |
| "Effects of NEF on fully amygdala-kindled seizures and development of amygdala-kindled seizures were investigated in rats and compared with those of levetiracetam (LEV), a pyrrolidone-type antiepileptic drug (AED)." | 3.73 | Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. ( Kasai, Y; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A; Yamauchi, T; Yamazaki, O, 2005) |
| "This study assesses the use of the serial day Rapid Kindling with Recurrent Hippocampal Seizures (RKRHS) model in drug testing by investigating the anti-epileptic effect of levetiracetam (LEV), a novel anti-epileptic drug (AED) with a unique preclinical profile." | 3.73 | Rapid kindling in preclinical anti-epileptic drug development: the effect of levetiracetam. ( Boon, P; Claeys, P; De Smedt, T; Dedeurwaerdere, S; Legros, B; Raedt, R; Vonck, K; Wadman, W; Wyckhuys, T, 2005) |
| " We report a case of a patient with refractory epilepsy with daily seizures who initially responded to levetiracetam daily therapy, but then returned to baseline seizure frequency." | 3.73 | Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. ( French, JA; Friedman, D, 2006) |
| "0 mg/kg) as well as increasing the threshold to electrically- and pentylenetetrazole-induced seizures (TID(10)s 7." | 3.73 | In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant. ( Anderson, NJ; Slough, S; Watson, WP, 2006) |
| "The objective of the study was to analyze the short-term efficacy and safety of levetiracetam (LEV) to treat repetitive seizures in hospitalized patients." | 3.73 | Use of levetiracetam in hospitalized patients. ( Amaro, S; Carreño, M; Delgado, R; Donaire, A; Falip, M; Maestro, I; Toledo, M, 2006) |
| "), a structural analogue of piracetam, has recently been approved as an add-on treatment of refractory partial onset seizures in adults." | 3.72 | Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. ( Differding, E; Frycia, AM; Fuks, B; Gillard, MR; Kenda, BM; Klitgaard, HV; Lallemand, BI; Matagne, AC; Michel, P; Moureau, FG; Pasau, PM; Talaga, PE, 2004) |
| "Levetiracetam (LEV) is a new antiepileptic drug with efficacy in partial-onset seizures." | 3.72 | Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. ( Cavitt, J; Privitera, M, 2004) |
| "The protective and adverse effect potentials of levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide) in rodent models of seizures and epilepsy were compared with the profile of several currently prescribed and newly developed antiepileptic drugs." | 3.70 | Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. ( Gobert, J; Klitgaard, H; Matagne, A; Wülfert, E, 1998) |
| "The mean incidence of posttraumatic seizures with AED prophylaxis was 8% for early seizures and 7." | 3.01 | Use of antiepileptic drugs as prophylaxis against posttraumatic seizures in the pediatric population: a systematic review and meta-analysis. ( Al Jayyousi, O; Hazaimeh, E; Ifraitekh, AS; Jbarah, OF; Samara, QA; Sawan, S, 2023) |
| "Postoperative seizures occurred in 17." | 2.84 | Prophylactic Levetiracetam for Seizure Control After Cranioplasty: A Multicenter Prospective Controlled Study. ( Ding, P; Liang, S; Wu, Y; Zhang, J; Zhang, S, 2017) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 2.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| " Treatment-emergent adverse events (TEAEs) were reported by 68." | 2.82 | Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. ( Ben-Menachem, E; Eckhardt, K; Gamage, J; Johnson, ME; Klein, P; Mameniškienė, R; McDonough, B; Quarato, PP; Schiemann, J; Whitesides, J, 2016) |
| "Phenytoin (PHT) is routinely used for seizure prophylaxis in patients with brain tumours during and after craniotomy, despite incomplete evidence." | 2.80 | Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Kuwabara, K; Matsumoto, M; Sakaida, T, 2015) |
| "There was no difference in seizure rate (1." | 2.78 | A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. ( Branco, BC; Demetriades, D; Dubose, J; Gooch, J; Herrold, J; Inaba, K; Menaker, J; Okoye, OT; Scalea, TM, 2013) |
| " This study aims to compare the tolerability, safety, and side effect profiles of levetiracetam (LEV) against the standard agent phenytoin (PHT) when given intravenously and in total regimen for seizure prophylaxis in a neurosurgical setting." | 2.78 | Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. ( Cook, MJ; D'Souza, WJ; Fuller, KL; Murphy, MA; Wang, YY, 2013) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 2.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 2.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| " Prospective, open-label, steady-state pharmacokinetic study." | 2.76 | Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ( Fleck, JD; Jacobi, J; Juenke, JM; Kays, MB; Spencer, DD, 2011) |
| "Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment." | 2.75 | Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. ( Hepler, M; Irwin, D; Jenssen, S; Lippa, CF; Pillai, J; Rosso, A, 2010) |
| "At present, neonatal seizures are usually treated with Phenobarbital (PB) despite the limited efficacy and the potential risk this treatment holds for the developing brain." | 2.75 | Levetiracetam in the treatment of neonatal seizures: a pilot study. ( Bast, T; Bussmann, C; Ebinger, F; Fürwentsches, A; Philippi, H; Pöschl, J; Ramantani, G; Rating, D; Schubert, S, 2010) |
| "The age of seizures onset ranged from 6." | 2.74 | Levetiracetam monotherapy for childhood occipital epilepsy of gastaut. ( Balestri, P; Chiarelli, F; Curatolo, P; Grosso, S; Iannetti, P; Loiacono, G; Mohn, A; Parisi, P; Tozzi, E; Verrotti, A, 2009) |
| "Levetiracetam proved to be an effective and well-tolerated add-on treatment in this group of children with refractory epilepsy." | 2.73 | Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. ( Arts, WF; Augustijn, P; Brouwer, OF; Callenbach, PM; Geerts, AT; Geerts, Y; Gunning, WB; Peeters, EA; Stroink, H; ten Houten, R; Weber, AM, 2008) |
| "Seizure activity following spontaneous intracerebral hemorrhage (sICH) can worsen patients' comorbidity." | 2.72 | Phenytoin prophylaxis and functional outcomes following spontaneous intracerebral hemorrhage: A systematic review and meta-analysis. ( Bzhilyanskaya, V; Fairchild, M; Lurie, T; Pourmand, A; Powell, E; Rashid, A; Rehan, MA; Tran, QK, 2021) |
| "Outcomes were seizures, as defined by the authors, within 14 days of ICH and at the longest point of follow-up." | 2.72 | Preventing seizure occurrence following spontaneous intracerebral haemorrhage: A systematic review and meta-analysis of seizure prophylaxis. ( Afridi, LZ; Ahmad, M; Bzhilyanskaya, V; Menne, A; Palmer, J; Pourmand, A; Raffman, A; Rashid, A; Rehan, MA; Tran, QK, 2021) |
| "Levetiracetam (Keppra) was evaluated in a subset of patients aged >/=65 years (n=78) enrolled in a large (n=1030) open-label, phase IV trial (the KEEPER trial)." | 2.71 | Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. ( Ferrendelli, JA; French, J; Han, J; Herbeuval, A; Leppik, I; Magnus, L; Morrell, MJ, 2003) |
| "Treatment with levetiracetam is efficacious, and levetiracetam-treated patients require significantly lower doses of immunosuppressant medications to achieve an equivalent antirejection effect." | 2.71 | Levetiracetam for seizures after liver transplantation. ( Bergethon, PR; Freeman, R; Glass, GA; Mithoefer, A; Stankiewicz, J, 2005) |
| "Levetiracetam is an attractive choice of antiepileptic medication because of relatively fewer drug interactions and may be administered through the subcutaneous route." | 2.66 | Levetiracetam at the End of Life: A Case Report and Discussion. ( Clark, K; Mohamudally, A, 2020) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period." | 2.66 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2020) |
| "Levetiracetam (LEV) is a newer AED not approved for neonates." | 2.58 | A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures. ( Lancaster, S; Manganas, LN; McHugh, DC, 2018) |
| "Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first month of cranial surgery." | 2.58 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2018) |
| "Levetiracetam is an active, water-soluble S-enantiomer of racemic pyrrolidine acetamide which exerts its antiepileptic action by binding to the synaptic vesicle protein within the brain." | 2.55 | A Review on Pharmacokinetics of Levetiracetam in Neonates. ( Agrawal, A; Banergee, A, 2017) |
| "Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet." | 2.55 | Treatment of epilepsy in patients with Alzheimer's disease. ( Bonuccelli, U; Giorgi, FS; Guida, M; Vergallo, A; Zaccara, G, 2017) |
| "Many cases were reported on neonatal seizures control in using LEV in certain clinical conditions." | 2.53 | The treatment of neonatal seizures: focus on Levetiracetam. ( Loiacono, G; Masci, M; Verrotti, A; Zaccara, G, 2016) |
| "The use of AEDs for purposes other than seizure prophylaxis and their selection based on non-PK properties present a potential paradigm shift in the field of neuro-oncology." | 2.53 | Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. ( Gefroh-Grimes, HA; Gidal, BE, 2016) |
| "A meta-analysis found higher rates of seizure cessation with valproate 75." | 2.53 | Pharmacologic treatment of status epilepticus. ( Brigo, F; Höfler, J; Kalss, G; Leitinger, M; Rohracher, A; Trinka, E, 2016) |
| "Seizures are common complications for patients with brain tumors." | 2.53 | Levetiracetam for seizure prevention in brain tumor patients: a systematic review. ( Nasr, ZG; Paravattil, B; Wilby, KJ, 2016) |
| "This review discusses seizures associated with traumatic brain injury in children, including seizure incidence, relationship to severity of injury, potential detrimental effects of seizures, potential benefits of AED, adverse effects of AED, new developments in preventing epileptogenesis, and suggested recommendations for patient management." | 2.53 | Anti-epileptic drugs in pediatric traumatic brain injury. ( Litofsky, NS; Tanaka, T, 2016) |
| "Levetiracetam (LEV) has been proposed as an alternative to PHT." | 2.53 | The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis. ( Li, J; Qi, L; Shao, WZ; Shen, J; Sun, YZ; Tang, LJ; Xu, JC; Zhai, XF; Zheng, JY, 2016) |
| "Phenytoin has been the only recommended antiepileptic drug (AED) for seizure prophylaxis; however, several shortcomings have affected its use." | 2.53 | Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis. ( Wang, X; Xu, X; Yang, Y; Zheng, F, 2016) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| "Patients with brain tumors remain at risk for infections from the perioperative period through many months after treatment, and steroids may mask signs of infection." | 2.52 | Medical management of patients with brain tumors. ( Pruitt, AA, 2015) |
| "In most cases, either the seizure or the medications used to treat the seizure may contribute to cognitive and psychosocial difficulties of various degrees of severity." | 2.52 | Clinical Management of Seizures in Patients With Low-Grade Glioma. ( Blakeley, J; Piotrowski, AF, 2015) |
| "Occurrence of generalized tonic-clonic seizures (GTCS) is one of the most important risk factors of seizure-related complications and comorbidities in patients with epilepsy." | 2.50 | Pharmacotherapy for tonic-clonic seizures. ( Rheims, S; Ryvlin, P, 2014) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "Levetiracetam has been used in children and infants with good efficacy, an excellent safety profile, and near-ideal pharmacokinetic characteristics." | 2.49 | Newly emerging therapies for neonatal seizures. ( Mangum, B; Pressler, RM, 2013) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| "Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY)." | 2.48 | Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury - a meta analysis. ( Ghauri, AA; Khan, AA; Shamim, MS; Zafar, SN, 2012) |
| "The mainstay of treatment for seizures is medical therapy with antiepileptic drugs." | 2.47 | Antiepileptic drugs for treating seizures in adults with brain tumours. ( Grant, R; Kerrigan, S, 2011) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 2.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Epileptic seizures are a common clinical problem in children with brain tumors." | 2.46 | Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? ( Attinà, G; Battaglia, D; Mastrangelo, S; Riccardi, R; Rizzo, D; Ruggiero, A, 2010) |
| "Characteristics of ideal seizure prophylaxis include lack of overlapping toxicity with the conditioning regimen, lack of interference with engraftment of donor cells, and minimal potential for pharmacokinetic drug interactions." | 2.44 | Optimal prevention of seizures induced by high-dose busulfan. ( Anderson, GD; Bubalo, JS; Eberly, AL; McCune, JS, 2008) |
| " The overall conclusions from 2 recent studies in aneurysmal subarachnoid hemorrhage are that 1) many patients receive AEDs but should not; 2) long-term use is associated with worse outcome; and 3) short-term use is safer." | 2.44 | Antiepileptic drugs in aneurysmal subarachnoid hemorrhage. ( Wijdicks, EF; Zubkov, AY, 2008) |
| "Both seizures and antiepileptic drugs may induce disturbances in hormonal system." | 2.44 | [Endocrine effects of antiepileptic drugs]. ( Budziszewska, B; Lasoń, W; Leśkiewicz, M, 2008) |
| " In the second stage, the dose-response relationship in improving patients was determined by fitting the data to an E(max) model including a placebo effect." | 2.44 | Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. ( Snoeck, E; Stockis, A, 2007) |
| "Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
| "The minimum duration for assessing seizure freedom should be the entire stable dose period in short-term trials and at least six months for long-term follow-up studies." | 2.43 | Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. ( De Rue, K; Edrich, P; Leppik, I; Perucca, E, 2006) |
| "Levetiracetam may allow patients to decrease the number of concomi-tant antiepileptic medications or withdraw to monotherapy." | 2.42 | Long-term experience with levetiracetam. ( Abou-Khalil, B; Lazenby, B, 2003) |
| "Treatment of seizures in pediatric patients is complicated by the fact that the etiology of the disorder and the pharmacokinetics, efficacy, and safety of antiepileptic drugs (AEDs) may differ from that in adults." | 2.42 | Preliminary efficacy of levetiracetam in children. ( Dulac, O; Glauser, TA, 2003) |
| "Most patients with epilepsy are started on one of the classic AEDs and, if it proves ineffective, another drug is tried, usually as monotherapy." | 2.42 | Preliminary efficacy of levetiracetam in monotherapy. ( Ben-Menachem, E, 2003) |
| "Levetiracetam has specific characteristics that make it an optimal choice for many patient populations." | 2.42 | Role of levetiracetam in the treatment of epilepsy. ( Brodie, MJ; French, JA, 2003) |
| "Levetiracetam is a new antiepileptic drug (AED) devoid of anticonvulsant activity in the two classic screening models for AEDs, the maximal electroshock and pentylenetetrazol seizure tests in both mice and rats." | 2.41 | Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? ( Klitgaard, H, 2001) |
| "Levetiracetam appears to be a safe and effective medication for PTS prophylaxis in combat casualties." | 1.91 | Use of Levetiracetam for Post-Traumatic Seizure Prophylaxis in Combat-Related Traumatic Brain Injury. ( Atwood, R; Bradley, M; Elster, E; Walker, P; Walper, D, 2023) |
| "At higher doses, as part of long-term seizure management, in conjunction with multiple ASMs, LEV is associated with cognitive impairment." | 1.91 | Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function. ( Abdelmoneim, MS; Al Hail, HJ; Alrabi, A; El-Bardissy, A; Elalamy, O; Kamran, S; Melikyan, G; Mesraoua, B; Perkins, JD; Wilkins, SS, 2023) |
| " The non-habitual seizures completely disappeared, and the frequency of the habitual seizures improved to the baseline level after the LEV dosage was reduced." | 1.72 | Seizure Deterioration with Increased Levetiracetam Blood Concentration during the Postpartum Period in Refractory Temporal Lobe Epilepsy. ( Aoki, S; Iida, K; Kikumoto, M; Maruyama, H; Neshige, S; Shishido, T; Ueno, H, 2022) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 1.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "Palliative care patients experience seizures in different stages of their disease and may not tolerate oral medications toward the end of life." | 1.72 | Subcutaneous Levetiracetam and Sodium Valproate Use in Palliative Care Patients. ( Bradley, K; Kondasinghe, JS; Look, ML; Moffat, P, 2022) |
| "Levetiracetam (LEV) is an urgent control antiepileptic medication that offers relative lack of adverse effects and ease of monitoring." | 1.62 | Rapid administration of undiluted intravenous levetiracetam. ( Bonnin, S; Haller, JT; Radosevich, J, 2021) |
| "Levetiracetam has replaced sodium valproate as the most frequently prescribed ASM in pediatric patients." | 1.56 | Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018. ( Dai, H; Feng, J; Yu, L; Yu, Z, 2020) |
| "Furthermore, the girl developed a new seizure type after using LEV." | 1.51 | Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. ( Du, J; Gao, L; Lin, Y; Ren, L; Wang, D; Wang, Y; Zhou, Q, 2019) |
| "Pharmacological prophylaxis for early seizures following traumatic brain injury (TBI) is a recommendation in the Brain Trauma Foundation Guidelines." | 1.48 | Early Seizure Prophylaxis in Traumatic Brain Injuries Revisited: A Prospective Observational Study. ( Benjamin, E; Demetriades, D; Hong, Q; Inaba, K; Khor, D; Wu, J; Xiao, S, 2018) |
| " Plasma levels were obtained for analysis of potential pharmacokinetic interactions for each combination studied in the mouse 6-Hz model." | 1.48 | Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. ( Ceusters, M; Klein, BD; Lavreysen, H; Metcalf, CS; Pype, S; Smith, MD; Twyman, R; Van Osselaer, N; White, HS, 2018) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| "This case report describes a case of influenza B-related meningoencephalitis supported by evidence of an influenza B infection and temporal relation of the neurological event and respiratory illness in the absence of other identifiable cause." | 1.48 | Influenza B-related meningoencephalitis in adults. ( Norton, G; Vallat, W; Yong, CH, 2018) |
| "AD patients commonly have unprovoked seizures compared with age-matched controls." | 1.48 | Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. ( Caffrey, DR; Cheung, A; Futai, K; Germain, G; Golenbock, DT; Hasegawa, Y; Heneka, MT; Iguchi, R; Latz, E; Mao, W; Okabe, S; Tamburro, ND; Thatcher, EJ; Tzeng, TC, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Perioperative seizure prophylaxis with antiepileptic drugs (AED) has been advocated in patients undergoing supratentorial craniotomy." | 1.48 | The risk of hypotension and seizures in patients receiving prophylactic anti-epileptic drugs for supratentorial craniotomy. ( Brawanski, A; Höhne, J; Lange, M; Ott, C; Schebesch, KM, 2018) |
| "Levetiracetam (97%) was most commonly prescribed." | 1.46 | Prophylactic Anticonvulsants in Intracerebral Hemorrhage. ( Blatsioris, AD; Carter, RJL; Cohen-Gadol, AA; Hulin, AL; Leipzig, TJ; Mackey, J; Moser, EAS; O'Neill, DP; Saha, C; Stevenson, A; Williams, LS, 2017) |
| "Early myoclonus after cardiac arrest (CA) is traditionally viewed as a poor prognostic sign (status myoclonus)." | 1.46 | Early Lance-Adams syndrome after cardiac arrest: Prevalence, time to return to awareness, and outcome in a large cohort. ( Aicua Rapun, I; Novy, J; Oddo, M; Rossetti, AO; Solari, D, 2017) |
| " CASE REPORT We report the levetiracetam pharmacokinetic profile of a patient being treated with levetiracetam 1000 mg intravenously every 12 h who required continuous veno-venous hemofiltration (CVVH)." | 1.46 | Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ( Cava, LF; Fish, DN; Kiser, TH; MacLaren, R; Mueller, SW; Neumann, RT; Van Matre, ET, 2017) |
| "In this study, we evaluated the dose-response efficacy of levetiracetam (12." | 1.46 | Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury. ( Cao, Y; Liao, Z; Lu, XM; Mountney, A; Shear, DA; Tortella, FC, 2017) |
| " Following adjunctive AED treatment, neuropsychiatric adverse effects led to AED withdrawal in 1." | 1.46 | Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. ( Brodie, MJ; Stephen, LJ; Wishart, A, 2017) |
| " In end-stage renal disease (ESRD) patients on hemodialysis (HD), pharmacokinetic studies recommend daily dosing with 50% supplemental doses after 4-hour HD sessions." | 1.46 | Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. ( Sands, KA; Shiue, HJ; Taylor, M, 2017) |
| "We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis." | 1.46 | Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. ( Bongiovanni, LG; Casari, R; Faccini, M; Federico, A; Franchini, E; Lugoboni, F; Morbioli, L; Tamburin, S, 2017) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 1.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| "Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment." | 1.46 | Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients. ( Brozmanova, H; Grundmann, M; Kacirova, I; Koristkova, B, 2017) |
| "Antiseizure/anticonvulsant drugs and seizures in medial temporal lobe structures may cause gonadal dysfunction, including infertility, decreased libido, and potency." | 1.46 | Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats. ( Cincioğlu-Palabiyik, M; Ertoy-Baydar, D; Karahan, H; Kelicen-Uğur, P; Sara, Y; Üner, M, 2017) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 1.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| "Seizures are rare manifestation of thalamic disorder." | 1.46 | Unilateral Thalamic Infarct Presenting as a Convulsive Seizure. ( Brohi, H; Kumar, R; Mughul, A, 2017) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 1.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "Ciguatera fish poisoning is the most frequently reported seafood toxin illness associated with the ingestion of contaminated tropical fish." | 1.46 | Intractable Seizures and Rehabilitation in Ciguatera Poisoning. ( Derian, A; Khurana, S; Plumlee, C; Rothenberg, J, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "Antiepileptic prophylaxis reduces early seizures, but their use beyond 1 week does not prevent the development of post-traumatic epilepsy." | 1.43 | Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort. ( Craner, M; Cranley, MR; McGilloway, E, 2016) |
| "No convulsions were observed in fasted animals treated with 0." | 1.43 | Antimuscarinic-induced convulsions in fasted animals after food intake: evaluation of the effects of levetiracetam, topiramate and different doses of atropine. ( Allahverdiyev, O; Büget, B; Enginar, N; Türkmen, AZ, 2016) |
| "We present a case of neurogenic stunned myocardium, discovered intraoperatively after anesthetic induction, in a patient who presented to our operating room with a recent intraparenchymal hemorrhage." | 1.43 | Prolonged Cardiac Dysfunction After Intraparenchymal Hemorrhage and Neurogenic Stunned Myocardium. ( Krishnamoorthy, V; Sharma, D; Vavilala, MS; Wilson, T, 2016) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 1.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| " LEV3D treatment failed to improve cognitive or motor performance; however extending the dosing regimen through 10 days post-injury afforded significant neuroprotective benefit." | 1.43 | Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury. ( Caudle, KL; Lu, XC; Mountney, A; Shear, DA; Tortella, FC, 2016) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 1.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| "Seizures were induced at two weeks after FPI by KA in another group (FPI-LS)." | 1.43 | Levetiracetam prophylaxis ameliorates seizure epileptogenesis after fluid percussion injury. ( Chen, YH; Chiang, YH; Chou, YC; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, HI; Tsai, JJ; Wu, PJ, 2016) |
| "Posttraumatic seizure, one of the secondary injury sequelae, contributes to further damage to the injured brain." | 1.43 | Continuous electroencephalography in pediatric traumatic brain injury: Seizure characteristics and outcomes. ( Reuter-Rice, K; Vaewpanich, J, 2016) |
| "Lacosamide decreases seizure burden by modulating sodium channels." | 1.42 | Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks. ( Gudausky, TM; Kovach, J; Loomba, RS; Singh, AK, 2015) |
| "Levetiracetam was very well tolerated." | 1.42 | Epilepsy in patients with gliomas: incidence and control of seizures. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T, 2015) |
| "Pre-clinical trial of abbreviated LEV dosing in an experimental model of TBI Methods: After either controlled cortical impact (CCI) injury or sham surgery, rats received three 50 mg kg(-1) doses over 24 hours or vehicle." | 1.42 | Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI. ( Fowler, L; Hurwitz, M; Wagner, AK; Zou, H, 2015) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 1.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| " An intensive pharmacokinetic study was performed from immediately before to 11 hours after the morning LVT dose administration and suggested that the patient was not adequately exposed to the drug during the night." | 1.42 | Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring. ( Cappellari, AM; Cattaneo, D; Clementi, E; Kustermann, A, 2015) |
| "In a first step, we examined anti-seizure effects of 6 AEDs on spontaneous recurrent focal electrographic seizures and secondarily generalized convulsive seizures in epileptic mice, showing that the focal nonconvulsive seizures were resistant to carbamazepine and phenytoin, whereas valproate and levetiracetam exerted moderate and phenobarbital and diazepam marked anti-seizure effects." | 1.42 | Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice. ( Bankstahl, M; Klein, S; Löscher, W, 2015) |
| " Dose-response curves for phenytoin and levetiracetam were generated in the three strains at 32 and 44 mA current intensities using both devices." | 1.42 | Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. ( Kaminski, RM; Leclercq, K, 2015) |
| "In addition, the effect on seizure count was compared with that of various AED regimen and the vagus nerve stimulation (VNS)." | 1.42 | Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. ( Benninger, F; Dressler, A; Feucht, M; Grassl, R; Gröppel, G; Mühlebner, A; Reiter-Fink, E; Reithofer, E; Trimmel-Schwahofer, P, 2015) |
| "Only 29% of LEV-treated animals had seizures compared to all controls following a latent period that was similar in duration." | 1.42 | The anti-ictogenic effects of levetiracetam are mirrored by interictal spiking and high-frequency oscillation changes in a model of temporal lobe epilepsy. ( Avoli, M; Behr, C; Lévesque, M, 2015) |
| "Treatment-resistant seizures affect about a third of patients suffering from epilepsy." | 1.42 | Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish. ( Afrikanova, T; Buenafe, OE; Crawford, AD; De Prins, A; de Witte, PA; Esguerra, CV; Kaminski, RM; Langlois, M; Leclercq, K; Rospo, CC; Smolders, I; Van Eeckhaut, A, 2015) |
| "Levetiracetam (LEV) is a unique, effective, relatively safe antiepileptic drug that preferentially interacts with synaptic vesicle protein 2A (SV2A)." | 1.42 | Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats. ( Abdel-Wahab, BA; Habeeb, SM; Khateeb, MM; Shaikh, IA, 2015) |
| "The seizures were unresponsive to bolus midazolam, phenytoin infusion and levetiracetam infusion." | 1.42 | A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature. ( Çelik, T; Çelik, Ü; Gezgin, AE; Kaya, MS; Kömür, M; Tolunay, O, 2015) |
| "Seizures were induced by single application of a current intensity of 49 mA to i." | 1.42 | Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds. ( Bentea, E; Coppens, J; Maes, K; Massie, A; Smolders, I; Van Eeckhaut, A; Van Liefferinge, J; Walrave, L, 2015) |
| "In four of ten rats, seizure frequency was unaltered by LEV (non-responders)." | 1.42 | Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats. ( Kang, TC; Ko, AR, 2015) |
| " The dosage of immunosuppressants did not change before and after levetiracetam treatment, and there were no changes in hematological and biochemical data before and after treatment." | 1.42 | Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation. ( Chen, CL; Chen, NC; Chuang, YC; Lin, CH; Lin, TK; Tsai, MH, 2015) |
| "Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32mA, 6Hz, 3s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the various drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10." | 1.40 | Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis. ( Florek-Luszczki, M; Luszczki, JJ; Wlaz, A, 2014) |
| "Neonatal seizures are often refractory to treatment with initial antiseizure medications." | 1.40 | Levetiracetam-induced anaphylaxis in a neonate. ( Ariguloglu, EA; Koklu, E; Koklu, S, 2014) |
| " Collected data included age, gender, diagnosis on admission, dosing regimen, documented seizure activity, adverse reactions, concomitant use of other antiepileptic drugs, and condition on discharge." | 1.40 | The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients. ( Bashir, S; Burakgazi, E; Doss, V; Pellock, J, 2014) |
| " Pharmacokinetic changes associated with pregnancy may increase apparent clearance of extended-release formulations of levetiracetam, leading to periods of subtherapeutic blood or central nervous system concentrations." | 1.40 | Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam. ( Garrity, LC; Standridge, SM; Turner, M, 2014) |
| "Levetiracetam (LEV) is an alternative; however, no published data validate comparable efficacy." | 1.39 | Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. ( Goodwin, H; Harris, LH; Haut, ER; Kornbluth, J; Kruer, RM; Slater, LA; Thomas, KP, 2013) |
| "Levetiracetam was used most often (60%), followed by fosphenytoin (37%), for a usual duration of days (36%), weeks (47%), or months (17%)." | 1.39 | Survey of prophylactic antiseizure drug use for non-traumatic intracerebral hemorrhage. ( Al Sherbini, K; Jensen, MB; Sattar, A, 2013) |
| " Clinicians should be mindful that standard dosing of these agents may not achieve typical target concentrations in this clinical scenario." | 1.39 | Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient. ( Arora, S; Cook, AM; Davis, J; Pittman, T, 2013) |
| "This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid after a craniotomy for supratentorial brain tumors." | 1.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "53." | 1.39 | Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. ( Buniak, L; Henry, JC; Mohile, N; Wang, H; Wychowski, T, 2013) |
| "Li-PIL-induced seizures were accompanied by increased levels of hippocampal prostaglandin (PG) E2, myeloperoxidase (MPO), tumor necrosis factor-α, and interleukin-10." | 1.39 | Additional antiepileptic mechanisms of levetiracetam in lithium-pilocarpine treated rats. ( Abdallah, DM; Al-Shorbagy, MY; El Sayeh, BM, 2013) |
| " The canines were given three different dosage levels of anti-convulsant medication in an attempt to manipulate the excitability of the network." | 1.39 | A method for actively tracking excitability of brain networks using a fully implantable monitoring system. ( Cook, MJ; Freestone, DR; Frey, S; Giftakis, JE; Long, SN; Stypulkowski, PH, 2013) |
| "Onset of absence seizures in the first year of life is very rare." | 1.39 | Early-onset absence epilepsy aggravated by valproic acid: a video-EEG report. ( Belcastro, V; Caraballo, RH; Romeo, A; Striano, P, 2013) |
| "In these conditions, non-convulsive seizures (NCSs) propagate from the core of the focal lesion into perilesional tissue, enlarging the damaged area and promoting epileptogenesis." | 1.39 | The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion. ( Cataldi, M; Cuomo, O; di Renzo, G; Leo, A; Politi, GB; Rispoli, V; Vinciguerra, A, 2013) |
| "Neonatal seizures can result in chronic epilepsy and long-term behavioral and cognitive deficits." | 1.39 | Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. ( Chang, M; Fitzgerald, E; Folkerth, RD; Jensen, FE; Kosaras, B; Murphy, A; Talos, DM, 2013) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.38 | Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. ( Filip, D; Florek-Luszczki, M; Luszczki, JJ, 2012) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 1.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "fosphenytoin (fos-PHT) seizure prevention trial (NCT00618436)." | 1.38 | Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention. ( Lindsell, CJ; Shutter, LA; Steinbaugh, LA; Szaflarski, JP, 2012) |
| "Levetiracetam was well tolerated and was efficacious in preventing seizures." | 1.38 | Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. ( Bajwa, RP; Gross, TG; Pai, V; Skeens, M; Soni, S; Termuhlen, AM, 2012) |
| "Complete seizure freedom was defined as a favorable outcome." | 1.38 | Levetiracetam may favorably affect seizure outcome after temporal lobectomy. ( Bingaman, W; Irwin, AI; Jehi, LE; Kayyali, H; Najm, I; Vadera, S, 2012) |
| "No more seizures occurred in patients receiving 1-3 g LEV preoperatively." | 1.37 | Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. ( Donat, M; Oberndorfer, S; Roessler, K; Zachenhofer, I, 2011) |
| " No severe adverse effects were observed." | 1.37 | Levetiracetam: safety and efficacy in neonatal seizures. ( Dinger, J; Ikonomidou, C; Ramantani, G; Rating, D; Walter, B, 2011) |
| " Differential dosing led to seizure freedom in 64." | 1.37 | Higher evening antiepileptic drug dose for nocturnal and early-morning seizures. ( Bergin, A; Bourgeois, BF; Guilhoto, LM; Kothare, SV; Loddenkemper, T; Vendrame, M, 2011) |
| "Levetiracetam was considered effective if administration was associated with a greater than 50% seizure reduction within 24 hours." | 1.37 | Levetiracetam for treatment of neonatal seizures. ( Abend, NS; Clancy, RR; Dlugos, DJ; Gutierrez-Colina, AM; Monk, HM, 2011) |
| " In Group B, LEV was given at 420 mg/ml for the first 2 weeks followed by doubling the dosage (840 mg/ml) in the following 2 weeks." | 1.37 | Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats. ( Arita, K; Hanaya, R; Kumafuji, K; Kurisu, K; Sasa, M; Serikawa, T; Sugata, S; Tokudome, M, 2011) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Cerebral venous thrombosis is a rare entity in pregnancy and the postpartum period, with an incidence of 1:10,000 to 1:25,000." | 1.37 | Postpartum cerebral venous thrombosis. ( McCaulley, JA; Pates, JA, 2011) |
| "Patients who develop early seizures: 40% good outcome, 50% poor outcome, and 10% death." | 1.37 | Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. ( Cotton, BA; Holcomb, JB; Kao, LS; Kozar, R, 2011) |
| "The incidence of seizures is generally accepted to be greater in patients with multiple sclerosis (MS) than in the general population, and rarely, MS can initially present as seizure." | 1.37 | Seizures as a manifestation of multiple sclerosis. ( Kendrick-Adey, AC; Sponsler, JL, 2011) |
| " Maintenance dosing of Phenobarbital was initiated and no further seizures were noted." | 1.36 | Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. ( Brannon Morris, E; Ledet, DS; Rubnitz, JE; Wheless, JW, 2010) |
| "Levetiracetam therapy was effective in 58." | 1.36 | Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. ( Cai, F; Cao, J; Li, S; Xiao, N, 2010) |
| "The mean monthly seizure frequency for all types of seizures during the baseline period was 21." | 1.36 | Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. ( Balestri, M; Cilio, MR; Cusmai, R; D'Orsi, G; Fusco, L; Margiotta, ML; Nardello, R; Patanè, S; Russo, S; Specchio, LM; Specchio, N; Striano, P; Striano, S; Vigevano, F, 2010) |
| "Four cases of seizure activity in primary brain tumor patients after conversion from Keppra to generic levetiracetam are reported." | 1.36 | Seizure risk in brain tumor patients with conversion to generic levetiracetam. ( Armstrong, TS; Choi, S; Gilbert, MR; Walker, J, 2010) |
| "Levetiracetam (LEV) is a unique antiepileptic drug that preferentially interacts with synaptic vesicle protein 2A (SV2A)." | 1.36 | Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. ( Ishihara, S; Ohno, Y; Sasa, M; Serikawa, T; Terada, R, 2010) |
| "Levetiracetam treatment for 25 days, initiated 24 hours after induction of kainate-induced SE, significantly decreased the mean duration of spontaneous EEG seizures 58 days later." | 1.36 | Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. ( Kato, N; Kudo, K; Maru, E; Shibasaki, T; Sugaya, Y, 2010) |
| "Patients ≥ 16 years with partial-onset seizures (had received levetiracetam oral solution for ≥ 28 days) completed a study questionnaire assessing overall acceptability of levetiracetam oral solution, specific organoleptic characteristics (taste, taste intensity, aftertaste), ease of use and convenience." | 1.36 | Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study. ( Matías-Guíu, J; Mauri, JA; Molins, A; Villar, E, 2010) |
| "We reported a patient with epilepsy who took an overdose of 63 grams of levetiracetam with mild adverse events." | 1.36 | Acute levetiracetam overdose presented with mild adverse events. ( Chayasirisobhon, S; Chayasirisobhon, WV; Tsay, CC, 2010) |
| " Despite an absence of data on neonatal pharmacokinetics of either drug, neurologists made different dosing recommendations for these two drugs (P = 0." | 1.35 | Off-label use of antiepileptic drugs for the treatment of neonatal seizures. ( Ferriero, DM; Silverstein, FS, 2008) |
| "Piracetam is an effective prophylactic treatment for severe BHS." | 1.35 | Piracetam in severe breath holding spells. ( Azam, M; Bhatti, N; Shahab, N, 2008) |
| "Children with brain tumors and other cancers can suffer from seizures." | 1.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "A diagnosis of neurofibromatosis type 1 was made." | 1.35 | An unusual cause of collapse and neck pain. ( Barton, D; Buckley, M; Kuan, S, 2008) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "Levetiracetam is an antiepileptic drug widely prescribed." | 1.35 | Levetiracetam-induced platelet dysfunction. ( Hacquard, M; Lacour, JC; Lecompte, T; Richard, S; Vespignani, H, 2009) |
| "Status epilepticus is defined as a seizure lasting beyond 30 minutes." | 1.35 | Role of intravenous levetiracetam in acute seizure management of children. ( Crisp, ED; Kayani, S; Kirmani, BF; Rajab, H, 2009) |
| "Levetiracetam was more likely to be used in children who received chemotherapy or radiation therapy (8/14, or 57%) than in those who did not receive adjuvant therapies (3/18, or 17%) (P = 0." | 1.35 | The use of antiepileptic drugs in pediatric brain tumor patients. ( Kan, L; Levy, AS; Maytal, J; Shinnar, S; Sogawa, Y, 2009) |
| "The significant proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment." | 1.35 | Seizure-freedom with combination therapy in localization-related epilepsy. ( Auvinen, A; Keränen, T; Kharazmi, E; Peltola, J; Peltola, M; Raitanen, J, 2008) |
| " LEV and FBM brain concentrations were measured by HPLC in order to determine any pharmacokinetic contribution to the observed antiseizure effect." | 1.34 | Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. ( Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007) |
| "Levetiracetam (LEV) is a 2nd generation non-enzyme inducing AED with a novel mechanism of action, binding to neuronal synaptic vesicle protein SV2A, that has been previously shown to reduce seizure activity in patients with primary brain tumors." | 1.34 | Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. ( Dalton, J; Goldlust, S; Newton, HB; Pearl, D, 2007) |
| "Gelastic seizures were documented by video-EEG and were responsive to i." | 1.34 | Status gelasticus associated with levetiracetam as add-on treatment. ( Bellantone, D; Di Rosa, G; Pustorino, G; Sgro, DL; Spano, M; Tortorella, G; Tricomi, G, 2007) |
| "Levetiracetam has been a commonly prescribed oral anticonvulsant for the use of adjunctive therapy for partial seizures in adults with favorable tolerability, and it has been recently approved for children older than age 4 years." | 1.34 | Levetiracetam for the treatment of neonatal seizures. ( Rotenberg, JS; Shoemaker, MT, 2007) |
| "The anti-seizure activity of both compounds occurred 30 min following intraperitoneal (i." | 1.34 | Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. ( Tai, KK; Truong, DD, 2007) |
| "If the seizures also enhance the survival of neurons that are destined to undergo naturally occurring PCD, early childhood seizures may have deleterious effects by preventing this necessary component of normal development." | 1.34 | Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. ( Gale, K; Kim, JS; Kondratyev, A; Tomita, Y, 2007) |
| " Brain AED concentrations were determined to ascertain any pharmacokinetic contribution to the observed antiseizure effect." | 1.33 | Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. ( Andres, MM; Cioczek-Czuczwar, A; Czuczwar, P; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006) |
| "Levetiracetam (LEV) is a new AED with a novel mechanism of action, which includes reducing the Ca++ current through neuron-specific, high voltage activated Ca++ channels (n-type)." | 1.33 | Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. ( Goldlust, SA; Newton, HB; Pearl, D, 2006) |
| "Levetiracetam was generally well tolerated, and adverse events were relatively uncommon in patients who responded to treatment." | 1.33 | Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. ( Chuck, G; Collins, JJ; Franz, DN; Leonard, JM; Tudor, C, 2006) |
| "Levetiracetam (LEV) is a new antiepileptic drug highly effective as add-on treatment in refractory partial epilepsies." | 1.33 | Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. ( Rocamora, R; Schulze-Bonhage, A; Wagner, K, 2006) |
| "When the threshold for secondary generalized seizures (GST) was determined in addition to ADT, gabapentin and levetiracetam strikingly increased this threshold compared to predrug control." | 1.31 | Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. ( Ebert, U; Löscher, W; Reissmüller, E, 2000) |
| ", with a U-shape dose-response relationship." | 1.30 | Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. ( Margineanu, DG; Wülfert, E, 1997) |
| "Though the convulsions looked similar to morphine-induced seizures, naloxone failed to antagonize these effects." | 1.27 | Possible mechanism of digoxin-induced convulsions. ( Kulkarni, SK; Mehta, AK, 1983) |
| "We used the effect of ethanol on the convulsion threshold as model of injuriousness to analyse the CNS protective efficacy of nootropics." | 1.27 | [Effect of nootropic agents on the lowering of the spasm threshold after a single ethanol application]. ( Andreas, K; Dienel, A; Schmidt, J, 1984) |
| "The enhanced seizure susceptibility after a single dose of ethanol was abolished by piracetam and MGO." | 1.27 | Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility. ( Andreas, K; Dienel, A; Schmidt, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (1.01) | 18.7374 |
| 1990's | 6 (1.52) | 18.2507 |
| 2000's | 86 (21.72) | 29.6817 |
| 2010's | 271 (68.43) | 24.3611 |
| 2020's | 29 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Kenda, BM | 1 |
| Matagne, AC | 1 |
| Talaga, PE | 1 |
| Pasau, PM | 1 |
| Differding, E | 1 |
| Lallemand, BI | 1 |
| Frycia, AM | 1 |
| Moureau, FG | 1 |
| Klitgaard, HV | 1 |
| Gillard, MR | 1 |
| Fuks, B | 2 |
| Michel, P | 2 |
| Tran, QK | 2 |
| Bzhilyanskaya, V | 2 |
| Lurie, T | 1 |
| Fairchild, M | 1 |
| Rehan, MA | 2 |
| Rashid, A | 2 |
| Powell, E | 1 |
| Pourmand, A | 2 |
| Kikumoto, M | 1 |
| Neshige, S | 1 |
| Shishido, T | 1 |
| Ueno, H | 1 |
| Aoki, S | 1 |
| Iida, K | 1 |
| Maruyama, H | 1 |
| Wang, BC | 1 |
| Chiu, HY | 1 |
| Luh, HT | 1 |
| Lin, CJ | 1 |
| Hsieh, SH | 1 |
| Chen, TJ | 1 |
| Wu, CR | 1 |
| Chen, PY | 1 |
| Köle, MT | 1 |
| Sager, SG | 1 |
| Zeynel, H | 1 |
| Çağ, Y | 1 |
| Akın, Y | 1 |
| Methaneethorn, J | 1 |
| Konrath, E | 1 |
| Marhold, F | 1 |
| Kindler, W | 1 |
| Scheichel, F | 1 |
| Popadic, B | 1 |
| Blauensteiner, K | 1 |
| Calabek, B | 1 |
| Freydl, E | 1 |
| Weber, M | 1 |
| Ristl, R | 1 |
| Hainz, K | 1 |
| Sherif, C | 2 |
| Oberndorfer, S | 3 |
| Kondasinghe, JS | 1 |
| Look, ML | 1 |
| Moffat, P | 1 |
| Bradley, K | 1 |
| Ohman, K | 1 |
| Kram, B | 1 |
| Schultheis, J | 1 |
| Sigmon, J | 1 |
| Kaleem, S | 1 |
| Yang, Z | 1 |
| Lee, HJ | 1 |
| Vatsaas, C | 1 |
| Komisarow, J | 1 |
| van der Meer, PB | 1 |
| Dirven, L | 1 |
| Fiocco, M | 1 |
| Vos, MJ | 1 |
| Kouwenhoven, MCM | 1 |
| van den Bent, MJ | 1 |
| Taphoorn, MJB | 1 |
| Koekkoek, JAF | 1 |
| Schelhaas, M | 1 |
| Wegner, I | 1 |
| Edens, M | 1 |
| Wammes-Van Der Heijden, E | 1 |
| Touw, D | 1 |
| Ter Horst, P | 1 |
| Gaviria-Carrillo, M | 1 |
| Mora-Muñoz, L | 1 |
| Diaz-Forero, AF | 1 |
| Vargas-Osorio, J | 1 |
| Torres-Ballesteros, V | 1 |
| Estrada, J | 1 |
| Vélez Van Meerbeke, A | 1 |
| Rodríguez, JH | 1 |
| Samara, QA | 1 |
| Ifraitekh, AS | 1 |
| Al Jayyousi, O | 1 |
| Sawan, S | 1 |
| Hazaimeh, E | 1 |
| Jbarah, OF | 1 |
| Hedges, A | 1 |
| Findlay, MC | 1 |
| Davis, GE | 1 |
| Wolfe, BM | 1 |
| Hawryluk, GWJ | 1 |
| Menacho, ST | 1 |
| Ansari, S | 1 |
| Atwood, R | 1 |
| Walker, P | 1 |
| Walper, D | 1 |
| Elster, E | 1 |
| Bradley, M | 1 |
| Salamah, A | 1 |
| Darwish, AH | 1 |
| Perkins, JD | 1 |
| Abdelmoneim, MS | 1 |
| Wilkins, SS | 1 |
| Kamran, S | 1 |
| Mesraoua, B | 1 |
| Melikyan, G | 1 |
| Alrabi, A | 1 |
| El-Bardissy, A | 1 |
| Elalamy, O | 1 |
| Al Hail, HJ | 1 |
| Swami, M | 1 |
| Kaushik, JS | 1 |
| Dai, AI | 1 |
| Demiryürek, AT | 1 |
| Mohamudally, A | 1 |
| Clark, K | 1 |
| Greenhalgh, J | 2 |
| Weston, J | 2 |
| Dundar, Y | 2 |
| Nevitt, SJ | 2 |
| Marson, AG | 3 |
| DeMott, JM | 1 |
| Slocum, GW | 1 |
| Gottlieb, M | 1 |
| Peksa, GD | 1 |
| Yu, L | 1 |
| Feng, J | 1 |
| Yu, Z | 1 |
| Dai, H | 1 |
| Hnaini, M | 1 |
| Darwich, M | 1 |
| Koleilat, N | 1 |
| Jaafar, F | 1 |
| Hanneyan, S | 1 |
| Rahal, S | 1 |
| Mikati, IE | 1 |
| Shbarou, RM | 1 |
| Nabout, R | 1 |
| Maalouf, FI | 1 |
| Obeid, M | 1 |
| Sharma, D | 2 |
| Hussain, AM | 1 |
| Sharma, SS | 1 |
| Sutherland, A | 1 |
| Meldon, C | 1 |
| Harrison, T | 1 |
| Miller, M | 1 |
| Afridi, LZ | 1 |
| Ahmad, M | 1 |
| Palmer, J | 1 |
| Raffman, A | 1 |
| Menne, A | 1 |
| Gigliotti, MJ | 1 |
| Wilkinson, DA | 1 |
| Simon, SD | 1 |
| Cockroft, KM | 1 |
| Church, EW | 1 |
| Nagano, M | 1 |
| Tagami, T | 1 |
| Kaneko, J | 1 |
| Kondo, M | 1 |
| Hotta, M | 1 |
| Kubota, M | 1 |
| Sugaya, K | 1 |
| Takase, H | 1 |
| Kuno, M | 1 |
| Unemoto, K | 1 |
| Kumar, J | 1 |
| Meena, J | 1 |
| Yadav, A | 1 |
| Haller, JT | 1 |
| Bonnin, S | 1 |
| Radosevich, J | 1 |
| Liang, S | 1 |
| Ding, P | 1 |
| Zhang, S | 2 |
| Zhang, J | 2 |
| Wu, Y | 1 |
| Mackey, J | 1 |
| Blatsioris, AD | 1 |
| Moser, EAS | 1 |
| Carter, RJL | 1 |
| Saha, C | 1 |
| Stevenson, A | 1 |
| Hulin, AL | 1 |
| O'Neill, DP | 1 |
| Cohen-Gadol, AA | 1 |
| Leipzig, TJ | 1 |
| Williams, LS | 1 |
| Tountopoulou, M | 1 |
| Weschke, B | 1 |
| Kaindl, AM | 1 |
| Aicua Rapun, I | 1 |
| Novy, J | 1 |
| Solari, D | 1 |
| Oddo, M | 1 |
| Rossetti, AO | 1 |
| Ukai, K | 2 |
| Watanabe, M | 2 |
| Kılıç, B | 1 |
| Güngör, S | 1 |
| Arslan, M | 1 |
| Selimoğlu, MA | 1 |
| Yılmaz, S | 1 |
| Van Matre, ET | 1 |
| Mueller, SW | 1 |
| Fish, DN | 1 |
| MacLaren, R | 1 |
| Cava, LF | 1 |
| Neumann, RT | 1 |
| Kiser, TH | 1 |
| Ishikawa, H | 1 |
| Ii, Y | 1 |
| Niwa, A | 1 |
| Matsuura, K | 1 |
| Maeda, M | 1 |
| Tomimoto, H | 1 |
| Lu, XM | 1 |
| Cao, Y | 1 |
| Mountney, A | 2 |
| Liao, Z | 1 |
| Shear, DA | 2 |
| Tortella, FC | 2 |
| Gujjar, AR | 1 |
| Nandhagopal, R | 1 |
| Jacob, PC | 1 |
| Al-Hashim, A | 1 |
| Al-Amrani, K | 1 |
| Ganguly, SS | 1 |
| Al-Asmi, A | 1 |
| Stephen, LJ | 1 |
| Wishart, A | 1 |
| Brodie, MJ | 2 |
| Company-Albir, MJ | 1 |
| Ruíz-Ramos, J | 1 |
| Solana Altabella, A | 1 |
| Marqués-Miñana, MR | 1 |
| Vicent, C | 1 |
| Poveda, JL | 1 |
| Shiue, HJ | 1 |
| Taylor, M | 1 |
| Sands, KA | 1 |
| Agrawal, A | 1 |
| Banergee, A | 1 |
| Tamburin, S | 1 |
| Faccini, M | 1 |
| Casari, R | 1 |
| Federico, A | 1 |
| Morbioli, L | 1 |
| Franchini, E | 1 |
| Bongiovanni, LG | 1 |
| Lugoboni, F | 1 |
| Nakamura, K | 1 |
| Inokuchi, R | 1 |
| Daidoji, H | 1 |
| Naraba, H | 1 |
| Sonoo, T | 1 |
| Hashimoto, H | 1 |
| Tokunaga, K | 1 |
| Hiruma, T | 1 |
| Doi, K | 1 |
| Morimura, N | 1 |
| Grundmann, M | 1 |
| Koristkova, B | 1 |
| Brozmanova, H | 1 |
| Kacirova, I | 1 |
| Sutherland, AE | 1 |
| Curtin, J | 1 |
| Bradley, V | 1 |
| Bush, O | 1 |
| Presswood, M | 1 |
| Hedges, V | 1 |
| Naessens, K | 1 |
| Cincioğlu-Palabiyik, M | 1 |
| Üner, M | 1 |
| Ertoy-Baydar, D | 1 |
| Sara, Y | 1 |
| Karahan, H | 1 |
| Kelicen-Uğur, P | 1 |
| Chaari, A | 1 |
| Mohamed, AS | 1 |
| Abdelhakim, K | 1 |
| Kauts, V | 1 |
| Casey, WF | 1 |
| Nemes, AD | 1 |
| O'Dwyer, R | 1 |
| Najm, IM | 1 |
| Ying, Z | 1 |
| Gonzalez-Martinez, J | 1 |
| Alexopoulos, AV | 1 |
| Kelly, D | 1 |
| Raimondi, F | 1 |
| Shihab, N | 1 |
| Kumar, R | 3 |
| Brohi, H | 1 |
| Mughul, A | 1 |
| Kamate, M | 1 |
| Barnes Heller, H | 1 |
| Khor, D | 1 |
| Wu, J | 1 |
| Hong, Q | 1 |
| Benjamin, E | 1 |
| Xiao, S | 1 |
| Inaba, K | 2 |
| Demetriades, D | 2 |
| Lee, T | 1 |
| Warrick, BJ | 1 |
| Sarangarm, P | 1 |
| Alunday, RL | 1 |
| Bussmann, S | 1 |
| Smolinske, SC | 1 |
| Seifert, SA | 1 |
| Hieger, MA | 1 |
| Maskell, KF | 1 |
| McHugh, DC | 1 |
| Lancaster, S | 1 |
| Manganas, LN | 1 |
| Wielaender, F | 1 |
| James, FMK | 1 |
| Cortez, MA | 1 |
| Kluger, G | 1 |
| Neßler, JN | 1 |
| Tipold, A | 1 |
| Lohi, H | 1 |
| Fischer, A | 1 |
| Lima-Rogel, V | 1 |
| López-López, EJ | 1 |
| Medellín-Garibay, SE | 1 |
| Gómez-Ruiz, LM | 1 |
| Romero-Méndez, C | 1 |
| Milán-Segovia, RC | 1 |
| Romano-Moreno, S | 1 |
| Furtado, I | 1 |
| Gonçalves, F | 1 |
| Gonçalves, J | 1 |
| Neves, J | 1 |
| Metcalf, CS | 1 |
| Klein, BD | 1 |
| Smith, MD | 1 |
| Ceusters, M | 1 |
| Lavreysen, H | 1 |
| Pype, S | 1 |
| Van Osselaer, N | 1 |
| Twyman, R | 1 |
| White, HS | 1 |
| Jung, YS | 1 |
| Lee, SM | 1 |
| Park, MS | 1 |
| Park, K | 1 |
| Vargas, R | 1 |
| Beltrán, L | 1 |
| Lizama, R | 1 |
| Valenzuela, GR | 1 |
| Caraballo, R | 1 |
| Higashida, K | 1 |
| Tanaka, T | 3 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 1 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Novitskaya, Y | 1 |
| Hintz, M | 1 |
| Schulze-Bonhage, A | 3 |
| Cagnotti, G | 1 |
| Odore, R | 1 |
| Gardini, G | 1 |
| Amedeo, S | 1 |
| Bertone, I | 1 |
| Guerriero, G | 1 |
| Lentini, L | 1 |
| Dappiano, E | 1 |
| D'Angelo, A | 1 |
| Yong, CH | 1 |
| Vallat, W | 1 |
| Norton, G | 1 |
| Gha-Hyun, L | 1 |
| Dae, SJ | 1 |
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Tzeng, TC | 1 |
| Hasegawa, Y | 3 |
| Iguchi, R | 1 |
| Cheung, A | 1 |
| Caffrey, DR | 1 |
| Thatcher, EJ | 1 |
| Mao, W | 1 |
| Germain, G | 1 |
| Tamburro, ND | 1 |
| Okabe, S | 1 |
| Heneka, MT | 1 |
| Latz, E | 1 |
| Futai, K | 1 |
| Golenbock, DT | 1 |
| Wang, D | 1 |
| Zhou, Q | 1 |
| Ren, L | 1 |
| Lin, Y | 1 |
| Gao, L | 2 |
| Du, J | 1 |
| Wang, Y | 1 |
| Menaker, J | 1 |
| Branco, BC | 1 |
| Gooch, J | 1 |
| Okoye, OT | 1 |
| Herrold, J | 1 |
| Scalea, TM | 1 |
| Dubose, J | 1 |
| Nakken, KO | 1 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Kruer, RM | 1 |
| Harris, LH | 1 |
| Goodwin, H | 1 |
| Kornbluth, J | 1 |
| Thomas, KP | 1 |
| Slater, LA | 1 |
| Haut, ER | 1 |
| Jensen, MB | 1 |
| Sattar, A | 1 |
| Al Sherbini, K | 1 |
| DeDea, L | 1 |
| Tayah, T | 1 |
| Savard, M | 1 |
| Desbiens, R | 1 |
| Nguyen, DK | 1 |
| Rakshasbhuvankar, A | 1 |
| Rao, S | 1 |
| Kohan, R | 1 |
| Simmer, K | 1 |
| Nagarajan, L | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 3 |
| Zwinkels, H | 2 |
| Walchenbach, R | 2 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 3 |
| Boesebeck, F | 1 |
| Schwarz, O | 1 |
| Dohmen, B | 1 |
| Graef, U | 1 |
| Vestring, T | 1 |
| Kramme, C | 1 |
| Bien, CG | 1 |
| Pressler, RM | 1 |
| Mangum, B | 1 |
| Hommet, C | 1 |
| Beaufils, E | 1 |
| Roubeau, V | 1 |
| De Toffol, B | 1 |
| Ripault, H | 1 |
| Constans, T | 1 |
| Mondon, K | 1 |
| Weller, M | 2 |
| Cook, AM | 2 |
| Arora, S | 1 |
| Davis, J | 1 |
| Pittman, T | 1 |
| Khan, O | 2 |
| Cipriani, C | 2 |
| Wright, C | 2 |
| Crisp, E | 2 |
| Kirmani, B | 2 |
| Lee, YJ | 1 |
| Kim, T | 1 |
| Bae, SH | 1 |
| Kim, YH | 1 |
| Han, JH | 1 |
| Yun, CH | 1 |
| Kim, CY | 1 |
| Nakamura, H | 2 |
| Osawa, M | 2 |
| Yokoyama, T | 2 |
| Yoshida, K | 2 |
| Suzuki, A | 2 |
| Myhrer, T | 4 |
| Mariussen, E | 2 |
| Enger, S | 3 |
| Aas, P | 4 |
| Maitre, NL | 1 |
| Smolinsky, C | 1 |
| Slaughter, JC | 1 |
| Stark, AR | 1 |
| Wychowski, T | 1 |
| Wang, H | 3 |
| Buniak, L | 1 |
| Henry, JC | 1 |
| Mohile, N | 1 |
| Al-Shorbagy, MY | 1 |
| El Sayeh, BM | 1 |
| Abdallah, DM | 1 |
| Freestone, DR | 1 |
| Long, SN | 1 |
| Frey, S | 1 |
| Stypulkowski, PH | 1 |
| Giftakis, JE | 1 |
| Cook, MJ | 2 |
| Belcastro, V | 2 |
| Caraballo, RH | 2 |
| Romeo, A | 1 |
| Striano, P | 2 |
| Florek-Luszczki, M | 3 |
| Wlaz, A | 1 |
| Luszczki, JJ | 7 |
| Fang, Y | 1 |
| Wu, X | 1 |
| Xu, L | 1 |
| Tang, X | 1 |
| Wang, J | 1 |
| Zhu, G | 1 |
| Hong, Z | 1 |
| Cuomo, O | 1 |
| Rispoli, V | 1 |
| Leo, A | 1 |
| Politi, GB | 1 |
| Vinciguerra, A | 1 |
| di Renzo, G | 1 |
| Cataldi, M | 1 |
| Koklu, E | 1 |
| Ariguloglu, EA | 1 |
| Koklu, S | 1 |
| Bansal, S | 1 |
| Blalock, D | 1 |
| Kebede, T | 1 |
| Dean, NP | 1 |
| Carpenter, JL | 1 |
| Iyoda, K | 1 |
| Ogawa, K | 1 |
| Okazaki, T | 1 |
| Chen, XQ | 1 |
| Zhang, WN | 1 |
| Yang, ZX | 1 |
| Zhao, M | 1 |
| Cai, FC | 1 |
| Huang, SP | 1 |
| Pang, BD | 1 |
| Chen, X | 2 |
| Zou, LP | 2 |
| Burakgazi, E | 1 |
| Bashir, S | 1 |
| Doss, V | 1 |
| Pellock, J | 1 |
| Ott, DV | 1 |
| Kauert, A | 1 |
| Holtkamp, M | 1 |
| Radic, JA | 1 |
| Chou, SH | 1 |
| Du, R | 1 |
| Lee, JW | 1 |
| Dearborn, JL | 1 |
| Kaplan, PW | 2 |
| Stepanova, D | 1 |
| Beran, RG | 1 |
| Bahte, SK | 1 |
| Hiss, M | 1 |
| Lichtinghagen, R | 1 |
| Kielstein, JT | 1 |
| Shih, JL | 1 |
| Brenn, S | 1 |
| Schrope, DP | 1 |
| Meyer, S | 1 |
| Oster, I | 1 |
| Peterlini, S | 1 |
| Gortner, L | 1 |
| Kutschke, G | 1 |
| Rheims, S | 1 |
| Ryvlin, P | 1 |
| Cai, X | 1 |
| Bhattacharyya, S | 1 |
| Plitt, A | 1 |
| Raibagkar, P | 1 |
| LaBuzetta, JN | 1 |
| Schleicher, SM | 1 |
| Munshi, NC | 1 |
| Klein, JP | 1 |
| Garrity, LC | 1 |
| Turner, M | 1 |
| Standridge, SM | 1 |
| Nieoczym, D | 1 |
| Socała, K | 1 |
| Raszewski, G | 2 |
| Wlaź, P | 1 |
| Aksoy, D | 1 |
| Cevik, B | 1 |
| Kurt, S | 1 |
| Pekdas, E | 1 |
| Solmaz, V | 1 |
| Karamchandani, RR | 1 |
| Fletcher, JJ | 1 |
| Pandey, AS | 1 |
| Rajajee, V | 1 |
| Spengler, DC | 1 |
| Montouris, GD | 1 |
| Hohler, AD | 1 |
| Vajda, FJ | 1 |
| O'Brien, T | 1 |
| Lander, C | 1 |
| Graham, J | 1 |
| Eadie, M | 1 |
| Naha, S | 1 |
| Naha, K | 1 |
| Hande, HM | 1 |
| Vivek, G | 1 |
| Loomba, RS | 1 |
| Singh, AK | 1 |
| Kovach, J | 1 |
| Gudausky, TM | 1 |
| Matsumura, N | 1 |
| Nakaki, T | 1 |
| Gabriel, WM | 1 |
| Rowe, AS | 1 |
| İşgüder, R | 1 |
| Güzel, O | 1 |
| Ağın, H | 1 |
| Yılmaz, Ü | 1 |
| Akarcan, SE | 1 |
| Celik, T | 2 |
| Ünalp, A | 1 |
| Ueda, R | 1 |
| Saito, Y | 1 |
| Ohno, K | 1 |
| Maruta, K | 1 |
| Matsunami, K | 1 |
| Saiki, Y | 1 |
| Sokota, T | 1 |
| Sugihara, S | 1 |
| Nishimura, Y | 1 |
| Tamasaki, A | 1 |
| Narita, A | 1 |
| Imamura, A | 1 |
| Maegaki, Y | 1 |
| Iuchi, T | 2 |
| Kawasaki, K | 2 |
| Sakaida, T | 2 |
| Kulick, CV | 1 |
| Gutherz, SB | 1 |
| Beck, VC | 1 |
| Medvedeva, N | 1 |
| Soper, C | 1 |
| Forcelli, PA | 1 |
| Zou, H | 1 |
| Hurwitz, M | 1 |
| Fowler, L | 1 |
| Wagner, AK | 1 |
| Tinchon, A | 1 |
| Marosi, C | 1 |
| Gleiss, A | 1 |
| Geroldinger, A | 1 |
| Sax, C | 1 |
| Moser, W | 1 |
| Grisold, W | 1 |
| Cappellari, AM | 1 |
| Cattaneo, D | 1 |
| Clementi, E | 1 |
| Kustermann, A | 1 |
| Loiacono, G | 2 |
| Masci, M | 1 |
| Zaccara, G | 2 |
| Verrotti, A | 3 |
| Siniscalchi, A | 1 |
| Scaglione, F | 1 |
| Sanzaro, E | 1 |
| Iemolo, F | 1 |
| Albertini, G | 1 |
| Quirino, G | 1 |
| Manes, MT | 1 |
| Gratteri, S | 1 |
| Mercuri, NB | 1 |
| De Sarro, G | 2 |
| Gallelli, L | 1 |
| Lukawski, K | 1 |
| Czuczwar, SJ | 6 |
| Klein, S | 1 |
| Bankstahl, M | 1 |
| Löscher, W | 3 |
| Peyrl, A | 1 |
| Weichert, N | 1 |
| Kühl, JS | 1 |
| Ebell, W | 1 |
| Hernáiz Driever, P | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Kuwabara, K | 1 |
| Matsumoto, M | 1 |
| Leclercq, K | 4 |
| Kaminski, RM | 3 |
| Dressler, A | 1 |
| Trimmel-Schwahofer, P | 1 |
| Reithofer, E | 1 |
| Mühlebner, A | 1 |
| Gröppel, G | 1 |
| Reiter-Fink, E | 1 |
| Benninger, F | 1 |
| Grassl, R | 1 |
| Feucht, M | 1 |
| Iwasaki, T | 1 |
| Toki, T | 1 |
| Nonoda, Y | 1 |
| Ishii, M | 1 |
| Chen, J | 1 |
| Cai, F | 2 |
| Jiang, L | 1 |
| Hu, Y | 1 |
| Feng, C | 1 |
| Lévesque, M | 1 |
| Behr, C | 1 |
| Avoli, M | 1 |
| Hernández CH, M | 1 |
| Esquivel P, N | 1 |
| López E, M | 1 |
| Cranley, MR | 1 |
| Craner, M | 1 |
| McGilloway, E | 1 |
| Khongkhatithum, C | 1 |
| Thampratankul, L | 1 |
| Wiwattanadittakul, N | 1 |
| Visudtibhan, A | 1 |
| Pruitt, AA | 1 |
| Afrikanova, T | 1 |
| Langlois, M | 1 |
| De Prins, A | 1 |
| Buenafe, OE | 1 |
| Rospo, CC | 1 |
| Van Eeckhaut, A | 2 |
| de Witte, PA | 1 |
| Crawford, AD | 1 |
| Smolders, I | 2 |
| Esguerra, CV | 1 |
| Packer, RM | 1 |
| Nye, G | 1 |
| Porter, SE | 1 |
| Volk, HA | 1 |
| Vallianou, NG | 1 |
| Geladari, E | 1 |
| Chroni, P | 1 |
| Kokkinakis, E | 1 |
| Li, MQ | 1 |
| Zhang, WW | 1 |
| Chen, T | 1 |
| Liu, L | 1 |
| Gefroh-Grimes, HA | 1 |
| Gidal, BE | 1 |
| Abdel-Wahab, BA | 1 |
| Shaikh, IA | 1 |
| Khateeb, MM | 1 |
| Habeeb, SM | 1 |
| Taberner Bonastre, MT | 1 |
| Peralta Muñoz, S | 1 |
| Boza, FM | 1 |
| Gumà I Padró, J | 1 |
| Zagaja, M | 1 |
| Miziak, B | 1 |
| Piotrowski, AF | 1 |
| Blakeley, J | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Tolunay, O | 1 |
| Kömür, M | 1 |
| Gezgin, AE | 1 |
| Kaya, MS | 1 |
| Çelik, Ü | 1 |
| Lerche, H | 1 |
| Daniluk, J | 1 |
| Lotay, N | 1 |
| DeRossett, S | 1 |
| Edwards, S | 1 |
| Brandt, C | 1 |
| Walrave, L | 1 |
| Maes, K | 1 |
| Coppens, J | 1 |
| Bentea, E | 1 |
| Massie, A | 1 |
| Van Liefferinge, J | 1 |
| Flannery, AH | 1 |
| Willey, MD | 1 |
| Thompson Bastin, ML | 1 |
| Buch, KP | 1 |
| Bensadoun, ES | 1 |
| Neininger, MP | 1 |
| Ullmann, M | 1 |
| Dahse, AJ | 1 |
| Syrbe, S | 1 |
| Bernhard, MK | 1 |
| Frontini, R | 1 |
| Kiess, W | 1 |
| Merkenschlager, A | 1 |
| Thome, U | 1 |
| Bertsche, T | 1 |
| Bertsche, A | 1 |
| Ko, AR | 1 |
| Kang, TC | 1 |
| Incecik, F | 1 |
| Herguner, OM | 1 |
| Besen, S | 1 |
| Altunbasak, S | 1 |
| Lin, CH | 1 |
| Chen, CL | 1 |
| Lin, TK | 1 |
| Chen, NC | 1 |
| Tsai, MH | 1 |
| Chuang, YC | 1 |
| Motwani, N | 1 |
| Afsar, S | 1 |
| Dixit, NS | 1 |
| Sharma, N | 1 |
| Büget, B | 1 |
| Türkmen, AZ | 1 |
| Allahverdiyev, O | 1 |
| Enginar, N | 1 |
| Krishnamoorthy, V | 1 |
| Wilson, T | 1 |
| Vavilala, MS | 1 |
| Waheed, W | 1 |
| Nathan, MH | 1 |
| Allen, GB | 1 |
| Borden, NM | 1 |
| Babi, MA | 1 |
| Tandan, R | 1 |
| Patanwala, AE | 1 |
| Kurita, A | 1 |
| Truong, E | 1 |
| Trinka, E | 2 |
| Höfler, J | 1 |
| Leitinger, M | 1 |
| Rohracher, A | 1 |
| Kalss, G | 1 |
| Brigo, F | 1 |
| Fredsø, N | 1 |
| Sabers, A | 1 |
| Toft, N | 1 |
| Møller, A | 1 |
| Berendt, M | 1 |
| Chung, MG | 1 |
| O'Brien, NF | 1 |
| Lowrie, M | 1 |
| Thomson, S | 1 |
| Bessant, C | 1 |
| Sparkes, A | 1 |
| Harvey, RJ | 1 |
| Garosi, L | 1 |
| Chung, S | 1 |
| Ceja, H | 1 |
| Gawłowicz, J | 1 |
| McShea, C | 1 |
| Schiemann, J | 2 |
| Lu, S | 1 |
| Wells, GH | 1 |
| Mason, LD | 1 |
| Foreman, E | 1 |
| Chambers, J | 1 |
| Murray-Brown, FL | 1 |
| Stewart, A | 1 |
| Abou-Khalil, BW | 1 |
| Caudle, KL | 1 |
| Lu, XC | 1 |
| Bektaş, G | 1 |
| Çalışkan, M | 1 |
| Aydın, A | 1 |
| Pembegül Yıldız, E | 1 |
| Tatlı, B | 1 |
| Aydınlı, N | 1 |
| Özmen, M | 1 |
| Ito, S | 1 |
| Yano, I | 1 |
| Hashi, S | 1 |
| Tsuda, M | 1 |
| Sugimoto, M | 1 |
| Yonezawa, A | 1 |
| Ikeda, A | 1 |
| Matsubara, K | 1 |
| Töllner, K | 1 |
| Twele, F | 1 |
| Pourzitaki, C | 1 |
| Tsaousi, G | 1 |
| Apostolidou, E | 1 |
| Karakoulas, K | 1 |
| Kouvelas, D | 1 |
| Amaniti, E | 1 |
| Bhoi, SK | 1 |
| Kalita, J | 1 |
| Misra, UK | 1 |
| Steinhoff, BJ | 1 |
| Eckhardt, K | 2 |
| Doty, P | 1 |
| De Backer, M | 1 |
| Brunnert, M | 1 |
| Chen, YH | 1 |
| Huang, EY | 1 |
| Kuo, TT | 1 |
| Hoffer, BJ | 1 |
| Wu, PJ | 1 |
| Ma, HI | 1 |
| Tsai, JJ | 1 |
| Chou, YC | 1 |
| Chiang, YH | 1 |
| Nasr, ZG | 1 |
| Paravattil, B | 1 |
| Wilby, KJ | 1 |
| Floeter, AE | 1 |
| McCune, JS | 2 |
| Litofsky, NS | 1 |
| Xu, JC | 1 |
| Shen, J | 1 |
| Shao, WZ | 1 |
| Tang, LJ | 1 |
| Sun, YZ | 1 |
| Zhai, XF | 1 |
| Qi, L | 1 |
| Li, J | 1 |
| Zheng, JY | 1 |
| Zangbar, B | 1 |
| Khalil, M | 1 |
| Gruessner, A | 1 |
| Joseph, B | 1 |
| Friese, R | 1 |
| Kulvatunyou, N | 1 |
| Wynne, J | 1 |
| Latifi, R | 1 |
| Rhee, P | 1 |
| O'Keeffe, T | 1 |
| Ben-Menachem, E | 3 |
| Mameniškienė, R | 1 |
| Quarato, PP | 1 |
| Klein, P | 1 |
| Gamage, J | 1 |
| Johnson, ME | 1 |
| Whitesides, J | 1 |
| McDonough, B | 1 |
| Sedighi, M | 1 |
| Asadi, F | 1 |
| Moradian, N | 1 |
| Vakiliamini, M | 1 |
| Moradian, M | 1 |
| Fujishiro, H | 1 |
| Kosaka, K | 1 |
| Ozaki, N | 1 |
| Yang, Y | 1 |
| Zheng, F | 1 |
| Xu, X | 1 |
| Wang, X | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Vaewpanich, J | 1 |
| Reuter-Rice, K | 1 |
| Smetana, KS | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Pohlmann-Eden, B | 1 |
| Noack-Rink, M | 1 |
| Ramirez, F | 1 |
| Tofighy, A | 1 |
| Werhahn, KJ | 1 |
| Wild, I | 1 |
| Lin, Z | 1 |
| Xiaoyi, Z | 1 |
| Halbert, RK | 1 |
| Derian, A | 1 |
| Khurana, S | 1 |
| Rothenberg, J | 1 |
| Plumlee, C | 1 |
| Giorgi, FS | 1 |
| Guida, M | 1 |
| Vergallo, A | 1 |
| Bonuccelli, U | 1 |
| Khan, NR | 1 |
| VanLandingham, MA | 1 |
| Fierst, TM | 1 |
| Hymel, C | 1 |
| Hoes, K | 1 |
| Evans, LT | 1 |
| Mayer, R | 1 |
| Barker, F | 1 |
| Klimo, P | 1 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Tutka, P | 1 |
| Kondrat-Wróbel, MW | 1 |
| Zaluska, K | 1 |
| Żółkowska, D | 1 |
| Florek-Łuszczki, M | 1 |
| Łuszczki, JJ | 1 |
| Ahmad, KA | 1 |
| Desai, SJ | 1 |
| Bennett, MM | 1 |
| Ahmad, SF | 1 |
| Ng, YT | 2 |
| Clark, RH | 1 |
| Tolia, VN | 1 |
| Li, JN | 1 |
| Chen, YM | 1 |
| Höhne, J | 1 |
| Schebesch, KM | 2 |
| Ott, C | 1 |
| Brawanski, A | 1 |
| Lange, M | 2 |
| Naidech, AM | 1 |
| Beaumont, J | 1 |
| Jahromi, B | 1 |
| Prabhakaran, S | 1 |
| Kho, A | 1 |
| Holl, JL | 1 |
| Venkatesan, C | 1 |
| Young, S | 1 |
| Schapiro, M | 1 |
| Thomas, C | 1 |
| Rhee, SJ | 1 |
| Shin, JW | 1 |
| Lee, S | 1 |
| Moon, J | 1 |
| Kim, TJ | 1 |
| Jung, KY | 1 |
| Park, KI | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Mäkinen, J | 1 |
| Rainesalo, S | 1 |
| Raitanen, J | 2 |
| Peltola, J | 2 |
| Shahbaz, N | 1 |
| Younus, SM | 1 |
| Khan, SA | 1 |
| Ain, Q- | 1 |
| Khan, MA | 1 |
| Memon, MH | 1 |
| Matveeva, EA | 1 |
| Vanaman, TC | 1 |
| Whiteheart, SW | 1 |
| Slevin, JT | 1 |
| Michaelides, C | 1 |
| Thibert, RL | 1 |
| Shapiro, MJ | 1 |
| Kinirons, P | 1 |
| John, T | 1 |
| Manchharam, D | 1 |
| Thiele, EA | 1 |
| Silverstein, FS | 1 |
| Ferriero, DM | 1 |
| Wang, SB | 1 |
| Weng, WC | 1 |
| Fan, PC | 1 |
| Lee, WT | 1 |
| Bidlack, JM | 1 |
| Morris, HH | 1 |
| Azar, AE | 1 |
| Ballas, ZK | 1 |
| Azam, M | 1 |
| Bhatti, N | 1 |
| Shahab, N | 1 |
| Wade, JF | 1 |
| Dang, CV | 1 |
| Nelson, L | 1 |
| Wasserberger, J | 1 |
| Partap, S | 1 |
| Fisher, PG | 1 |
| Lippa, CF | 1 |
| Rosso, A | 1 |
| Hepler, M | 1 |
| Jenssen, S | 1 |
| Pillai, J | 1 |
| Irwin, D | 1 |
| López-Góngora, M | 1 |
| Martínez-Domeño, A | 1 |
| García, C | 1 |
| Escartín, A | 1 |
| Eberly, AL | 1 |
| Anderson, GD | 1 |
| Bubalo, JS | 1 |
| Buckley, M | 1 |
| Kuan, S | 1 |
| Barton, D | 1 |
| Zubkov, AY | 1 |
| Wijdicks, EF | 1 |
| Dudra-Jastrzebska, M | 2 |
| Andres-Mach, MM | 3 |
| Sielski, M | 1 |
| Ratnaraj, N | 4 |
| Patsalos, PN | 4 |
| Lim, DA | 1 |
| Tarapore, P | 1 |
| Chang, E | 2 |
| Burt, M | 1 |
| Chakalian, L | 1 |
| Barbaro, N | 1 |
| Chang, S | 1 |
| Lamborn, KR | 1 |
| McDermott, MW | 1 |
| Xiao, Z | 1 |
| Li, JM | 1 |
| Wang, XF | 1 |
| Xiao, F | 1 |
| Xi, ZQ | 1 |
| Lv, Y | 1 |
| Sun, HB | 1 |
| Ledet, DS | 1 |
| Wheless, JW | 2 |
| Rubnitz, JE | 1 |
| Brannon Morris, E | 1 |
| Leśkiewicz, M | 1 |
| Budziszewska, B | 1 |
| Lasoń, W | 1 |
| Clarke, D | 1 |
| Hovinga, CA | 1 |
| Ellis, M | 1 |
| Durmeier, M | 1 |
| McGregor, A | 1 |
| Perkins, F | 1 |
| Abend, NS | 2 |
| Monk, HM | 2 |
| Licht, DJ | 1 |
| Dlugos, DJ | 2 |
| Davis, GP | 1 |
| McCarthy, JT | 1 |
| Magill, DB | 1 |
| Coffey, B | 1 |
| Dinapoli, L | 1 |
| Maschio, M | 1 |
| Jandolo, B | 1 |
| Fabi, A | 1 |
| Pace, A | 1 |
| Sperati, F | 1 |
| Muti, P | 1 |
| Rijsman, RM | 1 |
| Hacquard, M | 1 |
| Richard, S | 1 |
| Lacour, JC | 1 |
| Lecompte, T | 1 |
| Vespignani, H | 2 |
| Gurses, C | 2 |
| Ekizoglu, O | 2 |
| Orhan, N | 2 |
| Ustek, D | 1 |
| Arican, N | 2 |
| Ahishali, B | 2 |
| Elmas, I | 2 |
| Kucuk, M | 2 |
| Bilgic, B | 1 |
| Kemikler, G | 2 |
| Kalayci, R | 2 |
| Karadeniz, A | 1 |
| Kaya, M | 2 |
| Kirmani, BF | 1 |
| Crisp, ED | 1 |
| Kayani, S | 1 |
| Rajab, H | 1 |
| Hurwitz, KA | 1 |
| Ingulli, EG | 1 |
| Krous, HF | 1 |
| Sethi, NK | 1 |
| Milligan, TA | 1 |
| Hurwitz, S | 1 |
| Bromfield, EB | 1 |
| Sogawa, Y | 1 |
| Kan, L | 1 |
| Levy, AS | 1 |
| Maytal, J | 1 |
| Shinnar, S | 1 |
| Ruggiero, A | 1 |
| Rizzo, D | 1 |
| Mastrangelo, S | 1 |
| Battaglia, D | 1 |
| Attinà, G | 1 |
| Riccardi, R | 1 |
| Parisi, P | 1 |
| Mohn, A | 1 |
| Grosso, S | 1 |
| Balestri, P | 1 |
| Tozzi, E | 1 |
| Iannetti, P | 1 |
| Chiarelli, F | 1 |
| Curatolo, P | 1 |
| Li, S | 1 |
| Cao, J | 1 |
| Xiao, N | 1 |
| Modur, PN | 1 |
| Milteer, WE | 1 |
| Kassab, MY | 1 |
| Lobeck, IN | 1 |
| Majid, A | 1 |
| Xie, Y | 1 |
| Farooq, MU | 1 |
| Szaflarski, JP | 2 |
| Sangha, KS | 1 |
| Lindsell, CJ | 2 |
| Shutter, LA | 2 |
| Specchio, N | 1 |
| Balestri, M | 1 |
| Cilio, MR | 1 |
| Nardello, R | 1 |
| Patanè, S | 1 |
| Margiotta, ML | 1 |
| D'Orsi, G | 1 |
| Striano, S | 1 |
| Russo, S | 1 |
| Specchio, LM | 1 |
| Cusmai, R | 1 |
| Fusco, L | 1 |
| Vigevano, F | 1 |
| Armstrong, TS | 1 |
| Choi, S | 1 |
| Walker, J | 1 |
| Gilbert, MR | 1 |
| Kuba, R | 1 |
| Novotná, I | 1 |
| Brázdil, M | 1 |
| Kocvarová, J | 1 |
| Tyrlíková, I | 1 |
| Mastík, J | 1 |
| Rektor, I | 1 |
| Frycia, A | 1 |
| Starck, JP | 1 |
| Jadot, S | 1 |
| Lallemand, B | 1 |
| Lo Brutto, P | 1 |
| Matagne, A | 5 |
| Verbois, V | 1 |
| Mercier, J | 1 |
| Kenda, B | 2 |
| Christensen, KV | 1 |
| Leffers, H | 1 |
| Watson, WP | 2 |
| Sánchez, C | 1 |
| Kallunki, P | 1 |
| Egebjerg, J | 1 |
| Fürwentsches, A | 1 |
| Bussmann, C | 1 |
| Ramantani, G | 2 |
| Ebinger, F | 1 |
| Philippi, H | 1 |
| Pöschl, J | 1 |
| Schubert, S | 2 |
| Rating, D | 2 |
| Bast, T | 1 |
| Ohno, Y | 1 |
| Ishihara, S | 1 |
| Terada, R | 1 |
| Serikawa, T | 4 |
| Sasa, M | 4 |
| Usery, JB | 1 |
| Michael, LM | 1 |
| Sills, AK | 1 |
| Finch, CK | 1 |
| Depositario-Cabacar, DT | 1 |
| Peters, JM | 1 |
| Pong, AW | 1 |
| Roth, J | 1 |
| Rotenberg, A | 1 |
| Riviello, JJ | 1 |
| Takeoka, M | 1 |
| Juba, KM | 1 |
| Weiland, D | 1 |
| Coppola, G | 1 |
| Arcieri, S | 1 |
| D'Aniello, A | 1 |
| Messana, T | 1 |
| Signoriello, G | 1 |
| Pascotto, A | 1 |
| Hastriter, EV | 1 |
| Cardenas, JF | 1 |
| Khoury, EM | 1 |
| Chapman, KE | 1 |
| Cersósimo, R | 1 |
| De los Santos, C | 1 |
| Zachenhofer, I | 1 |
| Donat, M | 1 |
| Roessler, K | 1 |
| Merrell, RT | 1 |
| Anderson, SK | 1 |
| Meyer, FB | 1 |
| Lachance, DH | 1 |
| Sugaya, Y | 1 |
| Maru, E | 1 |
| Kudo, K | 1 |
| Shibasaki, T | 1 |
| Kato, N | 1 |
| Reiter, PD | 1 |
| Huff, AD | 1 |
| Knupp, KG | 1 |
| Valuck, RJ | 1 |
| Malikova, LA | 1 |
| Fedotova, IB | 1 |
| Surina, NM | 1 |
| Poletaeva, II | 1 |
| Raevskiĭ, KS | 1 |
| Khan, S | 1 |
| Taylor, S | 1 |
| Heinrichs, RJ | 1 |
| Janzen, JM | 1 |
| Ehtisham, A | 1 |
| Ignatenco, A | 1 |
| Arzy, S | 1 |
| Ghika, J | 1 |
| Genoud, D | 1 |
| Groppa, S | 1 |
| Seeck, M | 2 |
| Matías-Guíu, J | 1 |
| Molins, A | 1 |
| Mauri, JA | 1 |
| Villar, E | 1 |
| Ikonomidou, C | 1 |
| Walter, B | 1 |
| Dinger, J | 1 |
| Guilhoto, LM | 1 |
| Loddenkemper, T | 1 |
| Vendrame, M | 1 |
| Bergin, A | 1 |
| Bourgeois, BF | 1 |
| Kothare, SV | 1 |
| Chayasirisobhon, S | 1 |
| Chayasirisobhon, WV | 1 |
| Tsay, CC | 1 |
| Gutierrez-Colina, AM | 1 |
| Clancy, RR | 1 |
| Ishii, Y | 1 |
| Chaluvadi, S | 1 |
| Chiang, S | 1 |
| Tran, L | 1 |
| Goldsmith, CE | 1 |
| Friedman, DE | 1 |
| Andrade, DM | 1 |
| Tai, P | 1 |
| Dalmau, J | 1 |
| Wennberg, R | 1 |
| Fitzgerald, CL | 1 |
| Jacobson, MP | 1 |
| Jonassen, M | 1 |
| Merhar, SL | 1 |
| Schibler, KR | 1 |
| Sherwin, CM | 1 |
| Meinzen-Derr, J | 1 |
| Shi, J | 1 |
| Balmakund, T | 1 |
| Vinks, AA | 1 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| De Fazio, S | 1 |
| Perrotta, I | 1 |
| Perrota, I | 1 |
| Di Paola, ED | 1 |
| Constanti, A | 1 |
| Sugata, S | 1 |
| Hanaya, R | 2 |
| Kumafuji, K | 1 |
| Tokudome, M | 1 |
| Kurisu, K | 2 |
| Arita, K | 2 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| McCaulley, JA | 1 |
| Pates, JA | 1 |
| Cotton, BA | 1 |
| Kao, LS | 1 |
| Kozar, R | 1 |
| Holcomb, JB | 1 |
| Kerrigan, S | 1 |
| Grant, R | 1 |
| Ooi, WW | 1 |
| Wijemanne, S | 1 |
| Thomas, CB | 1 |
| Quezado, M | 1 |
| Brown, CR | 1 |
| Nash, TE | 1 |
| Bähr, O | 1 |
| Hermisson, M | 1 |
| Rona, S | 1 |
| Rieger, J | 1 |
| Nussbaum, S | 1 |
| Körtvelyessy, P | 1 |
| Franz, K | 1 |
| Tatagiba, M | 1 |
| Seifert, V | 1 |
| Steinbach, JP | 1 |
| Lyseng-Williamson, KA | 1 |
| Filip, D | 1 |
| Aggarwal, A | 1 |
| Sharma, DD | 1 |
| Sharma, RC | 1 |
| Spencer, DD | 1 |
| Jacobi, J | 1 |
| Juenke, JM | 1 |
| Fleck, JD | 1 |
| Kays, MB | 1 |
| Kiura, Y | 1 |
| Delanty, N | 1 |
| Jones, J | 1 |
| Tonner, F | 1 |
| Deriaz, N | 1 |
| Willi, JP | 1 |
| Orihuela-Flores, M | 1 |
| Galli Carminati, G | 1 |
| Ratib, O | 1 |
| Mahta, A | 1 |
| Kim, RY | 1 |
| Kesari, S | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 1 |
| Singhi, P | 1 |
| Kern, K | 1 |
| Schlaier, J | 1 |
| Hansen, E | 1 |
| Feigl, GC | 1 |
| Brawanski, AT | 1 |
| Sponsler, JL | 1 |
| Kendrick-Adey, AC | 1 |
| Osman, NI | 1 |
| Lorincz, MT | 1 |
| Hulsing, KL | 1 |
| Gebarski, SS | 1 |
| Pieracci, FM | 1 |
| Moore, EE | 1 |
| Beauchamp, K | 1 |
| Tebockhorst, S | 1 |
| Barnett, CC | 1 |
| Bensard, DD | 1 |
| Burlew, CC | 1 |
| Biffl, WL | 1 |
| Stoval, RT | 1 |
| Johnson, JL | 1 |
| Steinbaugh, LA | 1 |
| Drust, A | 1 |
| Luchtmann, M | 1 |
| Firsching, R | 1 |
| Tröger, U | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Soni, S | 1 |
| Skeens, M | 1 |
| Termuhlen, AM | 1 |
| Bajwa, RP | 1 |
| Gross, TG | 1 |
| Pai, V | 1 |
| Hayashi, T | 1 |
| Inoue, K | 1 |
| Shinoda, J | 1 |
| Jehi, LE | 1 |
| Irwin, AI | 1 |
| Kayyali, H | 1 |
| Vadera, S | 1 |
| Bingaman, W | 1 |
| Najm, I | 1 |
| Sharpe, CM | 1 |
| Capparelli, EV | 1 |
| Mower, A | 1 |
| Farrell, MJ | 1 |
| Soldin, SJ | 1 |
| Haas, RH | 1 |
| Fisch, L | 1 |
| Mégevand, P | 1 |
| Badoud, S | 1 |
| Badoud, A | 1 |
| Burkhard, PR | 1 |
| Azzopardi, L | 1 |
| Quirk, J | 1 |
| Zafar, SN | 1 |
| Khan, AA | 1 |
| Ghauri, AA | 1 |
| Shamim, MS | 1 |
| Hoeritzauer, I | 1 |
| Mawhinney, E | 1 |
| Irwin, B | 1 |
| Hunt, SJ | 1 |
| Morrow, J | 1 |
| Craig, J | 1 |
| McTague, A | 1 |
| Kneen, R | 1 |
| Spinty, S | 1 |
| Appleton, R | 1 |
| Fuller, KL | 1 |
| Wang, YY | 1 |
| Murphy, MA | 1 |
| D'Souza, WJ | 1 |
| Aysal, F | 1 |
| Baybas, S | 1 |
| Selçuk, HH | 1 |
| Sozmen, V | 1 |
| Ozturk, M | 1 |
| Kucukoglu, H | 1 |
| Urer, NH | 1 |
| Mathew, T | 1 |
| Aroor, S | 1 |
| Nadig, R | 1 |
| Sarma, G | 1 |
| Droz-Perroteau, C | 1 |
| Marchal, C | 1 |
| Dureau-Pournin, C | 1 |
| Lassalle, R | 1 |
| Jové, J | 1 |
| Robinson, P | 1 |
| Lavernhe, G | 1 |
| Moore, N | 1 |
| Fourrier-Réglat, A | 1 |
| Ding, CH | 1 |
| Song, ZJ | 1 |
| Li, XF | 1 |
| Consoli, D | 1 |
| Bosco, D | 1 |
| Postorino, P | 1 |
| Galati, F | 1 |
| Plastino, M | 1 |
| Perticoni, GF | 1 |
| Ottonello, GA | 1 |
| Passarella, B | 1 |
| Ricci, S | 1 |
| Neri, G | 1 |
| Toni, D | 1 |
| Parentelli, AS | 1 |
| Phulpin-Weibel, A | 1 |
| Mansuy, L | 1 |
| Contet, A | 1 |
| Trechot, P | 1 |
| Chastagner, P | 1 |
| Talos, DM | 1 |
| Chang, M | 1 |
| Kosaras, B | 1 |
| Fitzgerald, E | 1 |
| Murphy, A | 1 |
| Folkerth, RD | 1 |
| Jensen, FE | 1 |
| Edrich, P | 2 |
| Van Vleymen, B | 1 |
| Sander, JW | 1 |
| Schmidt, B | 1 |
| Stratton, SC | 1 |
| Large, CH | 1 |
| Cox, B | 1 |
| Davies, G | 1 |
| Hagan, RM | 1 |
| Abou-Khalil, B | 1 |
| Lazenby, B | 1 |
| Kasteleijn-Nolst Trenité, DG | 1 |
| Hirsch, E | 1 |
| Glauser, TA | 1 |
| Dulac, O | 1 |
| Arroyo, S | 1 |
| Crawford, P | 1 |
| French, JA | 2 |
| Leppik, I | 3 |
| Morrell, M | 1 |
| Godfroid, P | 1 |
| Arrigo, C | 1 |
| Wagner, GL | 1 |
| Wilms, EB | 1 |
| Van Donselaar, CA | 1 |
| Vecht, ChJ | 1 |
| Ferrendelli, JA | 1 |
| French, J | 1 |
| Morrell, MJ | 1 |
| Herbeuval, A | 1 |
| Han, J | 1 |
| Magnus, L | 1 |
| Lynch, BA | 1 |
| Lambeng, N | 1 |
| Nocka, K | 1 |
| Kensel-Hammes, P | 1 |
| Bajjalieh, SM | 1 |
| Stahl, SM | 1 |
| Cavitt, J | 1 |
| Privitera, M | 1 |
| Glass, GA | 1 |
| Stankiewicz, J | 1 |
| Mithoefer, A | 1 |
| Freeman, R | 1 |
| Bergethon, PR | 1 |
| Kitano, Y | 2 |
| Komiyama, C | 2 |
| Makino, M | 2 |
| Takasuna, K | 2 |
| Takazawa, A | 2 |
| Sakurada, S | 2 |
| Oliveira, AA | 2 |
| Nogueira, CR | 1 |
| Nascimento, VS | 2 |
| Aguiar, LM | 2 |
| Freitas, RM | 2 |
| Sousa, FC | 2 |
| Viana, GS | 2 |
| Fonteles, MM | 2 |
| Yan, HD | 1 |
| Ji-qun, C | 1 |
| Ishihara, K | 1 |
| Nagayama, T | 1 |
| Kasai, Y | 1 |
| Kinoshita, M | 1 |
| Yamazaki, O | 1 |
| Yamauchi, T | 1 |
| Stoner, SC | 1 |
| Lea, JW | 1 |
| Wolf, AL | 1 |
| Berges, AA | 1 |
| Willmore, LJ | 2 |
| De Smedt, T | 1 |
| Vonck, K | 1 |
| Raedt, R | 1 |
| Dedeurwaerdere, S | 1 |
| Claeys, P | 1 |
| Legros, B | 1 |
| Wyckhuys, T | 1 |
| Wadman, W | 1 |
| Boon, P | 1 |
| Andres, MM | 1 |
| Czuczwar, P | 1 |
| Cioczek-Czuczwar, A | 1 |
| Mula, M | 1 |
| Trimble, MR | 1 |
| Friedman, D | 1 |
| Newton, HB | 2 |
| Goldlust, SA | 1 |
| Pearl, D | 2 |
| Collins, JJ | 1 |
| Tudor, C | 1 |
| Leonard, JM | 1 |
| Chuck, G | 1 |
| Franz, DN | 1 |
| De Rue, K | 1 |
| Perucca, E | 1 |
| Rocamora, R | 1 |
| Wagner, K | 1 |
| Anderson, NJ | 1 |
| Slough, S | 1 |
| Snoeck, E | 1 |
| Stockis, A | 1 |
| Falip, M | 1 |
| Carreño, M | 1 |
| Amaro, S | 1 |
| Donaire, A | 1 |
| Delgado, R | 1 |
| Toledo, M | 1 |
| Maestro, I | 1 |
| Almeida, JP | 1 |
| Júnior, HV | 1 |
| Fonseca, FN | 1 |
| Bootsma, HP | 1 |
| Ricker, L | 1 |
| Diepman, L | 1 |
| Gehring, J | 1 |
| Hulsman, J | 1 |
| Lambrechts, D | 1 |
| Leenen, L | 1 |
| Majoie, M | 1 |
| Schellekens, A | 1 |
| de Krom, M | 1 |
| Aldenkamp, AP | 1 |
| Papacostas, SS | 1 |
| Papathanasiou, ES | 1 |
| Myrianthopoulou, P | 1 |
| Stylianidou, G | 1 |
| Ueda, Y | 1 |
| Doi, T | 1 |
| Nagatomo, K | 1 |
| Tokumaru, J | 1 |
| Takaki, M | 1 |
| Dalton, J | 1 |
| Goldlust, S | 1 |
| Auriel, E | 1 |
| Chistik, V | 1 |
| Blatt, I | 1 |
| Margolin, N | 1 |
| Neufeld, M | 1 |
| Pustorino, G | 1 |
| Spano, M | 1 |
| Sgro, DL | 1 |
| Di Rosa, G | 1 |
| Tricomi, G | 1 |
| Bellantone, D | 1 |
| Tortorella, G | 1 |
| Shoemaker, MT | 1 |
| Rotenberg, JS | 1 |
| Tai, KK | 1 |
| Truong, DD | 1 |
| Awaad, Y | 1 |
| Costa, C | 1 |
| Galletti, F | 1 |
| Pisani, F | 1 |
| Calabresi, P | 1 |
| Parnetti, L | 1 |
| Kim, JS | 1 |
| Kondratyev, A | 1 |
| Tomita, Y | 1 |
| Gale, K | 1 |
| Peltola, M | 1 |
| Keränen, T | 1 |
| Kharazmi, E | 1 |
| Auvinen, A | 1 |
| Callenbach, PM | 1 |
| Arts, WF | 1 |
| ten Houten, R | 1 |
| Augustijn, P | 1 |
| Gunning, WB | 1 |
| Peeters, EA | 1 |
| Weber, AM | 1 |
| Stroink, H | 1 |
| Geerts, Y | 1 |
| Geerts, AT | 1 |
| Brouwer, OF | 1 |
| Margineanu, DG | 2 |
| Klitgaard, H | 4 |
| Kulkarni, SK | 1 |
| Mehta, AK | 1 |
| Dienel, A | 2 |
| Andreas, K | 2 |
| Schmidt, J | 2 |
| Wülfert, E | 3 |
| Gobert, J | 2 |
| Rüthrich, H | 1 |
| Grecksch, G | 1 |
| Krug, M | 2 |
| Reissmüller, E | 1 |
| Ebert, U | 1 |
| Rauca, C | 1 |
| Jantze, H | 1 |
| Dooley, M | 1 |
| Plosker, GL | 1 |
| Chatterjie, N | 1 |
| Alexander, G | 1 |
| Gower, AJ | 1 |
| Noyer, M | 1 |
| Verloes, R | 1 |
| Fischer, W | 1 |
| Kittner, H | 1 |
| Georgiev, V | 1 |
| Petkova, B | 1 |
| Kambourova, T | 1 |
| Opitz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on Glioma Patients: Understanding Their Glioma Clinical Trial Experiences[NCT05958472] | 500 participants (Anticipated) | Observational | 2024-08-31 | Not yet recruiting | |||
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Relation Between Renal Resistive Index, Glomerular Hyperfiltration and Hyperdynamic Circulation in Critically Ill Patients With Trauma or Sepsis.[NCT02560402] | 40 participants (Actual) | Observational | 2015-08-31 | Completed | |||
| An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs[NCT01063764] | Phase 3 | 73 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?[NCT03054285] | Phase 4 | 2,300 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures[NCT00464269] | Phase 3 | 400 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures[NCT01261325] | Phase 3 | 768 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.[NCT00490035] | Phase 3 | 399 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study[NCT03517423] | 51 participants (Actual) | Observational | 2018-10-04 | Completed | |||
| A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/[NCT00175903] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide[NCT01110187] | 11 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to Lack of enrollement) | |||
| Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study[NCT02707965] | Phase 1 | 21 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)[NCT00571155] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less T[NCT00150748] | Phase 3 | 217 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit[NCT00618436] | Phase 4 | 52 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures[NCT00884052] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures[NCT01720667] | Phase 1/Phase 2 | 280 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children[NCT04926844] | Phase 2 | 144 participants (Actual) | Interventional | 2021-06-20 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The outcome was also calculated for each 3-month Period but here only the result for the total Second Evaluation Period (Second Period without following 6-weeks Withdrawal Period for withdrawers) is presented.~Change in partial seizure frequency from Baseline (B) over Second Evaluation Period (E) is given as a percentage reduction computed as:~(B values- E values) / B values x 100. Positive values in percent reduction show a decrease from Baseline. Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7." (NCT01063764)
Timeframe: From Baseline (Week 0-8) until the time of approval granted (up to three years from date of informed consent (Week 0); without 6-weeks Withdrawal Period)
| Intervention | Percent reduction (Median) |
|---|---|
| Levetiracetam | 41.32 |
"The change in partial seizure frequency from Baseline (B) over the Evaluation Period (E) is given as a percentage reduction computed as:~(B values- E values) / B values x 100. Positive values in percent reduction mean that the value decreased from Baseline to the 10-week Evaluation Period.~Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7.~Partial seizures can be classified into:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: From Baseline (Week 0-8) to the 10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)
| Intervention | Percent reduction (Median) |
|---|---|
| Levetiracetam | 39.02 |
"The change in partial seizure frequency from Baseline (B) over the Treatment Period (T) is given as a percentage reduction computed as:~(B values- T values) / B values x 100.~Positive values in percent reduction mean that the value decreased from Baseline during the first 14-week Period.~Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7.~Partial seizures can be classified into:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: From Baseline (Week 0-8) to the 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22)); Week 0-22
| Intervention | Percent reduction (Median) |
|---|---|
| Levetiracetam | 43.21 |
An Adverse Drug Reaction (ADR) is an Adverse Event for which a causal relationship between the product and the occurrence is suspected. Incidence of ADRs is reported by the number of subjects with at least one ADR. (NCT01063764)
Timeframe: During the second Period from Visit 8 (Week 22) to the end of the Follow-up Period (up to three years until the time of approval granted)
| Intervention | participants (Number) |
|---|---|
| Levetiracetam | 15 |
An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with the pharmaceutical product. Incidence of treatment-emergent AEs is reported by the percentage of subjects with at least one treatment-emergent AE. (NCT01063764)
Timeframe: During the second Period from Visit 8 (Week 22) to the end of the Follow-up Period (up to three years until the time of approval granted)
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 98.2 |
"Seizure-free means not having a seizure of type I (Partial seizure).~Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)
| Intervention | participants (Number) |
|---|---|
| Levetiracetam | 3 |
"Seizure-free means not having a seizure of type I (Partial seizure).~Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))
| Intervention | participants (Number) |
|---|---|
| Levetiracetam | 2 |
"The seizure frequency per week was calculated as:~Frequency per week of partial seizures = (Total number of partial seizures in the Evaluation Period/number of days for observation in the Evaluation Period) x 7. Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)
| Intervention | Seizures per week (Median) |
|---|---|
| Levetiracetam | 3.90 |
"The seizure frequency per week was calculated as:~Frequency per week of partial seizures = (Total number of partial seizures in the Treatment Period/number of days for observation in the Treatment Period) x 7. Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))
| Intervention | Seizures per week (Median) |
|---|---|
| Levetiracetam | 3.92 |
"50 % responders are those subjects which have a 50 % or more reduction in the frequency of partial seizures from Baseline to the Evaluation Period. The results show the percentage of participants that are 50 % responders.~Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 38.2 |
"50 % responders are those subjects which have a 50 % or more reduction in the frequency of partial seizures from Baseline to the Treatment Period. The results show the percentage of participants that are 50 % responders.~Partial seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to secondarily generalized seizures." (NCT01063764)
Timeframe: 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 38.4 |
"There are three different types of seizures:~Type I: Partial seizures~Type II: Generalized seizures~Type III: Unclassified epileptic seizures.~All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.77 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.79 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.26 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.36 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 3.37 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.97 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.03 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.06 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.14 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.69 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 2.07 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.97 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 6.41 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 2.24 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.94 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 0.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 8.1 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 6.9 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.3 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.5 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 7.44 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.32 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.55 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 7.99 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.97 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 4.82 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.81 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.02 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | -2.61 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 0.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 6.07 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.49 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.39 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.66 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.33 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 9.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.34 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.69 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.97 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3.88 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.07 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5.19 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.88 |
"Partial (Type I) seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to generalized tonic-clonic convulsions.~Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as:~(Total Type I seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.70 |
"Percent change from Baseline was calculated as percent reduction by:~(weekly seizure frequency Baseline - weekly seizure frequency Treatment)*100/(weekly seizure frequency Baseline).~The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | Percent change in POS frequency (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 17.75 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.95 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 22.52 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 30.47 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 56.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 50.0 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 77.8 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 63.6 |
The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 14 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 19 |
The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4 |
The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 28 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 30 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 34 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 37 |
"Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: <-25 %, -25 % to <25 %, 25 % to <50 %, 50 % to <75 %, 75 % to <100 %, and 100 %.~Subjects having zero for Baseline seizure frequency per week were classified in the <-25 % category." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 14.1 | 38.4 | 24.2 | 15.2 | 6.1 | 2.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21.9 | 31.3 | 25.0 | 12.5 | 8.3 | 1.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 9.9 | 31.7 | 25.7 | 19.8 | 8.9 | 4.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 14.6 | 44.8 | 24.0 | 12.5 | 4.2 | 0 |
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17.2 | 18.2 | 31.3 | 32.3 | 1.0 | 0 | 0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 12.2 | 18.9 | 24.4 | 34.4 | 2.2 | 7.8 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 16.3 | 27.6 | 24.5 | 25.5 | 2.0 | 3.1 | 1.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 12.6 | 20.0 | 21.1 | 41.1 | 3.2 | 1.1 | 1.1 |
Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 18.8 | 26.3 | 21.3 | 27.5 | 1.3 | 3.8 | 1.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.8 | 24.7 | 18.5 | 23.5 | 6.2 | 7.4 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 26.7 | 19.8 | 22.1 | 23.3 | 4.7 | 1.2 | 2.3 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15.5 | 25.0 | 23.8 | 28.6 | 4.8 | 1.2 | 1.2 |
The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 23 | 76 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21 | 75 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 33 | 68 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 16 | 80 |
"Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as:~(total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Seizure-free | No seizures but non-completer | Not seizure-free | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.0 | 1.0 | 98.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.0 | 0 | 99.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4.0 | 0 | 96.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 0 | 0 | 100.0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | number of seizures/ 28-day (Median) |
|---|---|
| Placebo | 8.7 |
| Brivaracetam 100 mg/Day | 6.3 |
| Brivaracetam 200 mg/Day | 5.8 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of change (Median) |
|---|---|
| Placebo | 17.6 |
| Brivaracetam 100 mg/Day | 37.2 |
| Brivaracetam 200 mg/Day | 35.6 |
Primary endpoint: United States of America (FDA) (NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | Percentage of reduction (Number) |
|---|---|
| Brivaracetam 100 mg/Day | 22.8 |
| Brivaracetam 200 mg/Day | 23.2 |
| Placebo | 0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Brivaracetam 100 mg/Day | 21 |
| Brivaracetam 200 mg/Day | 23 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 3 |
| Brivaracetam 100 mg/Day | 5 |
| Brivaracetam 200 mg/Day | 6 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 32 |
| Brivaracetam 100 mg/Day | 37 |
| Brivaracetam 200 mg/Day | 43 |
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration. (NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | Percentage of subjects (Number) | |
|---|---|---|
| Responders | Non-Responders | |
| Brivaracetam 100 mg/Day | 38.9 | 61.1 |
| Brivaracetam 200 mg/Day | 37.8 | 62.2 |
| Placebo | 21.6 | 78.4 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of subjects (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to <25 % | 25 % to <50 % | 50 % to <75 % | 75 % to <100 % | 100 % | |
| Brivaracetam 100 mg/Day | 14.3 | 28.6 | 18.3 | 19.0 | 13.9 | 6.0 |
| Brivaracetam 200 mg/Day | 10.8 | 29.3 | 22.1 | 18.1 | 13.7 | 6.0 |
| Placebo | 16.6 | 40.5 | 21.2 | 13.9 | 6.9 | 0.8 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| Seizure free | No seizures but discontinued | Not seizure free | |
| Brivaracetam 100 mg/Day | 5.2 | 1.2 | 93.7 |
| Brivaracetam 200 mg/Day | 4.0 | 1.2 | 94.8 |
| Placebo | 0.8 | 0.4 | 98.8 |
There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III). (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Times per week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 1.80 |
| Brivaracetam 20 mg/Day | 5.36 |
| Brivaracetam 50 mg/Day | 1.02 |
| Brivaracetam 100 mg/Day | 0.69 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Brivaracetam 20 mg/Day | 3.35 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 3.50 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.80 |
| Brivaracetam 20 mg/Day | 3.75 |
| Brivaracetam 50 mg/Day | 3.13 |
| Brivaracetam 100 mg/Day | -2.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.49 |
| Brivaracetam 20 mg/Day | 3.53 |
| Brivaracetam 50 mg/Day | 1.95 |
| Brivaracetam 100 mg/Day | 1.99 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 6.6 |
| Brivaracetam 20 mg/Day | 6.9 |
| Brivaracetam 50 mg/Day | 9.7 |
| Brivaracetam 100 mg/Day | 4.9 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.54 |
| Brivaracetam 20 mg/Day | -0.59 |
| Brivaracetam 50 mg/Day | -0.41 |
| Brivaracetam 100 mg/Day | 0.08 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.65 |
| Brivaracetam 20 mg/Day | -0.10 |
| Brivaracetam 50 mg/Day | 0.26 |
| Brivaracetam 100 mg/Day | -0.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.92 |
| Brivaracetam 20 mg/Day | 3.64 |
| Brivaracetam 50 mg/Day | -0.85 |
| Brivaracetam 100 mg/Day | 3.00 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 5.11 |
| Brivaracetam 20 mg/Day | 4.52 |
| Brivaracetam 50 mg/Day | 4.55 |
| Brivaracetam 100 mg/Day | 2.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 8.25 |
| Brivaracetam 20 mg/Day | 6.23 |
| Brivaracetam 50 mg/Day | 5.34 |
| Brivaracetam 100 mg/Day | 8.04 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.29 |
| Brivaracetam 20 mg/Day | 4.50 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 1.78 |
"The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: Assess the Overall change in the severity of patient's illness, compared to start of study medication." (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.78 |
| Brivaracetam 20 mg/Day | 4.99 |
| Brivaracetam 50 mg/Day | 4.99 |
| Brivaracetam 100 mg/Day | 5.34 |
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Seizure Frequency per Week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
"The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: Overall, has there been a change in your seizures since the start of the study medication?" (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.93 |
| Brivaracetam 20 mg/Day | 5.17 |
| Brivaracetam 50 mg/Day | 5.04 |
| Brivaracetam 100 mg/Day | 5.47 |
The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percent change in seizures per week (Median) |
|---|---|
| Placebo | -17.03 |
| Brivaracetam 20 mg/Day | -30.03 |
| Brivaracetam 50 mg/Day | -26.83 |
| Brivaracetam 100 mg/Day | -32.45 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.9 |
| Brivaracetam 20 mg/Day | 47.2 |
| Brivaracetam 50 mg/Day | 62.5 |
| Brivaracetam 100 mg/Day | 41.0 |
The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 19 |
| Brivaracetam 20 mg/Day | 25 |
| Brivaracetam 50 mg/Day | 24 |
| Brivaracetam 100 mg/Day | 24 |
The time to first Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 4 |
| Brivaracetam 20 mg/Day | 6 |
| Brivaracetam 50 mg/Day | 6 |
| Brivaracetam 100 mg/Day | 4 |
The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 39 |
| Brivaracetam 20 mg/Day | 49 |
| Brivaracetam 50 mg/Day | 40 |
| Brivaracetam 100 mg/Day | 46 |
"The categories are:~<= 25 %~- 25 % to < 25 %~25 % to < 50 %~50 % to < 75 %~75 % to < 100 %~100 %" (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| <= 25 % | - 25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Brivaracetam 100 mg/Day | 10.0 | 33.0 | 21.0 | 14.0 | 18.0 | 4.0 |
| Brivaracetam 20 mg/Day | 10.1 | 35.4 | 27.3 | 18.2 | 7.1 | 2.0 |
| Brivaracetam 50 mg/Day | 15.2 | 33.3 | 24.2 | 17.2 | 9.1 | 1.0 |
| Placebo | 19.0 | 41.0 | 20.0 | 12.0 | 8.0 | 0 |
"Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.~The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a >= 50 % reduction in seizure frequency per week from Baseline." (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Non-responders | Responders | |
| Brivaracetam 100 mg/Day | 64.0 | 36.0 |
| Brivaracetam 20 mg/Day | 72.7 | 27.3 |
| Brivaracetam 50 mg/Day | 72.7 | 27.3 |
| Placebo | 80.0 | 20.0 |
Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Seizure free | No Seizures but non-completer | Not Seizure-free | |
| Brivaracetam 100 mg/Day | 4.0 | 0 | 96.0 |
| Brivaracetam 20 mg/Day | 2.0 | 0 | 98.0 |
| Brivaracetam 50 mg/Day | 0 | 1.0 | 99.0 |
| Placebo | 0 | 0 | 100.0 |
The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7. (NCT01110187)
Timeframe: baseline to 7 days
| Intervention | number of events experienced (Number) |
|---|---|
| IV LCM | 12 |
| IV fPHT | 21 |
Number of seizures in the first 72 hours based on EEG recording (NCT01110187)
Timeframe: baseline to 72 hours
| Intervention | number of participants with seizures (Number) |
|---|---|
| IV LCM | 0 |
| IV fPHT | 0 |
summed for each anti-epileptic drug from when taking brand and generic. (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | events (Number) |
|---|---|
| Topiramate | 29 |
| Lamotrigine ER | 9 |
| Levetiracetam IR | 17 |
| Levetiracetam ER | 4 |
| Carbamazepine ER Capsule | 15 |
| Zonisamide | 6 |
| Carbamazepine ER Tablet | 10 |
| Valproic Acid | 10 |
Average AUC (area under the drug plasma curve. (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | micro/mL/hr (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 114.96 | 106.45 |
| Carbamazepine ER Tablet | 104.6 | 115.16 |
| Lamotrigine ER Tablet | 62.76666667 | 67.19333333 |
| Levetiracetam ER Tablet | 260.3 | 262.305 |
| Levetiracetam IR Tablet | 419.97 | 445.2 |
| Topiramate Tablet | 92.884 | 94.456 |
| Zonisamide Capsule | 233.16 | 226.14 |
Average maximum drug plasma concentration; (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 10.95 | 9.91 |
| Carbamazepine ER Tablet | 10.00 | 10.6 |
| Lamotrigine ER Tablet | 6.24 | 6.903333333 |
| Levetiracetam ER Tablet | 31.05 | 28.04 |
| Levetiracetam IR Tablet | 71.02333333 | 69.29333333 |
| Topiramate Tablet | 9.874 | 9.646 |
| Zonisamide Capsule | 12.29 | 11.68 |
Average minimum drug plasma concentration (Cmin); (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 8.56 | 7.66 |
| Carbamazepine ER Tablet | 7.37 | 7.97 |
| Lamotrigine ER Tablet | 4.053333333 | 4.21 |
| Levetiracetam ER Tablet | 12.605 | 14.395 |
| Levetiracetam IR Tablet | 15.45333333 | 17.45666667 |
| Topiramate Tablet | 6.326 | 6.53 |
| Zonisamide Capsule | 8.46 | 8.34 |
Number of seizures reported in all groups (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | Number of Seizures (Number) | |
|---|---|---|
| Reference Product | Test (Generic) | |
| Carbamazepine ER Capsule | 3 | 1 |
| Carbamazepine ER Tablet | 0 | 0 |
| Lamotrigine ER Tablet Group | 44 | 25 |
| Lamotrigine IR Tablet Group | 0 | 0 |
| Levetiracetam ER Tablet Group | 42 | 72 |
| Levetiracetam IR Tablet Group | 16 | 5 |
| Topiramate Tablet Group | 9 | 5 |
| Valproic Acid ER Tablet Group | 12 | 0 |
| Zonisamide Capsule Group | 0 | 0 |
This was the number of patients in each group who demonstrated seizure activity during the course of the study (NCT00618436)
Timeframe: Duration of study, up to 6 months after the injury
| Intervention | Participants (Number) |
|---|---|
| Levetiracetam | 5 |
| Phenytoin | 3 |
The Disability rating scale (DRS) is frequently used in the rehabilitation literature as a measure of disability. It is a reliable, easily performed test that assesses 8 items (eye opening, verbalization, motor response, feeding, toileting, grooming, level of functioning, employability), and assigns each a numerical score ranging from 0 - 5 based on the category. The domains these 8 items are felt to assess include: alertness, cognition for self-care, dependence, and psychosocial adaptability. The scoring range is from 0-30, with increasing disability levels assigned to higher numerical values. The total DRS is then dichotomized into favorable (disability = none, mild, partial or moderate disability) and unfavorable (disability = moderately severe, severe, extremely severe, vegetative state, extreme vegetative state, death) outcomes. A DRS score of 0-6 was favorable, with any score greater than 6 categorized as unfavorable. (NCT00618436)
Timeframe: Discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 24 | 15 | 17 |
| Phenytoin | 23 | 13 | 9 |
This is an 8 point validated scale that measures disability after brain injury. It is assessed through an in person exam or by phone interview at hospital discharge, 3 months and 6 months after injury. The categories are: 1 = dead; 2 = vegetative state; 3 = severe disability, low level; 4 = severe disability, high level; 5 = moderate disability, low level; 6 = moderate disability, high level; 7 = good recovery - low level; 8 = good recovery - high level. Specific questions and activities are assessed to determine into which category the patient falls. (NCT00618436)
Timeframe: at discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 2 | 3 | 3 |
| Phenytoin | 2 | 3 | 3 |
(NCT00884052)
Timeframe: 7 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Levetiracetam Low Dose | 0 |
| Levetiracetam High Dose | 1 |
(NCT00884052)
Timeframe: Day 1 and Day 7
| Intervention | ml/min/kg (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| All Participants | 0.71 | 1.31 |
(NCT00884052)
Timeframe: Day 1 and Day 7
| Intervention | hr (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| All Participants | 18.5 | 9.1 |
Number of babies with seizure control at levetiracetam (60 mg/Kg load) who had not responded to 40 mg/kg load and number of babies with seizure control at 40 mg/kg who had not responded to 20 mg/kg. (NCT01720667)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Levetiracetam | 4 |
| Intravenous Phenobarbital | 3 |
"A head to head comparison of the efficacy of intravenous levetiracetam versus phenobarbital in the treatment of EEG proven neonatal seizures.~Seizure cessation from 15 minutes after completion of infusion for 24 hours as assessed by continuous EEG reviewed by neurophysiologists." (NCT01720667)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Levetiracetam | 15 |
| Intravenous Phenobarbital | 24 |
A head to head comparison of the efficacy of intravenous levetiracetam versus phenobarbital in the treatment of EEG proven neonatal seizures. (NCT01720667)
Timeframe: 48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Levetiracetam | 8 |
| Intravenous Phenobarbital | 18 |
(NCT01720667)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Levetiracetam | 6 |
| Intravenous Phenobarbital | 9 |
A head to head comparison of the efficacy of intravenous levetiracetam versus phenobarbital in the treatment of EEG proven neonatal seizures. (NCT01720667)
Timeframe: 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Levetiracetam | 26 |
| Intravenous Phenobarbital | 28 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
65 reviews available for piracetam and Seizures
| Article | Year |
|---|---|
Phenytoin prophylaxis and functional outcomes following spontaneous intracerebral hemorrhage: A systematic review and meta-analysis.
Topics: Anticonvulsants; Cerebral Hemorrhage; Humans; Phenytoin; Piracetam; Prospective Studies; Seizures | 2021 |
Comparative efficacy of prophylactic anticonvulsant drugs following traumatic brain injury: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Carbamazepine; Child; Humans; Levetiracetam; Network Met | 2022 |
Use of antiepileptic drugs as prophylaxis against posttraumatic seizures in the pediatric population: a systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Child; Humans; Levetiracetam; Phenytoin; Piraceta | 2023 |
Levetiracetam at the End of Life: A Case Report and Discussion.
Topics: Anticonvulsants; Death; Humans; Levetiracetam; Piracetam; Seizures | 2020 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2020 |
Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis.
Topics: Anticonvulsants; Benzodiazepines; Drug Therapy, Combination; Humans; Levetiracetam; Phenytoin; Pirac | 2020 |
Efficacy of Levetiracetam in neonatal seizures: a systematic review.
Topics: Adult; Anticonvulsants; Child; Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Pira | 2022 |
Subcutaneous Levetiracetam for the Management of Seizures at the End of Life: An Audit and Updated Literature Review.
Topics: Anticonvulsants; Death; Humans; Levetiracetam; Piracetam; Retrospective Studies; Seizures | 2021 |
Preventing seizure occurrence following spontaneous intracerebral haemorrhage: A systematic review and meta-analysis of seizure prophylaxis.
Topics: Aged; Anticonvulsants; Cerebral Hemorrhage; Female; Humans; Levetiracetam; Male; Middle Aged; Phenyt | 2021 |
A Systematic Review and Meta-Analysis of Antiepileptic Prophylaxis in Spontaneous Intracerebral Hemorrhage.
Topics: Anticonvulsants; Cerebral Hemorrhage; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2021 |
A case of 55-year-old man with first-ever generalized seizure diagnosed with Sturge-Weber syndrome type III by characteristic MRI findings.
Topics: Administration, Oral; Brain; Humans; Late Onset Disorders; Levetiracetam; Magnetic Resonance Imaging | 2017 |
A Review on Pharmacokinetics of Levetiracetam in Neonates.
Topics: Animals; Anticonvulsants; Humans; Infant, Newborn; Levetiracetam; Piracetam; Seizures | 2017 |
Subcutaneous levetiracetam for the management of seizures at the end of life.
Topics: Anticonvulsants; Disease Management; Humans; Infusions, Subcutaneous; Levetiracetam; Palliative Care | 2018 |
Levetiracetam versus phenytoin for seizure prophylaxis in brain injured patients: a systematic review and meta-analysis.
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Post-Exposure Prophyla | 2017 |
Feline Epilepsy.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsy; Levetiracetam; Phenobarbital; Piracetam; Pro | 2018 |
A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures.
Topics: Anticonvulsants; Humans; Infant, Newborn; Levetiracetam; Piracetam; PubMed; Seizures | 2018 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2018 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
Newly emerging therapies for neonatal seizures.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Child Development; Epilepsy; Fructose; Humans; Infant, | 2013 |
Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types.
Topics: Adult; Anticonvulsants; Child; Drug Therapy, Combination; Humans; Levetiracetam; Piracetam; Randomiz | 2014 |
Pharmacotherapy for tonic-clonic seizures.
Topics: Acetamides; Anticonvulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Fructose; Humans; Lacosa | 2014 |
Choice of approaches in developing novel medical countermeasures for nerve agent poisoning.
Topics: Animals; Anticonvulsants; Antidotes; Brain; Cholinergic Agents; Humans; Levetiracetam; Organophospha | 2014 |
Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect.
Topics: Animals; Anticonvulsants; Binding Sites; Carbamazepine; Dose-Response Relationship, Drug; Drug Thera | 2014 |
The treatment of neonatal seizures: focus on Levetiracetam.
Topics: Anticonvulsants; Humans; Infant, Newborn; Levetiracetam; Piracetam; Seizures; Treatment Outcome | 2016 |
Medical management of patients with brain tumors.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Brain Edema; Brain Neoplasms; Cognition Disorders; Dopamin | 2015 |
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.
Topics: Animals; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Levetiracetam; Piracetam; Seizures | 2016 |
Clinical Management of Seizures in Patients With Low-Grade Glioma.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Lamotrigine; Levetiracetam; Piracetam; Seizures; T | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Pharmacologic treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Humans; Ketamine; Levetiracetam; Piracetam; Randomized Controlled | 2016 |
Antiepileptic Drugs.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; O | 2016 |
Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis.
Topics: Anticonvulsants; Craniotomy; Humans; Levetiracetam; Perioperative Care; Phenytoin; Piracetam; Seizur | 2016 |
Skin rash following levetiracetam.
Topics: Adult; Anticonvulsants; Exanthema; Female; Humans; Levetiracetam; Male; Piracetam; Seizures; Young A | 2016 |
Levetiracetam for seizure prevention in brain tumor patients: a systematic review.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Observational Studies as Topic; Piracetam; | 2016 |
Anti-epileptic drugs in pediatric traumatic brain injury.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Child; Humans; Levetiracetam; Phenytoin; Piracetam; Seiz | 2016 |
The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2016 |
Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Cohort Studies; Humans; Levetiracetam; Observational Stu | 2016 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Response to "Response to Zhang et al.: Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison".
Topics: Adult; Anticonvulsants; Female; Humans; Levetiracetam; Male; Piracetam; Pyrrolidinones; Seizures | 2016 |
Treatment of epilepsy in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Seizures | 2017 |
Should Levetiracetam or Phenytoin Be Used for Posttraumatic Seizure Prophylaxis? A Systematic Review of the Literature and Meta-analysis.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2016 |
[Comparisons of efficacy and safety of levetiracetam versus phenytoin for seizure prophylaxis in patients with brain injury: a meta analysis].
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Randomized Controlled | 2016 |
Emergent complications of the newer anticonvulsants.
Topics: Acidosis; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Overdose; Fructo | 2010 |
Optimal prevention of seizures induced by high-dose busulfan.
Topics: Alkylating Agents; Animals; Anticonvulsants; Benzodiazepines; Busulfan; Dose-Response Relationship, | 2008 |
Antiepileptic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Animals; Anticonvulsants; Electroencephalography; Head Injuries, Closed; Humans; Levetiracetam; Neur | 2008 |
[Endocrine effects of antiepileptic drugs].
Topics: Anticonvulsants; Carbamazepine; Endocrine System Diseases; Estradiol; Female; Hormones; Humans; Leve | 2008 |
Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment?
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Interactions; | 2010 |
A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Dru | 2010 |
[Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
Topics: Acute Disease; Allosteric Regulation; Animals; Anticonvulsants; Calcium; Calcium Channel Blockers; C | 2011 |
Antiepileptic drugs for treating seizures in adults with brain tumours.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drug Substitution; Humans; Levetiracetam; Phenytoin; Pirace | 2011 |
Spotlight on levetiracetam in epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chemotherapy, Adjuvant; Epilepsy; Humans; Levetiracetam; Piracetam; | 2011 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury - a meta analysis.
Topics: Adult; Aged; Brain Injuries; Causality; Comorbidity; Convulsants; Female; Humans; Levetiracetam; Mal | 2012 |
Long-term experience with levetiracetam.
Topics: Anticonvulsants; Drug Evaluation; Drug Therapy, Combination; Epilepsy; Humans; Levetiracetam; Longit | 2003 |
Levetiracetam: preliminary efficacy in generalized seizures.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Electroencephalography; Epilepsy; Follow-Up Stud | 2003 |
Preliminary efficacy of levetiracetam in children.
Topics: Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Humans; Levetiracetam; Piracetam; Pr | 2003 |
Preliminary efficacy of levetiracetam in monotherapy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Seizures; Time Factors | 2003 |
Safety profile of levetiracetam.
Topics: Age Factors; Anticonvulsants; Drug Interactions; Epilepsy; Humans; Levetiracetam; Persons with Menta | 2003 |
Role of levetiracetam in the treatment of epilepsy.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Drug Resistance; Epilepsy; Female; Humans; Levetiracetam; | 2003 |
Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy.
Topics: Adult; Confidence Intervals; Dose-Response Relationship, Drug; Epilepsies, Partial; Female; Humans; | 2003 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience.
Topics: Adult; Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 2006 |
Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures.
Topics: Anticonvulsants; Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationshi | 2007 |
Levetiracetam. A review of its adjunctive use in the management of partial onset seizures.
Topics: Administration, Oral; Adult; Animals; Anticonvulsants; Child; Cognition; Dose-Response Relationship, | 2000 |
Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
Topics: Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug E | 2001 |
35 trials available for piracetam and Seizures
| Article | Year |
|---|---|
Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial.
Topics: Breath Holding; Child, Preschool; Combined Modality Therapy; Docosahexaenoic Acids; Humans; Infant; | 2023 |
Prophylactic Levetiracetam for Seizure Control After Cranioplasty: A Multicenter Prospective Controlled Study.
Topics: Adult; Anticonvulsants; Craniotomy; Electroencephalography; Female; Humans; Intracranial Hypertensio | 2017 |
Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study.
Topics: Adult; Anticonvulsants; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; Phenytoin; Pira | 2017 |
Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus.
Topics: Administration, Rectal; Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Levetiracetam; Male; P | 2018 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
[Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation].
Topics: Adolescent; Asian People; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, C | 2013 |
Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Female; Follow-Up Studies; | 2014 |
Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Cohort Studies; Cranio | 2015 |
The efficacy of levetiracetam for focal seizures and its blood levels in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Huma | 2015 |
Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Topics: Aged; Anticonvulsants; Carbamates; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
[Effects of Long-Term Treatment with Levetiracetam as an Adjunctive Therapy in Japanese Children with Uncontrolled Partial-Onset Seizures: A Multicenter, Open-Label Study].
Topics: Adolescent; Anticonvulsants; Asian People; Child; Child, Preschool; Dose-Response Relationship, Drug | 2015 |
A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Phenobarbital; | 2016 |
Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
Topics: Adult; Anticonvulsants; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2016 |
Efficacy and safety of levetiracetam in the management of seizures in neonates.
Topics: Anticonvulsants; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Iran; Levetiracetam; Ma | 2016 |
Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Levetiracetam; Ma | 2016 |
Tolerability and dosing experience of intravenous levetiracetam in children and infants.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Dr | 2008 |
Levetiracetam in continuous spike waves during slow-wave sleep syndrome.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Follow-Up Studies; Humans; | 2008 |
Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Cognition; Cognition Disorders; Disease-Free Surviv | 2010 |
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Craniotomy; Female; Glioma; Humans | 2009 |
Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Body Weight; Chemotherapy, Adjuvant; | 2009 |
Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study.
Topics: Adolescent; Adult; Anticonvulsants; Blood Pressure; Child; Child, Preschool; Electrocardiography; Ep | 2009 |
Levetiracetam monotherapy for childhood occipital epilepsy of gastaut.
Topics: Adolescent; Anticonvulsants; Child; Drug Administration Schedule; Electroencephalography; Epilepsies | 2009 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Levetiracetam in the treatment of neonatal seizures: a pilot study.
Topics: Anticonvulsants; Feasibility Studies; Female; Humans; Infant, Newborn; Levetiracetam; Male; Pilot Pr | 2010 |
Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Chemotherapy, Adjuvant; Electro | 2012 |
Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
Topics: Anticonvulsants; Brain Injuries; Critical Care; Female; Hematoma, Subdural; Humans; Infusions, Intra | 2011 |
Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety; Child; Child, Preschool; Depression; Dose-Response Rela | 2012 |
Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Craniotomy; Female; Hu | 2013 |
Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Female; Humans; | 2012 |
Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Topics: Adolescent; Adult; Anticonvulsants; Behavior; Cognition Disorders; Double-Blind Method; Drug Therapy | 2003 |
Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Admini | 2003 |
Levetiracetam for seizures after liver transplantation.
Topics: Anticonvulsants; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions | 2005 |
[Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Pira | 2007 |
Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dose-Response Relationship, D | 2008 |
296 other studies available for piracetam and Seizures
| Article | Year |
|---|---|
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
Topics: Acoustic Stimulation; Amides; Animals; Anticonvulsants; Binding Sites; Butyrates; Caco-2 Cells; Cere | 2004 |
Seizure Deterioration with Increased Levetiracetam Blood Concentration during the Postpartum Period in Refractory Temporal Lobe Epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Humans; Levetiracetam; Piracetam; Postpartu | 2022 |
Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous | 2022 |
Effect of Nonadherence on Levetiracetam Pharmacokinetics and Remedial Dose Recommendations Using Monte Carlo Simulations.
Topics: Anticonvulsants; Computer Simulation; Humans; Levetiracetam; Monte Carlo Method; Piracetam; Seizures | 2022 |
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Piracetam; Prospective Studies; Quality of | 2022 |
Subcutaneous Levetiracetam and Sodium Valproate Use in Palliative Care Patients.
Topics: Anticonvulsants; Humans; Levetiracetam; Palliative Care; Piracetam; Retrospective Studies; Seizures; | 2022 |
Evaluation of Levetiracetam Dosing Strategies for Seizure Prophylaxis Following Traumatic Brain Injury.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Cohort Studies; Humans; Levetiracetam; Piracetam; Retros | 2023 |
Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study.
Topics: Anticonvulsants; Cohort Studies; Glioma; Humans; Levetiracetam; Piracetam; Retrospective Studies; Se | 2022 |
Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnant Women; Retr | 2023 |
Experience of Subcutaneous Levetiracetam in Palliative Care.
Topics: Anticonvulsants; Humans; Levetiracetam; Palliative Care; Piracetam; Seizures; Treatment Outcome | 2023 |
Levetiracetam dosing for seizure prophylaxis in neurocritical care patients.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Female; Humans; Levetiracetam; Male; Middle Aged; | 2023 |
Use of Levetiracetam for Post-Traumatic Seizure Prophylaxis in Combat-Related Traumatic Brain Injury.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Female; Humans; Levetiracetam; Male; Piracetam; R | 2023 |
Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function.
Topics: Anticonvulsants; Cognition; Female; Humans; Levetiracetam; Male; Piracetam; Retrospective Studies; S | 2023 |
Levetiracetam in Neonatal seizures.
Topics: Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Piracetam; Seizures | 2019 |
Effectiveness Oral Theophylline, Piracetam, and Iron Treatments in Children With Simple Breath-Holding Spells.
Topics: Breath Holding; Child, Preschool; Female; Humans; Iron; Male; Piracetam; Retrospective Studies; Seiz | 2020 |
Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; China; Epilepsy; Female; Humans | 2020 |
High-Dose Levetiracetam for Neonatal Seizures: A Retrospective Review.
Topics: Aged; Anticonvulsants; Humans; Infant, Newborn; Levetiracetam; Piracetam; Prospective Studies; Retro | 2020 |
Blood concentration of levetiracetam after bolus administration in patients with status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Levetiracetam; Piracetam; Seizures; Status Epilepticus | 2021 |
Comparison of efficacy and safety of levetiracetam and phenobarbitone in neonatal seizure.
Topics: Anticonvulsants; Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Piracetam; Seizure | 2022 |
Rapid administration of undiluted intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2021 |
Prophylactic Anticonvulsants in Intracerebral Hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cerebral Hemorrhage; Drug Prescriptions; Female; Gu | 2017 |
Lacosamide Lowers Valproate and Levetiracetam Levels.
Topics: Acetamides; Adolescent; Anticonvulsants; Brain Neoplasms; Drug Interactions; Epilepsies, Partial; Hu | 2017 |
Early Lance-Adams syndrome after cardiac arrest: Prevalence, time to return to awareness, and outcome in a large cohort.
Topics: Adult; Aged, 80 and over; Anticonvulsants; Cardiopulmonary Resuscitation; Clonazepam; Drug Combinati | 2017 |
Transient epileptic amnesia without epileptic seizures: proposal of a new entity.
Topics: Amnesia; Anticonvulsants; Electroencephalography; Epilepsy; Humans; Levetiracetam; Male; Middle Aged | 2017 |
Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Humans; Infant | 2017 |
Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration.
Topics: Aged; Anticonvulsants; Hemofiltration; Humans; Intracranial Hemorrhages; Levetiracetam; Male; Pirace | 2017 |
Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2017 |
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dibenzazepines; Drug-Relate | 2017 |
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Renal Dialysis; Seizures | 2017 |
Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis.
Topics: Adult; Aged; Anticonvulsants; Clinical Protocols; Drug Administration Schedule; Female; Humans; Kidn | 2017 |
Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Antidotes; Benzodiazepines; Female; Flumaze | 2017 |
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.
Topics: Administration, Intravenous; Administration, Oral; Anticonvulsants; Blood Pressure; Databases, Factu | 2017 |
Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Clonazepam; Drug Interactions; Drug Monitoring; Drug Therapy, | 2017 |
Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats.
Topics: Animals; Aromatase; Cerebral Cortex; Epididymis; Hippocampus; Kainic Acid; Levetiracetam; Male; Nerv | 2017 |
Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia.
Topics: Acetamides; Animals; Anticonvulsants; Electroencephalography; Female; GABA Antagonists; Lacosamide; | 2017 |
Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015).
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Follow-Up Studies; Levetiracetam; Piracetam; | 2017 |
Unilateral Thalamic Infarct Presenting as a Convulsive Seizure.
Topics: Aspirin; Atorvastatin; Cerebral Angiography; Cerebral Infarction; Humans; Hydrocephalus; Levetiracet | 2017 |
Autistic Regression: Should it Prompt Urgent EEG?
Topics: Anticonvulsants; Autism Spectrum Disorder; Early Diagnosis; Electroencephalography; Humans; Infant; | 2017 |
Early Seizure Prophylaxis in Traumatic Brain Injuries Revisited: A Prospective Observational Study.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Female; Humans; Incidence; Levetiracetam; Male; M | 2018 |
Authors' response to letter on "levetiracetam in toxic seizures".
Topics: Humans; Levetiracetam; Piracetam; Seizures | 2018 |
Letter in response to "Levetiracetam in toxic seizures".
Topics: Humans; Levetiracetam; Piracetam; Seizures | 2018 |
Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Electroencephalography; Epilepsies, Myoclonic; Female; | 2018 |
Population pharmacokinetics of levetiracetam in neonates with seizures.
Topics: Anticonvulsants; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Leve | 2018 |
Continuous subcutaneous levetiracetam in end-of-life care.
Topics: Aged, 80 and over; Anticonvulsants; Dementia, Vascular; Disease Progression; Female; Humans; Infusio | 2018 |
Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model.
Topics: Allosteric Regulation; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Synergism; E | 2018 |
Population pharmacokinetic model of levetiracetam in Korean neonates with seizures
.
Topics: Age Factors; Anticonvulsants; Drug Dosage Calculations; Drug Monitoring; Female; Hospitals, Pediatri | 2018 |
Benign rolandic epilepsy and generalized paroxysms: A study of 13 patients.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy, Rolandic; Female; | 2018 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Rapid antiepileptic drug withdrawal may obscure localizing information obtained during presurgical EEG recordings.
Topics: Acetamides; Anticonvulsants; Brain; Electroencephalography; Epilepsy; Humans; Lacosamide; Levetirace | 2018 |
Influenza B-related meningoencephalitis in adults.
Topics: Aged, 80 and over; Antiviral Agents; Betainfluenzavirus; Confusion; Humans; Influenza, Human; Leveti | 2018 |
Brand name to generic substitution of levetiracetam in patients with epilepsy.
Topics: Adult; Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Female; Follow-Up Studies; Huma | 2018 |
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice.
Topics: Alzheimer Disease; Amyloid; Animals; Inflammasomes; Interleukin-18; Interleukin-1beta; Levetiracetam | 2018 |
Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
Topics: Anticonvulsants; Brain; Child, Preschool; Female; Humans; Levetiracetam; Membrane Glycoproteins; Mut | 2019 |
Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam.
Topics: Abbreviated Injury Scale; Adult; Anticonvulsants; Brain Injuries; Female; Humans; Levetiracetam; Mal | 2013 |
Survey of prophylactic antiseizure drug use for non-traumatic intracerebral hemorrhage.
Topics: Anticonvulsants; Brain; Cerebral Hemorrhage; Drug Prescriptions; Drug Utilization; Electroencephalog | 2013 |
Phenytoin or levetiracetam for seizure prophylaxis in TBI.
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2012 |
Ictal bradycardia and asystole in an adult with a focal left insular lesion.
Topics: Anticonvulsants; Benzodiazepines; Bradycardia; Brain Diseases; Cerebral Cortex; Clobazam; Drug Resis | 2013 |
Intravenous levetiracetam for treatment of neonatal seizures.
Topics: Administration, Intravenous; Anticonvulsants; Electroencephalography; Gestational Age; Humans; Infan | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Faciobrachial dystonic seizures arise from cortico-subcortical abnormal brain areas.
Topics: Adult; Anticonvulsants; Autoantibodies; Autoantigens; Brain; Dystonia; Female; Functional Laterality | 2013 |
Encephalopathy induced by levetiracetam in an elderly woman.
Topics: Aged, 80 and over; Anticonvulsants; Female; Humans; Levetiracetam; Neurotoxicity Syndromes; Piraceta | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient.
Topics: Anti-Bacterial Agents; Anticonvulsants; Bacterial Infections; Brain Injuries; Drug Monitoring; Femal | 2013 |
Role of intravenous levetiracetam for acute seizure management in preterm neonates.
Topics: Acute Disease; Anticonvulsants; Electroencephalography; Female; Humans; Infant; Infant, Newborn; Inf | 2013 |
Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Child; Child, Preschoo | 2013 |
Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats.
Topics: Acetylcholinesterase; Animals; Anticonvulsants; Butyrylcholinesterase; Cyclopropanes; Drug Interacti | 2013 |
Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cohort Studies; Gestational Age; Humans; Infan | 2013 |
Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Midd | 2013 |
Additional antiepileptic mechanisms of levetiracetam in lithium-pilocarpine treated rats.
Topics: Animals; Anticonvulsants; Dinoprostone; Dopamine; Glutathione; Hippocampus; Interleukin-10; Levetira | 2013 |
A method for actively tracking excitability of brain networks using a fully implantable monitoring system.
Topics: Animals; Anticonvulsants; Brain; Brain Mapping; Circadian Rhythm; Deep Brain Stimulation; Dogs; Drug | 2013 |
Early-onset absence epilepsy aggravated by valproic acid: a video-EEG report.
Topics: Age of Onset; Anticonvulsants; Child, Preschool; Electroencephalography; Epilepsy, Absence; Humans; | 2013 |
Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Drug Combinatio | 2014 |
The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Infarction, Middle Cerebra | 2013 |
Levetiracetam-induced anaphylaxis in a neonate.
Topics: Anaphylaxis; Anticonvulsants; Asphyxia Neonatorum; Contraindications; Drug Eruptions; Exanthema; Fac | 2014 |
Levetiracetam versus (fos)phenytoin for seizure prophylaxis in pediatric patients with intracranial hemorrhage.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Incidence; Infant; Intracrania | 2014 |
[Efficacy and psychiatric adverse events as short-term adjunctive levetiracetam for epileptic children with refractory convulsive seizures].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Levetiracetam; Male; Piracetam | 2013 |
The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Infusi | 2014 |
Toothbrushing-induced seizures at onset of cryptogenic partial epilepsy: a case report.
Topics: Acetamides; Anticonvulsants; Electroencephalography; Epilepsies, Partial; Humans; Lacosamide; Leveti | 2014 |
Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis.
Topics: Aged; Anticonvulsants; Female; Hematoma, Subdural; Humans; Levetiracetam; Male; Middle Aged; Phenyto | 2014 |
Generalised electrographic seizures presenting as perioral myoclonia.
Topics: Adult; Diagnosis, Differential; Electroencephalography; Humans; Levetiracetam; Male; Myoclonic Epile | 2014 |
Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Dr | 2014 |
A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient.
Topics: Aged; Anticonvulsants; Fatigue; Humans; Levetiracetam; Male; Metabolic Clearance Rate; Peritoneal Di | 2014 |
Cardiac involvement secondary to mediastinal lymphoma in a cat: regression with chemotherapy.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Asparaginase; Cat Diseases; Cats; Drug Therapy, Com | 2014 |
Recurrent severe ulcers due to seizures.
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Levetiracetam; Mouth Protectors; Or | 2014 |
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
Topics: Anticonvulsants; Antihypertensive Agents; Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Brai | 2016 |
Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam.
Topics: Adolescent; Anticonvulsants; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levetirac | 2014 |
Effect of quercetin and rutin in some acute seizure models in mice.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ther | 2014 |
Hypokalemia and hypomagnesaemia related to levetiracetam use.
Topics: Adult; Anticonvulsants; Humans; Hypokalemia; Lamotrigine; Levetiracetam; Magnesium; Male; Nephritis, | 2014 |
Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Female; Follow-Up Stud | 2014 |
Levetiracetam as a possible contributor to acute kidney injury.
Topics: Acute Kidney Injury; Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Seizures; Young Adul | 2014 |
The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy.
Topics: Anticonvulsants; Female; Fructose; Humans; Lamotrigine; Levetiracetam; Piracetam; Pregnancy; Registr | 2014 |
A young woman with seizures and psychosis.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Hallucinations; Humans; Levetiracetam; Neuropsychological | 2014 |
Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks.
Topics: Acetamides; Anticonvulsants; Arrhythmias, Cardiac; Child, Preschool; Comorbidity; Humans; Hypoplasti | 2015 |
Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury.
Topics: Adult; Aged; Anticonvulsants; Brain Injuries; Female; Humans; Levetiracetam; Male; Mental Status Sch | 2014 |
Efficacy and safety of IV levetiracetam in children with acute repetitive seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Follow-Up Stud | 2014 |
Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Bromides; Child; Chronic Disease; Encephalitis; F | 2015 |
Epilepsy in patients with gliomas: incidence and control of seizures.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Female; Glioma; Humans; Inci | 2015 |
Profile of anticonvulsant action of levetiracetam, tiagabine and phenobarbital against seizures evoked by DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) in neonatal rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Carbolines; Levetiracetam; Male; Nipecotic Acids; Phenob | 2014 |
Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI.
Topics: Animals; Brain Injuries; Contusions; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2015 |
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Cells; Brain Neoplasms; Chemoradiotherapy; Fem | 2015 |
Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levetirac | 2015 |
Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Levetiracetam; Long QT Syndrome; Male; Mid | 2014 |
Interactions between levetiracetam and cardiovascular drugs against electroconvulsions in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticonv | 2014 |
Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Drug Resistance; Electrod | 2015 |
Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation.
Topics: Adolescent; Anticonvulsants; Blood Cell Count; Graft Rejection; Hematopoietic Stem Cell Transplantat | 2015 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Levetiracetam; Male; Mice; Phenytoin | 2015 |
Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Bromides; Child; Child, Preschool; Clobazam; Diet, Ket | 2015 |
[Clinical efficacy of levetiracetam on bone mineral density and bone metabolism in middle-aged and elderly patients with generalized tonic-clonic seizures].
Topics: Aged; Alkaline Phosphatase; Anticonvulsants; Bone and Bones; Bone Density; Humans; Levetiracetam; Mi | 2014 |
Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Epilepsy; Female; Humans; Infant; Levet | 2015 |
The anti-ictogenic effects of levetiracetam are mirrored by interictal spiking and high-frequency oscillation changes in a model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electrodes, Implanted; Electroencephalography; Epi | 2015 |
[Pathophysiology, differential diagnosis and treatment of severe emotional apnea: based on report case].
Topics: Apnea; Diagnosis, Differential; Electroencephalography; Emotions; Female; Humans; Infant; Magnetic R | 2014 |
Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Case-Control Studies; Chemoprevention; Cohort | 2016 |
Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Infus | 2015 |
Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish.
Topics: Allylglycine; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Fructose; Levetiracetam; M | 2015 |
Assessment into the usage of levetiracetam in a canine epilepsy clinic.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Piracetam; Retr | 2015 |
Levetiracetam-associated Hypokalemia and Hypomagnesaemia among Two Patients Treated for Seizures.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Hypokalemia; Levetiracetam; Magnesium Defi | 2015 |
[Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models].
Topics: Animals; Calpain; Disease Models, Animal; Epilepsy; Hippocampus; Levetiracetam; Pilocarpine; Piracet | 2015 |
Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats.
Topics: Animals; Anticonvulsants; Anxiety; Avoidance Learning; Cognition Disorders; Convulsants; DNA Damage; | 2015 |
Neutropenia secondary to exposure to levetiracetam.
Topics: Adenocarcinoma; Anticonvulsants; Brain Neoplasms; Craniotomy; Drug Administration Schedule; Humans; | 2015 |
Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis.
Topics: Animals; Brain; Carbamates; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combinat | 2015 |
Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Levetiracetam; Male; Mice | 2015 |
A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature.
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Infant; Levetiracetam; Midazolam; Piracetam; | 2015 |
Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Capillary Permeability; Catheters, Indwelling; Cornea | 2015 |
Eosinophilia and Fever with Levetiracetam: A Case Report.
Topics: Anticonvulsants; Eosinophilia; Fever; Humans; Levetiracetam; Male; Piracetam; Seizures; Young Adult | 2015 |
Use of Levetiracetam in Neonates in Clinical Practice: A Retrospective Study at a German University Hospital.
Topics: Anticonvulsants; Female; Germany; Gestational Age; Hospitals, University; Humans; Infant, Newborn; I | 2015 |
Supralethal poisoning by any of the classical nerve agents is effectively counteracted by procyclidine regimens in rats.
Topics: Animals; Anticonvulsants; Antidotes; Body Weight; Brain; Disease Models, Animal; Dose-Response Relat | 2015 |
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Topics: Animals; Anticonvulsants; Brain; Chronic Disease; Disease Models, Animal; Endothelin B Receptor Anta | 2015 |
Acute rhabdomyolysis associated with levetiracetam therapy in a child.
Topics: Adolescent; Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Rhabdomyolysis; Seizures | 2016 |
Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation.
Topics: Adult; Anticonvulsants; Drug Monitoring; End Stage Liver Disease; Female; Humans; Levetiracetam; Liv | 2015 |
Landau-Kleffner syndrome: an uncommon dealt with case in Southeast Asia.
Topics: Anticonvulsants; Aphasia; Asia, Southeastern; Child; Electroencephalography; Humans; Landau-Kleffner | 2015 |
First 3D-printed pill.
Topics: Drug Compounding; Drug Design; Humans; Levetiracetam; Piracetam; Printing, Three-Dimensional; Seizur | 2015 |
Antimuscarinic-induced convulsions in fasted animals after food intake: evaluation of the effects of levetiracetam, topiramate and different doses of atropine.
Topics: Animals; Anticonvulsants; Atropine; Eating; Fasting; Fructose; Levetiracetam; Male; Mice, Inbred BAL | 2016 |
Prolonged Cardiac Dysfunction After Intraparenchymal Hemorrhage and Neurogenic Stunned Myocardium.
Topics: Adult; Anesthesia, General; Cerebral Hemorrhage; Emergency Service, Hospital; Heart; Hemangioma, Cav | 2016 |
Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Antiviral Agents; Brain Diseases; Cafe-au-Lait Spots; | 2015 |
Low-dose levetiracetam for seizure prophylaxis after traumatic brain injury.
Topics: Adult; Aged; Anticonvulsants; Brain Injuries, Traumatic; Cohort Studies; Dose-Response Relationship, | 2016 |
Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis.
Topics: Adolescent; Anticonvulsants; Brain Injuries; Child; Child, Preschool; Female; Humans; Infant; Infant | 2016 |
Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsies, Myoclonic; Epilepsy, Generalized; Female; | 2017 |
Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report.
Topics: Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplas | 2016 |
Remember Keppra: seizure control with subcutaneous levetiracetam infusion.
Topics: Anticonvulsants; Drug Combinations; Female; Humans; Infusions, Subcutaneous; Levetiracetam; Middle A | 2016 |
Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Electroencephalography; Gait Disorders, Neuro | 2016 |
Aggravation of atonic seizures by rufinamide: A case report.
Topics: Anticonvulsants; Benzodiazepines; Brain; Child; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Com | 2016 |
Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Child; Child, | 2016 |
Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Drug Resistance; Epilepsy; GABA Antagoni | 2016 |
A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures.
Topics: Acetamides; Adult; Aged; Anticonvulsants; Combined Modality Therapy; Drug Therapy, Combination; Epil | 2016 |
Levetiracetam prophylaxis ameliorates seizure epileptogenesis after fluid percussion injury.
Topics: Animals; Anticonvulsants; Brain Injuries, Traumatic; CA1 Region, Hippocampal; Disease Models, Animal | 2016 |
Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoiet | 2017 |
Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis.
Topics: Adolescent; Adult; Anticonvulsants; Brain Injuries, Traumatic; Chemoprevention; Databases, Factual; | 2016 |
Similarity of symptoms between transient epileptic amnesia and Lewy body disease.
Topics: 3-Iodobenzylguanidine; Aged; Amnesia; Anticonvulsants; Cognition Disorders; Electroencephalography; | 2017 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Continuous electroencephalography in pediatric traumatic brain injury: Seizure characteristics and outcomes.
Topics: Adolescent; Brain; Brain Injuries, Traumatic; Child; Child, Preschool; Electroencephalography; Epile | 2016 |
Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Study.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Cyclophosphamide; Fatal Out | 2016 |
Intractable Seizures and Rehabilitation in Ciguatera Poisoning.
Topics: Adolescent; Animals; Anticonvulsants; Ciguatera Poisoning; Gait Disorders, Neurologic; Humans; Levet | 2017 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Topics: Alkaloids; Animals; Anticonvulsants; Azocines; Dose-Response Relationship, Drug; Electroshock; Levet | 2017 |
Changing antiepileptic drug use for seizures in US neonatal intensive care units from 2005 to 2014.
Topics: Anticonvulsants; Child; Drug Utilization; Female; Humans; Infant; Infant, Newborn; Intensive Care Un | 2017 |
The risk of hypotension and seizures in patients receiving prophylactic anti-epileptic drugs for supratentorial craniotomy.
Topics: Acetamides; Adult; Anticonvulsants; Blood Pressure; Craniotomy; Female; Humans; Hypotension; Lacosam | 2018 |
Evolving use of seizure medications after intracerebral hemorrhage: A multicenter study.
Topics: Adult; Aged; Anticonvulsants; Cerebral Hemorrhage; Cohort Studies; Craniotomy; Electronic Health Rec | 2017 |
Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy.
Topics: Adult; Anticonvulsants; Female; Follow-Up Studies; Humans; Hypothermia, Induced; Hypoxia-Ischemia, B | 2017 |
Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Dose-Response Relationship | 2017 |
The effect of newer antiepileptic drugs in combination therapy.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Drug Therapy, Combination; Epi | 2017 |
Levetiracetam Induced Increase in Creatine Phosphokinase Levels.
Topics: Adult; Anticonvulsants; Creatine Kinase; Humans; Levetiracetam; Male; Piracetam; Seizures | 2017 |
Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Disease Models, Animal; Electric Stimulati | 2008 |
Levetiracetam: new indication. Tonic-clonic seizures: another second-line option. No comparison with other antiepileptics.
Topics: Epilepsy; France; Humans; Piracetam; Randomized Controlled Trials as Topic; Seizures | 2008 |
Off-label use of antiepileptic drugs for the treatment of neonatal seizures.
Topics: Anticonvulsants; Drug Utilization; Guidelines as Topic; Health Surveys; Humans; Infant, Newborn; Lev | 2008 |
Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism.
Topics: Anticonvulsants; Data Collection; Female; Humans; Lamotrigine; Levetiracetam; Middle Aged; Phenobarb | 2009 |
Reversible panhypogammaglobulinemia associated with the antiepileptic agent levetiracetam.
Topics: Adult; Agammaglobulinemia; Anticonvulsants; Brain Abscess; Humans; Immunoglobulins; Levetiracetam; M | 2008 |
Piracetam in severe breath holding spells.
Topics: Anemia, Iron-Deficiency; Apnea; Child, Preschool; Crying; Dose-Response Relationship, Drug; Female; | 2008 |
Levetiracetam for seizures in children with brain tumors and other cancers.
Topics: Adolescent; Anticonvulsants; Brain Neoplasms; Child; Drug Evaluation; Female; Humans; Levetiracetam; | 2009 |
Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
Topics: Adult; Aged; Anticonvulsants; Cognition; Epilepsy; Female; Follow-Up Studies; Humans; Levetiracetam; | 2008 |
An unusual cause of collapse and neck pain.
Topics: Anticonvulsants; Humans; Levetiracetam; Male; Neck Pain; Neurofibromatosis 1; Piracetam; Seizures; S | 2008 |
Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug I | 2009 |
Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia.
Topics: Anticonvulsants; Electroencephalography; Humans; Infant, Newborn; Levetiracetam; Magnetic Resonance | 2010 |
Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Critical Illnes | 2009 |
Behavioral effects of levetiracetam mitigated by pyridoxine.
Topics: Anticonvulsants; Behavioral Symptoms; Child; Drug Therapy, Combination; Humans; Levetiracetam; Male; | 2009 |
Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study.
Topics: Activities of Daily Living; Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Combine | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
Levetiracetam-induced platelet dysfunction.
Topics: Aged; Anticonvulsants; Blood Platelet Disorders; Clopidogrel; Humans; Levetiracetam; Magnetic Resona | 2009 |
Levetiracetam decreases the seizure activity and blood-brain barrier permeability in pentylenetetrazole-kindled rats with cortical dysplasia.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Capillary Permeability; Endothelium; Fluoresce | 2009 |
Role of intravenous levetiracetam in acute seizure management of children.
Topics: Adolescent; Anticonvulsants; Brain; Chemotherapy, Adjuvant; Child; Child, Preschool; Electroencephal | 2009 |
Levetiracetam induced interstitial nephritis and renal failure.
Topics: Adolescent; Adrenal Cortex Hormones; Anticonvulsants; Contraindications; Female; Humans; Kidney; Lev | 2009 |
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery.
Topics: Anticonvulsants; Brain; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2009 |
Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model.
Topics: Animals; Anticonvulsants; Clonazepam; Convulsants; Disease Models, Animal; Drug Interactions; Drug T | 2009 |
The use of antiepileptic drugs in pediatric brain tumor patients.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Child; Drug Interactions; Fo | 2009 |
Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Topics: Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Leve | 2010 |
Sequential intrarectal diazepam and intravenous levetiracetam in treating acute repetitive and prolonged seizures.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Diazepam; Drug Therapy, Combination; Female; Hum | 2010 |
Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Chi-Square Distribution; Female; Humans; Hypotension | 2009 |
Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome.
Topics: Adolescent; Analysis of Variance; Anticonvulsants; Child; Drug Administration Schedule; Electroencep | 2010 |
Seizure risk in brain tumor patients with conversion to generic levetiracetam.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drugs, Generic; Female; Humans; Levetiracetam; Male; Middle | 2010 |
Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chemotherapy, Adjuvant; Cohort Studies; Epilepsy; Female; | 2010 |
Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression.
Topics: Acetamides; Animals; Anticonvulsants; Disease Models, Animal; Indoles; Levetiracetam; Ligands; Membr | 2010 |
Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Electric Stimulation; Epilepsy, Temporal | 2010 |
Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model.
Topics: Animals; Anticonvulsants; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2010 |
High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy.
Topics: Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Injections, Intravenous; Levetiracetam; M | 2010 |
Seizure management in a complex hospice patient.
Topics: Anti-Retroviral Agents; Anticonvulsants; Drug Interactions; Female; HIV Infections; Hospice Care; Hu | 2010 |
Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
Topics: Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Electroshock; Epilepsy, Gen | 2010 |
Intravenous levetiracetam in children with seizures: a prospective safety study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side E | 2010 |
Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Ep | 2010 |
Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Levetiracetam; Male; Middle Aged; N | 2011 |
Seizures in patients with glioma treated with phenytoin and levetiracetam.
Topics: Adult; Aged; Anticonvulsants; Female; Glioma; Humans; Levetiracetam; Male; Middle Aged; Phenytoin; P | 2010 |
Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus.
Topics: Animals; Animals, Newborn; Bromodeoxyuridine; Dentate Gyrus; Disease Models, Animal; Electroencephal | 2010 |
Intravenous levetiracetam in the management of acute seizures in children.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, | 2010 |
[Levetiracetam modifies the pattern of audiogenic locomotive response in Wistar and Krushinsky-Molodkina strain rats].
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Levetiracetam; Male; Motor Activity; Piracetam; Rats | 2010 |
Juvenile myoclonic epilepsy.
Topics: Anticonvulsants; Electroencephalography; Family Health; Humans; Levetiracetam; Mutation; Myoclonic E | 2010 |
Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Disease Models, Animal; Female; Fever; Fluorescein; G | 2010 |
Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cognition Disorders; Female; Humans; Intracranial H | 2011 |
Nonepileptic seizures under levetiracetam therapy.
Topics: Adult; Anticonvulsants; Female; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Seizures | 2010 |
Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cross-Sectional Studies; Female; Humans | 2010 |
Levetiracetam: safety and efficacy in neonatal seizures.
Topics: Administration, Oral; Anticonvulsants; Feasibility Studies; Female; Humans; Infant, Newborn; Infant, | 2011 |
Higher evening antiepileptic drug dose for nocturnal and early-morning seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diethylcarbamazine; Dose-Response Relationship | 2011 |
Acute levetiracetam overdose presented with mild adverse events.
Topics: Adult; Humans; Levetiracetam; Male; Neurotoxicity Syndromes; Piracetam; Seizures | 2010 |
Levetiracetam for treatment of neonatal seizures.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Female; Gestational Age; Humans; Levetira | 2011 |
Use of intravenous levetiracetam for management of acute seizures in neonates.
Topics: Anticonvulsants; Female; Follow-Up Studies; Humans; Infant; Injections, Intravenous; Levetiracetam; | 2011 |
Clinical experience with generic levetiracetam in people with epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Drug Substitution; Drugs, Generic; Epilepsy; Female; Hospita | 2011 |
Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Electroencephalo | 2011 |
Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures.
Topics: Adult; Aged, 80 and over; Anticonvulsants; Drug Substitution; Drugs, Generic; Female; Humans; Incide | 2011 |
Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats.
Topics: Animals; Anticonvulsants; Antidotes; Chemical Warfare Agents; Cholinesterase Inhibitors; Cholinester | 2011 |
Pharmacokinetics of levetiracetam in neonates with seizures.
Topics: Anticonvulsants; Body Weight; Chromatography, Liquid; Creatinine; Female; Half-Life; Humans; Infant, | 2011 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats.
Topics: Animals; Anticonvulsants; Brain-Derived Neurotrophic Factor; Hippocampus; Levetiracetam; Neurons; Ne | 2011 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Postpartum cerebral venous thrombosis.
Topics: Anticoagulants; Anticonvulsants; Brain; Female; Heparin; Humans; Hypertension; Levetiracetam; Magnes | 2011 |
Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Cost-Benefit Analysis; Decision Trees; Female; Glasgow Outco | 2011 |
Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Calcinosis; Edema; Granuloma; Humans; Levetira | 2011 |
Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Confidence Intervals; Cyclohexanecarboxylic Ac | 2012 |
Probable psychosis associated with levetiracetam: a case report.
Topics: Anticonvulsants; Humans; Levetiracetam; Male; Piracetam; Psychotic Disorders; Seizures; Young Adult | 2011 |
Modulation of abnormal synaptic transmission in hippocampal CA3 neurons of spontaneously epileptic rats (SERs) by levetiracetam.
Topics: Action Potentials; Animals; Anticonvulsants; CA3 Region, Hippocampal; Calcium; Electrophysiology; Hu | 2011 |
Treatment with levetiracetam in a patient with pervasive developmental disorders, severe intellectual disability, self-injurious behavior, and seizures: a case report.
Topics: Anticonvulsants; Child; Child Development Disorders, Pervasive; Humans; Intellectual Disability; Lev | 2012 |
Levetiracetam-induced interstitial nephritis in a patient with glioma.
Topics: Acute Kidney Injury; Anticonvulsants; Astrocytoma; Brain Neoplasms; Humans; Levetiracetam; Male; Mid | 2012 |
Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; Contraindications; Craniotomy; F | 2012 |
Seizures as a manifestation of multiple sclerosis.
Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Humans; Levet | 2011 |
Leukoencephalopathy, cerebral calcifications, and cysts: case report.
Topics: Adult; Anticonvulsants; Basal Ganglia Diseases; Brain; Calcinosis; Central Nervous System Cysts; Dys | 2012 |
A cost-minimization analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury.
Topics: Adult; Anticonvulsants; Brain Injuries; Cost Control; Cost-Benefit Analysis; Decision Trees; Drug Co | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function?
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Middle Aged; Piracetam; Recurrence; Seizures; Subara | 2012 |
Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anticonvulsants; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Trans | 2012 |
[Effect of levetiracetam on intractable secondarily generalized seizure and depression].
Topics: Anticonvulsants; Brain Injuries; Depression; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Se | 2012 |
Levetiracetam may favorably affect seizure outcome after temporal lobectomy.
Topics: Adolescent; Adult; Aged; Anterior Temporal Lobectomy; Anticonvulsants; Child; Child, Preschool; Epil | 2012 |
A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.
Topics: Electroencephalography; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Injections, Int | 2012 |
A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.
Topics: Electroencephalography; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Injections, Int | 2012 |
A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.
Topics: Electroencephalography; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Injections, Int | 2012 |
A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.
Topics: Electroencephalography; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Injections, Int | 2012 |
Pilomotor seizure: when paroxysmal gooseflesh heralds brain tumor.
Topics: Aged; Amygdala; Anticonvulsants; Astrocytoma; Brain Neoplasms; Electroencephalography; Hippocampus; | 2012 |
An acquired source of seizures.
Topics: Adult; Albendazole; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antiparasitic Agents; Develo | 2012 |
Increased levetiracetam clearance in pregnancy: is seizure frequency affected?
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnancy Complications; Seizu | 2012 |
Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Hospitals, Pediatric; Humans; Infant; | 2012 |
Paraneoplastic extralimbic encephalitis associated with thymoma and myastenia gravis: three years follow up.
Topics: Anticonvulsants; Cholinesterase Inhibitors; Electroencephalography; Follow-Up Studies; Levetiracetam | 2013 |
Focal meningoencephalitis of hepatitis A: a clinico-radiologic picture.
Topics: Anticonvulsants; Brain; Child; Electroencephalography; Hepatitis A; Humans; Immunoglobulin M; Leveti | 2012 |
Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users.
Topics: Adult; Anticonvulsants; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; France | 2012 |
Stevens-Johnson syndrome induced by levetiracetam.
Topics: Anticonvulsants; Cardiovascular Surgical Procedures; Child, Preschool; Female; Heart Defects, Congen | 2012 |
Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Hu | 2013 |
Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Blotting, Western; Brain; Immunohistochemistry; Kainic A | 2013 |
Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Electric Stimulation; Electrodes, Implanted; K | 2003 |
Levetiracetam: preliminary experience in patients with primary brain tumours.
Topics: Brain Neoplasms; Follow-Up Studies; Glioma; Humans; Levetiracetam; Piracetam; Prospective Studies; S | 2003 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Topics: Animals; Anticonvulsants; Binding Sites; Brain; Fibroblasts; Gene Deletion; Humans; Inhibitory Conce | 2004 |
Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Exocytosis; Humans; Levetiracetam; Membrane Glycop | 2004 |
Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.
Topics: Adult; Anticonvulsants; Delta Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule | 2004 |
Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, | 2005 |
Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement.
Topics: Animals; Anticonvulsants; Convulsants; Disease Models, Animal; Hippocampus; Levetiracetam; Male; Mic | 2005 |
Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).
Topics: Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Drug Administration Schedule; El | 2005 |
Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats.
Topics: Administration, Oral; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; | 2005 |
Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Female; Fructose; Humans; Levetiracetam; | 2005 |
Rapid kindling in preclinical anti-epileptic drug development: the effect of levetiracetam.
Topics: Animals; Anticonvulsants; Convulsants; Electric Stimulation; Electrodes, Implanted; Electroencephalo | 2005 |
Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Models, Animal; Dose-Respo | 2006 |
Re: Drug-induced psychosis with levetiracetam.
Topics: Acute Disease; Anticonvulsants; Humans; Levetiracetam; Piracetam; Psychoses, Substance-Induced; Seiz | 2005 |
Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures.
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lev | 2006 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Mal | 2006 |
Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.
Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Dose-Res | 2006 |
Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epilepsy, Gen | 2006 |
In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant.
Topics: Animals; Anticonvulsants; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; | 2006 |
Use of levetiracetam in hospitalized patients.
Topics: Adult; Aged; Anticonvulsants; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; | 2006 |
Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures.
Topics: Animals; Anticonvulsants; Antioxidants; Brain; Catalase; Glutathione; Levetiracetam; Lipid Peroxidat | 2007 |
Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Mod | 2007 |
Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Co | 2007 |
Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up.
Topics: Anticonvulsants; Child; Follow-Up Studies; Humans; Levetiracetam; Male; Piracetam; Seizures; Tuberou | 2007 |
Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection.
Topics: Amino Acid Transport System X-AG; Amygdala; Analysis of Variance; Animals; Anticonvulsants; Dose-Res | 2007 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2007 |
Status gelasticus associated with levetiracetam as add-on treatment.
Topics: Anticonvulsants; Brain; Child, Preschool; Electroencephalography; Epilepsies, Partial; Female; Human | 2007 |
Levetiracetam for the treatment of neonatal seizures.
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Infant, Newborn; Levetiracetam; Mal | 2007 |
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsies, Myoc | 2007 |
Accidental overdosage of levetiracetam in two children caused no side effects.
Topics: Anticonvulsants; Child, Preschool; Drug Overdose; Female; Humans; Levetiracetam; Piracetam; Seizures | 2007 |
Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Levetiracetam; Male; Piracetam; Prospect | 2007 |
Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Basal Ganglia; Behavior, Animal; Body Weight; | 2007 |
Seizure-freedom with combination therapy in localization-related epilepsy.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Drug Therapy, Combination; Female; Frontal Lobe; Fruct | 2008 |
Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Hippocampus; Levetiracetam | 2008 |
Possible mechanism of digoxin-induced convulsions.
Topics: Animals; Calcium Chloride; Clonidine; Diazepam; Digoxin; Female; gamma-Aminobutyric Acid; Magnesium; | 1983 |
[Effect of nootropic agents on the lowering of the spasm threshold after a single ethanol application].
Topics: Animals; Brain; Ethanol; Male; Meclofenoxate; Meglumine; Mice; Orotic Acid; Picrotoxin; Piracetam; P | 1984 |
Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus.
Topics: Animals; Anticonvulsants; Bicuculline; Convulsants; Flunarizine; GABA Antagonists; Hippocampus; Leve | 1997 |
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cornea; Disease Models, Animal; Dizocilpine Malea | 1998 |
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbolines; Convulsants; Diazepam; Disease Mod | 1998 |
Effects of piracetam on pentylenetetrazol-kindling development, hippocampal potentiation phenomena and kindling-induced learning deficit.
Topics: Animals; Convulsants; Drug Interactions; Evoked Potentials; Hippocampus; Kindling, Neurologic; Learn | 1999 |
Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Evaluation; Drug Resis | 2000 |
Does fucose or piracetam modify the effect of hypoxia preconditioning against pentylenetetrazol-induced seizures?
Topics: Animals; Fucose; Hypoxia; Male; Neuroprotective Agents; Pentylenetetrazole; Piracetam; Rats; Rats, W | 2000 |
Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests.
Topics: Amantadine; Animals; Melatonin; Pentylenetetrazole; Piracetam; Rodentia; Seizures; Valproic Acid | 2001 |
ucb L059, a novel anti-convulsant drug: pharmacological profile in animals.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Convulsants; Dizocilpine Maleate; Female; Kindling, | 1992 |
[The action of piracetam, meclofenoxate and vinpocetine in comparative disease models in mice].
Topics: Animals; Anticonvulsants; Electroshock; Meclofenoxate; Mice; Pentylenetetrazole; Piracetam; Postural | 1991 |
Interactions of angiotensin II with piracetam in exploratory behavior and convulsive-seizure threshold.
Topics: Angiotensin II; Animals; Exploratory Behavior; Male; Mice; Piracetam; Pyrrolidinones; Rats; Rats, In | 1989 |
Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility.
Topics: Alcohol Drinking; Alcoholism; Animals; Dihydroergotoxine; Ethanol; Male; Meglumine; Mice; Mice, Inbr | 1985 |